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In forensic investigations, human biological traces have great potential to serve as 
strong evidence in placing a suspect at the scene of a crime. In cases where activities leading 
to the deposition of an individual’s biological materials are disputed, the identification of 
body fluids and tissues may be crucial. Current catalytic, enzymatic and immunological 
techniques used to identify body fluids present numerous limitations such as lack of 
sensitivity and specificity. Hence, forensic scientists are constantly seeking exciting, novel 
methods to identify and analyse body fluids and aid in the reconstruction of crime scenes. 
Recently, DNA methylation-based markers have emerged as a reliable tool for identification 
of body fluids. Genome-wide methylation analysis using high throughput DNA technologies 
has discovered numerous differentially methylated regions (tDMRs) that differ in levels of 
methylation in various cell types and tissues. tDMRs may be unmethylated in particular body 
fluids/tissues yet display varying degrees of methylation in others, hence providing 
distinguishing characteristics between tissues. tDMRs can be targeted to develop markers for 
body fluid identification. To date, only a few DNA methylation-based markers have been 
reported to identify body fluids, most of which have yet to be validated. To enhance the 
specificity and robustness of DNA methylation-based identification, novel markers are 
required. Furthermore, as DNA methylation levels have been found to differ between ethnic 
groups of human populations, it is worthwhile to test previously documented tDMR-based 
markers on different ethnic groups to determine if there are significant methylation 
differences. 
The present study developed new potential tDMRs-based markers to differentiate 
between saliva, semen, blood and vaginal fluid; and tested the methylation status of 
previously documented tDMRs for saliva on the diverse South African population. To 
identify new tDMRs, 1833 differentially expressed (over-expressed) genes, proposed to be 
regulated by DNA methylation, were identified in four body fluids; namely saliva, blood, 
semen and vaginal fluid. CpG dinucleotide methylation information from non-target tissues 
was mapped to genes and heavily methylated CpG islands (CGIs) were targeted for primer 
design. Sixty-three CGI sequences were selected and analysed for specificity in the human 
genome, and a total of four CGIs were targeted to design PCR primers. The primers were 
tested on saliva, blood, semen and vaginal fluid by methylation-specific restriction enzyme 
(MSRE)–PCR. The study has identified two potential body fluid-specific tDMRs: a tDMR of 
the HPCAL1 gene was identified as a potential blood-specific hypomethylation marker, and a 
tDMR of the PTPRS gene is a potential vaginal fluid-specific hypermethylation marker. To 
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our knowledge, this is the first study where these genes have been targeted to identify tDMRs 
and develop markers for body fluid identification. 
To determine if DNA methylation levels of previously documented tDMRs differ 
between four ethnic groups of South Africa, saliva samples were collected from 80 healthy 
individuals, male and female, belonging to four different ethnic groups of SA; Blacks, 
Indians, Whites and Coloureds. A multiplex MSRE-PCR assay was used to determine the 
methylation levels of four tDMRs in the USP49, DACT1, L81528 and PFN3 genes. The 
methylation levels of all selected tDMRs were highest in the Coloured ethnic group, while 
the lowest methylation levels were evident in the Black ethnic group. Promising results were 
found for two tDMRs; DACT1 and L81528, as both these markers displayed significant 
variations between the Coloured and Black ethnic groups. Significant differences in DNA 
methylation levels could assist forensic analysts in future, not only to accurately identify 
saliva but also to narrow down the search of sample donors, link them to the crime or 
exonerate them with confidence. 
The analysis of tDMRs represents a novel, efficient and reliable technique to identify 
biological fluids and tissues and to differentiate between human populations. Future prospects 
involve validation of new tDMRs based markers on a wider population size and to determine 
methylation differences in other forensically relevant body fluids among ethnic groups of 
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1.1  Introduction 
Every cell of a multicellular organism contains essentially the same genome. 
However, organisms contain a huge variety of differentiated and specialized cells, all of them 
using only a small proportion of available genes.  These patterns of differential gene activity 
are clonally inherited through cell division. It is crucial to understand why genetically 
homogenous cells are different from each other and how this is controlled. The precise degree 
of epigenetic control of gene expression and development has been controversially discussed 
and researched to a vast extent (Reik, 2007; Storey et al., 2007). Early studies of DNA 
methylation in genomic DNA successfully demonstrate tissue-specific differences in global 
methylation levels (Ayoubi and Van de Ven, 1996; Bird, 1986). Determining biological 
importance of this tissue-specificity is at present an area of active interest, especially since 
new roles of DNA methylation in growth and development have been discovered. Ever since 
researchers have discovered that DNA methylation is an epigenetic mark of supreme 
significance for normal development, the biochemical process is now being researched on a 
genome-wide as well as a tissue-specific level (Bock et al., 2010; Dyson et al., 2014; Vidaki 
et al., 2013).  
Exploiting DNA methylation for various applications such as medicine and forensic 
sciences is now well under way.  The introduction of genome-wide DNA methylation 
analysis comparing tumorous and non-malignant tissues resulted in the discovery of many 
regions that undergo aberrant methylation during carcinogenesis (Tost, 2010; Ma et al., 
2013b). Those regions can potentially be used as biomarkers for cancer detection. Once 
methylation is acquired, it is chemically and biologically stable over time, while expression 
of mRNA and/or proteins can be modified by non-disease related environmental conditions 
and varies over the cell cycle (Jain et al., 2013; Simon, 2005; Wild and Flanagan, 2010). 
DNA methylation profiles are tissue-specific and there are several chromosome segments 
called tissue-specific differentially methylated regions (tDMRs) that are known to show 
varying methylation patterns according to tissue or cell type (An et al., 2013; Choi et al., 
2014; Lee et al., 2012; Rakyan et al., 2008). Since methylation patterns of tDMRs differ 
according to cell and tissue type, which reciprocally influences tissue-specific gene 
expression, tDMRs serve as dynamic, targetable, candidates for biomarkers in medical and 
forensic research (Choi et al., 2014; Levenson and Melnikov, 2012; Rakyan et al., 2008; Wan 
et al., 2015).  
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In forensic sciences, detection and identification of body fluids present at crime 
scenes are crucial aspects of forensic investigations.  Current molecular technologies allow 
for methylation profiling of tDMRs to reveal information about exactly what biological tissue 
or fluid source the sample originated from, as well as provides estimates of age, gender, 
phenotypic characteristics and ethnic backgrounds of perpetrators or victims (Gunn et al., 
2014; Vidaki et al., 2013). Differential DNA methylation profiling may be the absolute best 
method to use when only a limited quantity of an unknown sample is collected as evidence 
and little information about the donor is known. Establishing the identity and origin of the 
body fluid helps to reconstruct the crime scene (An et al., 2013; Choi et al., 2014; Lam et al., 
2012; Lee et al., 2012; Melnikov et al., 2005). 
Although research has been successful at identifying tDMR-based markers for precise 
differentiation between body fluids and tissues (An et al., 2013; Frumkin et al., 2011; Lee et 
al., 2012; Madi et al., 2012; Park et al., 2014a), these studies have encountered various 
hurdles such as false positives and false negatives, inability to multiplex, incomplete bisulfite 
conversions, and inconclusive results for certain tDMRs due to over/underestimation of 
methylation levels. Some of these problems may be alleviated with the identification and 
addition of more tDMR-based markers and development of new methods for methylation 
profiling. 
Having gathered scientist’s attention only in the past few decades, the application of 
methylation in forensics is still relatively new and hence scientists are continually seeking 
novel methods to correctly identify biological fluids found at crime scenes.  The present 
study endeavoured to identify new potential gene-specific tDMRs in the human genome for 
differentiation of four body fluids (saliva, blood, semen and vaginal fluid). The newly 
discovered tDMRs may serve as novel markers for body fluid and tissue identification and 
thus aid in the reconstruction of crime scenes.  
DNA methylation patterns have also proven to be highly divergent between 
populations (Bell et al., 2011; Fraser et al., 2012; Heyn et al., 2013; Moen et al., 2013; Zhang 
et al., 2011a). Thus, the second objective was to decipher whether the tissue-specific 
methylation levels of previously documented tDMRs differ in saliva of four ethnic groups of 
South Africa; namely Blacks, Whites, Indians and Coloureds. tDMRs for the USP49, 
DACT1, PFN3 (Ubiquitin-Specific Peptidase 49, Dapper 1 Isoform II, Profilin III) genes and 
L81528; a semen-specific marker, were used in a multiplex PCR assay for methylation 
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profiling of saliva. If significant differences are observed, the results could enable scientists 
to narrow down the search to a particular ethnic group.  
Since numerous tDMRs exist in the mammalian genome, the identification of novel 
body fluid tDMRs, as well as validation of previous tDMRs is expected to spur the 






















1.2  Literature Review 
1.2.1 Epigenetics  
The human genome project resulted in vast amounts of genomic raw data. There are 
two meters of tightly compacted DNA, containing roughly 30 000 genes, coiled into the 
nucleus of each cell. However, identity and developmental potential of individual cells within 
organisms is not only defined by its genetic component. It is important to understand changes 
that occur in the function of genes without a change in the genome sequence. Referred to as 
epigenetics, the term describes various reversible modifications of the genome. The precise 
definition of epigenetics has baffled scientists for several years. On top of the genetic code, 
the epigenetic code comprises an additional layer of information. Whereas the former 
provides a framework for RNA and structure of protein; the epigenetic code controls 
packaging of DNA as well as gene regulation (Goldberg et al., 2007; Schilling and Rehli, 
2008; Tammen et al., 2013).  
The term epigenetics was first introduced by Conrad Waddington in early 1940, who 
defined epigenetics as ‘‘the branch of biology which studies the causal interactions between 
genes and their products which bring the phenotype into being’’ (Waddington, 1942; 
Waddington, 1968). Currently, a widely acknowledged definition is the ‘‘study of processes 
that produce a heritable phenotype that does not strictly depend on the DNA sequence’’ (Lieb 
et al., 2006). Epigenetic modifications include DNA methylation, histone modifications, 
chromatin remodelling and non-coding RNAs; all of which play a pertinent role in regulation 
of gene expression devoid of changes in DNA sequence (Schaukowitch and Kim, 2014; 
Vidaki et al., 2013). Epigenetic processes include imprinting, reprogramming, gene silencing, 
X chromosome inactivation and carcinogenesis. In mammals, a vital cell function regulated 
by epigenetic processes is cell differentiation wherein during embryogenesis; stem cells are 
completely differentiated (Heyn et al., 2013; Tammen et al., 2013; Vidaki et al., 2013). 
During the entire lifespan of an organism, epigenetic mechanisms provide a link between 




















Figure 1.1: The association of epigenetic processes and phenotypic changes throughout an organism’s lifespan 
(Tammen et al., 2013). 
 
The molecular basis of epigenetics is multifaceted and principally involves alterations 
in the activation of specific genes. Furthermore, chromatin proteins in association with DNA 
may be silenced or activated, thus ensuring that cells express only necessary genes required 
for an activity. Epigenetic programming is believed to begin as early as foetal development in 
the uterus. As DNA is inherited from one generation to the next, so too are epigenetic 
patterns preserved during cell division, yet modifications have been observed over an 
individual’s lifetime. These changes have been found to occur in response to environmental 
exposure and various factors such as smoking and diet. Epigenetic research nowadays 
includes the study of covalent and non-covalent modifications of DNA and histone proteins, 
and the mechanisms by which such modifications influence overall chromatin structure. Of 
all the intriguing epigenetic phenomena, investigation in the field of DNA methylation is 
perhaps progressing at the most astonishing pace, rendering it superbly well explored and 
thus, best characterized. The present study focuses solely on DNA methylation, in particular 
tissue-specific differential DNA methylation which provides a stable, heritable and critical 




1.3 DNA Methylation  
DNA methylation is the first epigenetic modification identified on DNA. It is an 
epigenetic mark of paramount importance for normal development in the human genome. 
Methyl-cytosine is the product of covalent attachment of a methyl group to a cytosine residue 
of the DNA sequence (Figure 1.2). The reaction is mediated by methyltransferases (DNMTs), 
namely; DNMT1, DNMT3A and DNMT3B which introduce onto the C5 position of cytosine 
residue a methyl group derived from S-Adenosylmethionine (SAM). The enzymes are crucial 
in mammalian development; partaking in two enzymatic activities: sustaining methylation 
post-replication and de novo methylation to institute new DNA methylation patterns 
throughout early development (Kader and Ghai, 2015; Lalruatfela, 2013; Zampieri et al., 
2015). The loss of DNA methylation leads to apoptosis or growth arrest in normal cells 
(Lister et al., 2009; Yan et al., 2011). Methyl-cytosine was thought to be as the only chemical 
modification of the mammalian genomic DNA. However, the existence of hydroxymethyl-
cytosine in mammalian cells was proven by Kriaucionis and Heintz (2009) and Tahiliani et 
al. (2009). Hydroxymethyl-cytosine is an oxidation product of methyl-cytosine and the 
conversion of methyl-cytosine into hydroxymethyl-cytosine could be the first step in a 
pathway leading towards DNA demethylation. Due to its probable regulatory role in gene 
transcription, not unlike methyl-cytosine, hydroxymethyl-cytosine has been termed the ‘fifth 









Figure 1.2: Basic overview of DNA methylation. A methyl group (CH3), donated by S-Adenosylmethionine 






1.3.1 Localisation of DNA Methylation in the Human Genome 
DNA methylation occurs chiefly in CpG dinucleotides; however methylation 
elsewhere has been documented (Pinney, 2014; Yan et al., 2011). Residing within the human 
genome are approximately 30 million CpG dinucleotides which are unmethylated, hemi-
methylated or abundantly methylated; varying according to region on chromosome, alleles, 
type of cell or phase of development (Rienius et al., 2012; Tammen et al., 2013). 
The arrangement of methylation in human DNA comprises of two categories; a large 
segment wherein CpGs are intermittent yet highly methylated and a minor portion that is rich 
in CpGs however, mostly deficient of methylation. This minor portion is referred to as a CpG 
island; demarcated as a region of unmethylated CpGs that consists of 300-3000 bp and a GC 
content of less than 55% (Ghosh et al., 2010; Illingworth et al., 2008; Kader and Ghai, 2015). 
A minute portion, of below 20% of CpGs within the genome may be located in CGIs. Over 
70% of gene promoters are in association with CGIs; the islands are shown to localise with 
promoters of housekeeping genes, just about 40% of tissue-specific genes and regulatory 
genes (Deaton and Bird, 2001; Ghosh et al., 2010). A conspicuous characteristic of islands 
are that they are not methylated in germ-cells and most somatic cells; the promoters are 
generally hypomethylated whilst promoters containing decreased CpG density are highly 
methylated (Day et al., 2013; Illingworth and Bird, 2009; Kader and Ghai, 2015).  
In order to decipher the cause of global methylation in the genome, Bell et al. (2011) 
found a link between variations in DNA methylation patterns that surround single nucleotide 
polymorphisms (SNPs) in cis. The study deciphered that the genetic codes of promoters are 
the crucial contributing factors of methylation of surrounding cytosine bases on the same 
DNA strand. Lienert et al. (2011) reported another important determinant of DNA 
methylation; mutations occurring at transcription factor-binding sites within the genome that 
deter the maintenance of DNA methylation in surrounding regions. 
Despite numerous studies defining the purpose and function of DNA methylation, 
there is still an immense lack of understanding of exact characteristics of DNA methylation 
particularly in individual human tissues. This lack of understanding necessitates detailed 
analysis of tissue-specific methylation of individual tissues (Igarashi et al., 2008). Genome-
wide studies have revealed that DNA methylation profiles are tissue-specific and there are 
several chromosome segments called tissue-specific differentially methylated regions 
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(tDMRs) that are known to show varying methylation patterns according to tissue or cell type 
(An et al., 2013; Choi et al., 2014; Lee et al., 2012; Rakyan et al., 2008). 
1.3.2 Tissue-Specific Differential DNA Methylation 
Tissue-specific differentially methylated regions, or tDMRs are enriched at the 
margins of CpG islands and both CpG and G/C content is lower than that of surrounding 
regions. tDMRs are generally assumed to play the role of developmental switches; providing 
cells with epigenetic memory by generating cell-type-specific hypo- and hypermethylation 
patterns. These tDMRs have been implicated in indispensable involvement of mammalian 
development and tissue differentiation. Differentially methylated regions are believed to 
function by either preventing or attracting the binding of specific factors in a methyl-
dependent manner (Cohen et al., 2011; Igarashi et al., 2008; Illingworth and Bird, 2009; 
Ohgane et al., 2008; Vidaki et al., 2013). Numerous studies have characterised a large 
number of tDMRs via comparison of DNA methylation profiles amongst various cell lines 
and tissues (An et al., 2013; Choi et al., 2014; Christensen et al., 2009; Day et al., 2013; Huh 
et al., 2013; Lee et al., 2012; Rakyan et al., 2008). These tDMRs are categorised based on 
collective behaviour (hypo- or hypermethylation) of a group of spatially clustered CpGs. 
Despite the fact that correlations of tDMR methylation levels with transcriptional state have 
been documented, the precise active regulatory role of tDMRs is not quite clear. However, 
major links between gene silencing and tDMRs have been established (Cohen et al., 2011; 
Huh et al., 2013; Ohgane et al., 2008). 
Research over the past few years has established that individual genetic background 
and environmental factors are intertwined to lifestyle in determining the overall genetic and 
hence, health status of individuals. Increasing evidence shows that environmental and 
lifestyle factors may influence epigenetic mechanisms and these influences are rather 
apparent in DNA methylation patterns (Alegria-Torres et al., 2011; Hunter, 2005; Tammen et 
al., 2013).  Such influences include, but are certainly not confined to nutrition and diets 
(King-Batoon et al., 2008; Park et al., 2011), life experiences (McGowan et al., 2009), 
ageing, stress, exposure to pollutants (Alegria-Torres et al., 2011), alcohol (Hines et al., 
2001; Mason and Choi, 2005) as well as economic status and even institutionalised care 
(Naumova et al., 2012). As methylation patterns are altered and this is portrayed in 




1.4 Environmental Influences and Differential DNA Methylation 
1.4.1 Age 
The relationship between environmental signals and epigenetics is not well defined in 
mammals; however hypo- and hypermethylation have been associated with ageing (Day et 
al., 2013; Fraser et al., 2012; Jaenisch and Bird, 2003; Tammen et al., 2013). Studies that 
focus on monozygotic twins have defined links between environment or ageing and long-
term epigenetic effects on phenotype. Due to sharing the same genetic basis, monozygotic 
twins serve as the perfect system to study epigenetics. During early years, twins display 
similar methylation patterns; however later in life they demonstrate different amounts and 
patterns of methylation (Fraga et al., 2005; Li et al., 2013; Vidaki et al., 2013). Studies of the 
H19/Igf2 (Insulin-like Growth Factor II) locus by Pirazzini et al. (2012) led to the discovery 
of two regions in which, after 60 years of age, twins displayed considerable increase in intra-
couple variation. It was observed that the range of methylation values increased only in the 
Igf2 shore region thus emphasizing that the range of variation in methylation depends on the 
genomic location (Schneider et al., 2010). With increase in age, DNA methylation machinery 
tends to lose its ability to maintain methylation patterns across cellular divisions (Goyal et al., 
2006). Variation in methylation of imprinted genes, such as the H19/Igf2 locus has also been 
previously observed by Woodfine et al. (2011). 
Furthermore, methylation of CpG islands linked with various genes such as that 
encoding oestrogen receptor, MYOD and Igf2 was untraceable in young individuals, however, 
with age became detectable in normal tissue. The correlation between age and DNA 
methylation spurs questions regarding how epigenetic alterations influence various tissue 
types over time. It has been proposed that such variation in DNA methylation patterns could 
have been a stochastic process of random epigenetic drift (Boks et al., 2009; Christensen et 
al., 2009; Jaenisch and Bird, 2003; Vidaki et al., 2013). Studies by Bjornsson et al. (2008), 
Calvanese et al. (2009) and Zhang et al. (2011a) have demonstrated that with age, comes a 
general genomic decrease in DNA methylation. The study by Zhang et al. (2011a) found that 
in a population of individuals between the ages of 45-75, ageing tissues do in fact 
demonstrate a progressive decrease in methyl-cytosine, however although the age-related 
reduction in methylation was not too significant; this could possibly have been due to the 
limited population size and age range. Day and colleagues (2013) provided a few 
speculations to explain changes in DNA methylation with age. CpG methylation changes 
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were observed in blood and various other tissues. Such changes were attributed to variation in 
chromatin structure over time since enrichment of methylation with age has been noted 
within bivalent or repressive chromatin, and DNTM1 was found to reside in hypermethylated 
regions of transcribed genes (Day et al., 2013). 
1.4.2 Nutrition and Diets 
Possibly ensuing an ‘epigenetic diet’, various dietary bioactive food components have 
been observed to alter gene expression via changes in DNA methylation (Hardy and 
Tollefsbol, 2011; Park et al., 2011). The availability of the methyl-donor, S-
Adenosylmethionine (SAM) is determined by one-carbon metabolism. This is a pathway that 
involves vitamins B6 and B12, betaine, folate and choline as well as various amino acids such 
as glycine, methionine, serine and cysteine. If a component of the pathway is missing, such as 
deficiency in B vitamins, DNA methylation is altered (Niculescu and Zeisel, 2002). In 
addition to altering availability of B vitamins, alcohol consumption causes wastage of choline 
and methionine, reducing the amount of SAM available and thereby altering DNA 
methylation (Mason and Choi, 2005; Tammen et al., 2013).  The diet is found to be an 
imperative determinant in the manifestation of late-onset disease. Vitamins and folates 
influence activity of enzymes that partake in cellular methylation processes and very much 
influence the rate of disease symptoms. Genomic instability and hypomethylation is allied 
with reduced amounts of folates (Jacob, 1999; Jaenisch and Bird, 2003). Fruit and vegetables 
contain numerous antioxidants and specific enzymes that also participate in methylation 
processes. Diets rich in fruits and vegetables have been shown to have anticancer properties 
(Alegria-Torres et al., 2011; Borek, 2004). In mice, increased intake of folic acid increased 
DNA methylation of an allele in the coat colour agouti locus, resulting in gene silencing and 
phenotypic modifications (Tost, 2010; Waterland and Jirtle, 2003). Additionally, methyl-
deficient diets induce liver cancers associated with hypomethylation and enhanced expression 
of oncogenes such as c-fos and c-ras (Friso et al., 2002; Jaenisch and Bird, 2003).  
Other bioactive ingredients may have the opposite effects on DNA methylation. 
Epigallocatechin-3-gallate, which is a primary polyphenol found in green tea was found to 
reduce global DNA methylation in cancer cell lines via competitive inhibition of DNA 
methyltransferases. This reverses repression of tumour suppressor genes such as p16, O-6-
methylguanine-DNA methyltransferase and reversion-inducing-cysteine rich protein with 
kazal motifs (Fang et al., 2003; Kato et al., 2008).  The red carotenoid, lycopene was 
observed to have demethylating capabilities in a breast cancer cell line (King-Batoon et al., 
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2008). Selenium, found in some vegetables and grains alter DNA methylation, as a reduction 
in this mineral leads to decrease in global DNA methylation with reduced expression of 
DNMT1 in colon and prostate cancer cell lines, and rat colon and liver tissue (Tammen et al., 
2013; Xiang et al., 2008). 
Maternal diets also affect the offspring phenotypes and disease-risks. Intake of B-
vitamins is linked to change in the susceptibility of offspring to breast and colon cancers 
(Sakatani et al., 2005; Tammen et al., 2013). Protein-restriction in rats has been found to 
epigenetically program the metabolism of offspring. With mothers that were fed low-protein 
diets, decreased methylation along with increased expression of peroxisome proliferator-
activated receptor α in the liver of pups has been demonstrated (Lillycrop et al., 2008). 
Although a similar trend was observed for the glucocorticoid receptor gene, the effect was 
lost in pups of mothers fed a low-protein high-folate diet, demonstrating influences of the 
maternal diet on offspring carbohydrate and fat metabolism. Effects on global DNA 
methylation in genomes of pigs has been demonstrated; with changes in expression of DNA 
methyltransferases in liver and skeletal muscles of new-born offspring being observed during 
high and low protein diets of maternal pigs. Clearly, instead of using the term, ‘you are what 
you eat’, the phrase ‘you are what your parents ate’ seems more suitable (Altmann et al., 
2012; Jimenez-Chillaron et al., 2012; Tammen et al., 2013).  
1.4.3 Life Experiences 
Adult risk factors such as tobacco smoking have been related with DNA methylation 
patterns in tumour tissues. Links between psycho-social factors such as cortisol output and 
perceived stress and DNA methylation have been established, as was early life socio-
economic status (Christensen et al., 2009; Lam et al., 2012; Terry et al., 2008). Exposure to 
chemical and environmental pollutants induces changes in DNA methylation without altering 
the genetic sequence, resulting in epimutation-associated phenotypes. The anti-androgenic 
fungicide vinclozolin, which is an endocrine disruptor, alters methylation patterns in sperm; 
effects of which have been shown to persist for at least four generations (Anway et al., 2005). 
During comparative studies of epigenetic patterns of suicide victims without a history of 
childhood abuse to suicide victims with a history of abuse, increased methylation of the 
promoter of Nuclear Receptor Subfamily III genes was found. This gene encodes neuron-
specific glucocorticoid receptor, which when stimulated inhibits the hypothalamic-pituitary-
adrenal stress response. These results were also found in a study of rats, where pups raised 
with less grooming and licking, as well as less arched-back nursing also demonstrated altered 
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stress response. ‘Cellular memory’ mechanisms cause cells to remember and maintain their 
chosen fates, even long after the stimulus is gone and hence perturbations at early stages have 
long-lasting effects (Liu et al., 1997; Tammen et al., 2013; Tost, 2010).  
Understanding DNA methylation marks and their biological regulation is central to 
understanding and targeting DNA methylation–associated changes. The past few years have 
seen unprecedented advances made in the development of new technologies to improve the 
study of DNA methylation. Advances include improvement in high-throughput methods to 
obtain quantitative data on locus-specific DNA methylation and development of various 
approaches to study DNA methylation on a genome-wide. No single method of DNA 
methylation analysis will be appropriate for every application. Nevertheless, by 
understanding the type of information provided by each method, and the inherent potential 
for bias and artefact associated with the method, investigators can select the method most 
appropriate for their specific research needs. Below is a brief review of these technological 
advances with examples of their adaptation to genome-wide DNA methylation profiling.  
1.5 Mapping of Genome-wide DNA Methylation 
Just as gene expression microarrays transformed and accelerated the study of 
transcriptional regulation, rapidly improving technologies are increasingly enabling 
researchers to assess locus-specific DNA methylation. Since DNA methylation plays an 
important role in many aspects of biology, including development and disease, and is now 
explored in forensics, precedence has been given to developing methods to determine the 
DNA methylation patterns of entire methylomes, individual genes and CpG sites.  
Detailed accounts of methods to detect methylation have been described in numerous 
reviews, however methods can be divided into three main procedures; namely methylation-
sensitive restriction enzymes, bisulfite conversion and affinity purification of methylated 
DNA. Combining these techniques with DNA microarrays and high throughput sequencing 
has made the mapping of DNA methylation feasible on a genome-wide scale (Ishkanian et 
al., 2004). For example, Rollins and colleagues (2006) used restriction enzymes and standard 
cloning and sequencing to analyse over 8 Mb of methylated DNA and nearly 14 Mb of 
unmethylated human DNA. The Human Epigenome Project has used standard sequencing 
approaches to sequence a massive amount of bisulfite-converted DNA from human tissues 
and primary cells, and has identified a substantial number of tissue–specific differentially 
methylated regions (tDMRs) (Eckhardt et al., 2006). 
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1.5.1 Sodium Bisulfite Treatment of DNA Templates 
Standard polymerase chain reaction (PCR) procedures remove methylation markers 
(Madi et al., 2012) and thus cytosine residues may be chemically modified with sodium 
bisulfite. Methylated cytosines remain unchanged whereas unmethylated cytosines are 
converted into uracil. The result is different DNA sequences for methylated and 
unmethylated DNA (Vidaki et al., 2013). Treated DNA is thereafter amplified by PCR using 
specifically designed primers. If DNA is unmethylated, a change in sequence occurs as 
unmethylated CpG pairs are converted to UpG pairs. Uracil will be converted to thymine 
during PCR, with corresponding drop in melting temperature and accordingly, specific 
amplification of methylated or unmethylated DNA may be accomplished by appropriate 
primer design (Madi et al., 2012). A technique known as Methylation-Specific Polymerase 
Chain Reaction (MS-PCR) may be applied to discriminate methylated from unmethylated 
cytosine residues (Lee et al., 2012). Base changes may also be detected by pyrosequencing 
which is a sequence-by-synthesis (enzymatic synthesis of DNA that is complementary to the 
DNA to be sequenced) method that allows monitoring of nucleotide addition and extension of 
DNA sequence in real-time (Madi et al., 2012; Tost and Gut, 2007).  Analysis of the PCR 
product by Sanger sequencing (Eckhardt et al., 2006) or mass spectrometry (Ehrich et al., 
2005; Igarashi et al., 2008), can also be used to quantify the extent of methylation at each 
cytosine. Conversion of DNA with sodium bisulfite allows for quantitative and qualitative 
analysis of CpG sites, but one must take into account the incomplete conversion of DNA 
which may lead to over-estimation of methylation (Frommer et al., 1992; Vidaki et al., 
2013).  
1.5.1.1 Infinium HumanMethylation BeadChip Arrays 
An outgrowth of their genotyping method, Illumina’s HumanMethylation BeadChip 
arrays is best suited for analysis of bisulfite-treated DNA. Fast becoming a popular technique 
to analyse DNA methylomes, the technique enables determining the methylation profiles of 
well over 480 000 CpG sites within the genome (Dedeurwaerder et al., 2013; Wu et al., 
2013). Chemical assays known as Infinium I and Infinium II are employed which are based 
on quantitative genotyping of C/T polymorphisms. These polymorphisms are generated at 
CpG sites by sodium bisulfite treatment with subsequent amplification of DNA. Additionally, 
the bisulfite modification generates a nearly ‘3-letter genome’ which includes the bases 
adenine, thymine and guanine, with the only cytosines remaining being those that are 
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methylated (Bibikova et al., 2009; Dedeurwaerder et al., 2013). Infinium I bears a large 
resemblance to a single-channel microarray. The method uses two probes, each for a 
methylated and unmethylated allele. For these alleles, base extension is identical.  In contrast, 
Infinium II has dual-colour readout. This method relies on one probe for both the methylated 
and unmethylated alleles and base extension is dependent on the methylation pattern of the 
hybridized DNA. Analysis of differential methylation is by statistical tests such as the Mann-
Whitney or t-test. Differentially methylated sites are those that generate a p value below 
certain threshold, such as below 0.05 (Dedeurwaerder et al., 2013; Geiss et al., 2008; 
Houseman et al., 2012).  HumanMethylation BeadChip allows unbiased coverage of CpG 
island regions and genes reaching up to 96% and 99% respectively, as well as CpG island 
shores (these are 2 kb regions upstream and downstream of CpG islands) to determine 
genome-wide methylation profiles (Day et al., 2013; Koch and Wagner, 2011; Lokk et al., 
2014). The chips also target sufficient CpG dinucleotides outside of these regions (Slieker et 
al., 2013). However, analysis and interpretation is more complex than initially considered, as 
it is necessary to filter probes that contain common single nucleotide polymorphisms (SNPs) 
as well as those that may be cross-reactive, due to possible generation of artefactual results. 
Within-array normalization must be conducted which will deal with colour/dye bias 
adjustment, Infinium I and II bias corrections and background correction (Dedeurwaerder et 
al., 2013). The ratio of the PCR products are ascertained using Illumina’s Sentrix Array 
Matrix bead array platform, which can assay up to 1536 sites in 96 samples in a single 
experiment. However, the approach provides less coverage than other array-based methods, 
and necessitates the development and evaluation of a large set of selective primers, thus 
limiting its utility for de novo genome analysis (Zilberman and Henikoff, 2007). 
1.5.1.2 MALDI-TOF MS 
High throughput identification of methylation sites and semi-quantitative 
measurement of their single or multiple CpG locations may be accomplished by Matrix-
Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry, or more commonly 
referred to as MALDI-TOF MS. The method employs base-specific cleavage of DNA 
(Ehrich et al., 2005; Stanssens et al., 2004). A low molecular weight organic acid matrix with 
high absorption at wavelength of the excitation laser contains the analytes which are desorbed 
by a laser pulse. An electric field will extract ionized DNA molecules, which are separated 
due to charge and mass by time-of-flight to the detector. Especially important for DNA 
methylation profiling, a quantitative signal is produced, facilitating determination of relative 
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abundance of products. Mass Spectrometry enables rapid, direct measurements of DNA 
instead of indirect data commonly obtained with other methods. With automated software, 
results may be easily stored. At present, the most frequently employed MS-based approaches 
rely initially on sodium bisulfite treatments followed by PCR amplification with subsequent 
sequencing and mass spectrometry (Igarashi et al., 2008; Meyers, 2012).  
1.5.1.3 Pyrosequencing 
A real-time sequencing by synthesis method, pyrosequencing is often employed for 
DNA methylation analysis of bisulfite-treated, amplified DNA (Shen et al., 2007; Zhang et 
al., 2011a). The method screens the incorporation of nucleotides via the conversion of 
released pyrophosphate into a relative light signal. The visible light is generated and may be 
viewed as peaks on a pyrogram. The heights of peaks are indicative of the amount of 
identical nucleotides that are incorporated into the sequence; a double peak would imply that 
two nucleotides were added. Degree of CpG methylation is software-calculated from the ratio 
of thymine to cytosine (Madi et al., 2012; Tost and Gut, 2007). Mainly employed in the 
analysis of single nucleotide polymorphisms (SNPs), the method is quantitative, reproducible 
and sequencing may be repeated for the analysis of different CpG sites of a single 
amplification product. Automation for large-scale screening is also an advantage. However, 
four enzymes are necessary for accurate detection of nucleic acid sequences, and when this is 
included in other costs of the reactions such as pre-treatment with sodium bisulfite, primers 
and use of software, it is very expensive. A high error rate and long fusion primers which 
may possibly introduce bias greatly contribute to limitations of the method. Moreover, the 
technique is also time-consuming, providing results in about one day hence reducing 
feasibility and practicality (Fakruddin et al., 2012; Tost and Gut, 2007). 
1.5.2 Methylation-Sensitive Restriction Enzyme PCR 
The classic tool of DNA Methylation analysis, Methylation-Sensitive Restriction 
Enzymes employ the use of restriction enzymes that recognize short pieces of DNA and 
cleave the DNA at distinct sites within or adjacent to these sequences. Some enzymes are 
sensitive to methylation and will not cleave the DNA if a cytosine residue is methylated, 
whilst other enzymes are insensitive to methylation and will specifically digest methylated 
DNA (Bird, 1986). An example of an enzyme that is insensitive to methylation is McrBC 
which is an Escherichia coli endonuclease that cleaves methylated DNA on one or both 
strands. Essentially, restriction enzyme-based methods either enrich for methylated DNA or 
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unmethylated DNA. Comparisons are made in one of the following ways; between a sample 
treated with an enzyme or a combination of enzymes and an untreated control; between a 
sample treated with a methylation-sensitive enzyme compared with a control treated with a 
methylation-insensitive isoschizomer or finally, between two test samples, such as two tissue 
types both digested with the same enzyme. Enrichment of unmethylated DNA, by digesting 
methylated DNA or by isolating smaller fragments generated by methylation-inhibited 
enzymes, is particularly useful for analysis of large, heavily methylated genomes. In the 
human genome, about 60-90% of CpG sites are methylated (Kader and Ghai, 2015), and 
hence enriching unmethylated DNA significantly reduces the complexity of the sample. The 
approach is robust, simple and does not require large quantities of DNA. However, efficient 
digestion of template DNA is absolutely vital, or else spurious results may be obtained. High 
quality DNA is necessary for efficient analysis and the main drawback of the method is 
dependence of the availability of recognition sequences that flank the sequences of interest. 
Frequently employed enzymes are the isoschizomers HpaII and MspI, both of which 
recognize the sequence CCGG. Whereas MspI is blocked only by methylation of the outer 
cytosine, HpaII is blocked by methylation of either cytosine. Since in mammalian genomes, 
methylation occurs chiefly in CpG sites HpaII is inhibited and MspI is not (Goll and Bestor, 
2005). Another useful enzyme employed frequently in genomic studies is McrBC, an E.coli 
endonuclease that cleaves between two methylated cytosines in the context (G/A) metC, 
(Lippman et al., 2006; Rollins et al., 2006; Schumacher et al., 2006; Sutherland et al., 1992). 
The two sites can be separated by up to 3 kb, but the optimal separation is 55-100 bp 
(Gowher et al., 2000; Zhou et al., 2002). For this reason, McrBC is an excellent tool for the 
removal of densely methylated DNA. Although less of an issue with McrBC, sequence 
polymorphisms between samples can mimic methylation differences if they affect the 
enzyme recognition site. Therefore, it is safest to use restriction enzymes to compare samples 
that have no or little polymorphism, such as different tissues from the same organism. 
Extensive digestion of genomic DNA by means of the restriction enzyme may be followed by 
multiplex PCR amplification (Figure 1.3) of user-defined genes via gene-specific primers that 
flank the recognition site of the enzyme in use, in an amplification reaction termed 
Methylation-Sensitive Restriction Enzyme Polymerase Chain Reaction (MSRE-PCR)  (Choi 
et al., 2014; Melnikov et al., 2005).  
MSRE combined with PCR may be followed with methylation analysis employing 
standard capillary electrophoresis platforms (An et al., 2013; Choi et al., 2014; Melnikov et 
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al., 2005). MSRE-PCR is ideal for rapid DNA methylation analysis in a user defined set of 
genes, which is based on extensive digestion of genomic DNA with a methylation-sensitive 
restriction enzyme and PCR amplification of surviving fragments. A fragment will be 
designated ‘unmethylated’ if no PCR product is observed after digestion. Alternatively, the 








Figure 1.3: Methylation-Sensitive Restriction Enzyme Polymerase Chain Reaction (MSRE-PCR). Genomic 
DNA is cleaved by the endonuclease, for example HhaI which cleaves at recognition sites (GCGC). This is 
followed by PCR amplification of surviving fragments. If a fragment may be amplified after PCR, it will be 
termed ‘methylated’. If a PCR product is not detected after digestion, the fragment is called ‘unmethylated’. 
 
MSRE-PCR allows simple multiplexing and avoids some of the problems inherent in 
bisulfite conversion, in particular the poorly controlled efficiency of modification, which can 
be incomplete due to incomplete denaturation or partial renaturation of DNA during 
treatment (Rein et al., 1997); comprehensive modification of unmethylated cytosines is 
required for correct readout, which can be influenced by various factors including DNA 
apurinization during bisulfite treatment (Harrison et al., 1998; Reeben and Pryds, 1994; 
Stirzaker et al., 1997) and downstream differentiation of the methylated versus unmethylated 
sequence in many bisulfite-based methods requires two pairs of primers and two PCR 
reactions for each potentially methylated fragment which reduces the throughput of MSP and 
similar techniques, making screening of clinical samples more labour-intensive in bisulfite 
conversions. Finally, the yield of each product depends on the quality of the corresponding 
primers and can result in biased PCR if the amplification efficiency is different (Melnikov et 
al., 2005; Stirzaker et al., 1997). MSRE-PCR is a major detection tool that provides many 
pros. Since analysis may be performed using a universally known method of electrophoresis 
special training is not necessary. Multiple DNA templates may be analysed in a single assay 
(An et al., 2013; Choi et al., 2014). An important feature of the MSRE-PCR assay is its 
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ability to detect promoter methylation in heterogeneous samples, even when methylated 
sequences represent a small fraction of the overall specimen (Melnikov et al., 2005). 
1.5.2.1 Capillary Electrophoresis 
The primary methodology used for separating and detecting short tandem repeat 
(STR) alleles, capillary electrophoresis is applied to numerous fields of research, especially in 
forensic DNA typing. To achieve trustworthy STR typing, three conditions must be met. 
Spatial resolution is needed to separate STR alleles that may differ in size by a single 
nucleotide; spectral resolution is needed to separate fluorescent dye colours from one another 
so that PCR products from loci labelled with different dyes can be resolved; and third, DNA 
sizing precision from run to run must be consistent enough so that samples can be related to 
allelic ladders that are run for calibration purposes (Butler, 2012). These specific 
requirements have been met with a variety of CE systems; and numerous studies have 
validated this with excellent findings. When capillary electrophoresis was applied to analyse 
53 promoters of breast cancer cell lines (MCF-7, MDA-MB-231 and T47D) that were 
subjected to MSRE-PCR using Hin61 enzyme, the MSRE-PCR followed by the CE system 
rectified the methylation status of genes analysed by other techniques (Melnikov et al., 2005).  
MSRE-PCR and electrophoresis is often used in the analysis of tDMRs to 
differentiate body fluids that may be located at crime scenes. When using tDMRs as markers, 
primers are designed to specifically target the methylated region within the tDMR. This is 
achieved by designing primers that flank the recognition site of the enzyme that will be used 
(An et al., 2013; Melnikov et al., 2005). Frumkin and colleagues (2011) subjected 50 DNA 
samples from blood, saliva, semen, and skin epidermis to digestion by HhaI, followed by 
multiplex amplification of specific genomic targets with fluorescent-labelled primers, 
capillary electrophoresis of amplification products, and automatic signal analysis by 
dedicated software (Figure 1.4). The investigation profitably yielded the source tissue of the 
samples. The system was described as fully automatable, provided operator-independent 
results, and allowed combining tissue identification with profiling in a single procedure 
which is quite favourable for forensic applications. Detection of semen and DNA profiling 
were combined into one assay and the ability to detect mixtures of semen and saliva in 
various ratios was demonstrated. The calculated percentage of semen was comparable to the 
fraction of semen in the samples. The same enzyme, HhaI was employed by An and 
colleagues (2013) and Choi et al. (2014); both studies successfully differentiated between 




1.5.2.2 Restriction Landmark Genomic Scanning 
Based on the notion that within any genome, restriction enzyme sites may signify 
landmarks, Restriction Landmark Genomic Scanning (RLGS) is a quantitative method 
(Costello et al., 2002; Song et al., 2005) that allows for high resolution two-dimensional 
display of direct radio-labelled genomic DNA digested fragments. It enables recognition of 
high amounts; possibly over two thousand restriction landmarks in just a single assay. The 
method may be employed to determine epigenetic alterations in tissues, tumours as well as 
cancer cell lines (Ando and Hayashizaki, 2006; Rush and Plass, 2002).  DNA is restricted 
with a rare-cutting enzyme, as methylation sensitivity of the endonuclease activity of the 











Figure 1.4: Detection of sample is performed automatically by measuring time span from sample injection to sample detection with a 
laser placed near the capillary end. Laser light is shone on the capillary where a window is burned into the coating of the capillary. 
DNA fragments are illuminated upon passing the window. Smaller DNA molecules are detected before larger molecules in order of 
migration speed which correlates with length or number of base pairs. Data from CE separations are plotted as a function of the 
relative fluorescence intensity observed from fluorescence emission of dyes passing the detector. The fluorescent emission signals 
from dyes attached to DNA molecules can then be used to detect and quantify the DNA molecules passing the detector (Butler, 2012). 
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Although the system is applicable to all organisms and demonstrates high scanning 
extensibility by use of a combination of enzymes, it is disadvantageous in terms of efficiency; 
as results may be obtained between five days and two weeks. Small amounts of DNA 
samples cannot be analysed as the method requires a few good quality micrograms (Ho and 
Tang, 2007; Smiraglia et al., 2007). Additionally the technique requires use of specific 
software such as Virtual Image-RLGS (VI-RLGS), expensive high-efficiency scanning 
capacity instruments and advanced image analysis systems such as a Fuji BAS2500 system 
(Costello et al., 2002; Ho and Tang, 2007; Okuizumi et al., 2010). 
1.5.3 Affinity Purification of Methylated DNA  
Another method to map DNA methylation uses column- or bead-immobilized 
recombinant methylated CpG binding domain (MBD) proteins or antibodies, specifically 
MeCP2 and MBD2 which are able to bind methylated DNA. This is a rather simple approach 
that exploits the MBD which binds methylated CpGs. A tagged MBD domain expressed in E. 
coli may be affinity purified and the MBD column is subsequently used to purify methylated 
DNA. This can be followed with detection by PCR or microarray hybridization (Cross et al., 
1994; Gebhard et al., 2006). 
On the other hand, a commercially available monoclonal antibody that specifically 
identifies methylated cytosine may be used to immuno-precipitate methylated DNA (Cheong 
et al., 2006; Weber et al., 2007; Zhang et al., 2006; Zilberman and Henikoff, 2007). Immuno-
precipitation of methylated DNA is commonly referred to as Methyl DNA IP or MeDIP. 
Thereafter DNA undergoes shearing by restriction enzymes or sonication, with subsequent 
denaturation to obtain fragments. Short fragments are required for reduction of fragment-
length effects and bias, as well as to improve efficiency and resolution. Then, immuno-
selection and immuno-precipitation can take place using the antibody directed against 5-
methyl-cytidine and antibody binding beads. The technique may be combined with PCR 
(Dalma-Weiszhausz et al., 2006; Vidaki et al., 2013). Importantly, affinity-based techniques 
measure methylation in a given region and thus, a methylated stretch of DNA where 
methylation target sites are scant might be difficult to differentiate from an unmethylated 
region. This is particularly an apprehension with mammalian genomes, where CpG density is 
commonly low and CpG-dense sequences are usually unmethylated (Kreil et al., 2006; 
Weber et al., 2007). A possible method to overcome the limitation, as suggested by 
Zilberman and Henikoff (2007) would be to enrich for unmethylated DNA by isolating the 
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unbound fraction from either affinity method. The ratio of antibody (or MBD domain) to 
DNA would have to be carefully optimized to ensure removal of all methylated DNA. 
Instead, another option is that unmethylated DNA, prepared by McrBC (an endonuclease) 
digestion, could be further enriched by the removal of residual methylated DNA by affinity 
reagents. This approach would greatly reduce sample complexity.   
1.6 Role of Epigenetic Modifications in Gene Expression and Development 
In addition to transcription factors, gene expression and hence development are 
complemented by or are an outcome of epigenetic mechanisms such as post-transcriptional 
histone alterations, histone variants, several non-coding and small RNAs, ATP-dependant 
chromatin remodelling and DNA methylation (Kabesch et al., 2010; Goldberg et al., 2007; 
Mazzio and Soliman, 2012; Reik, 2007). Consequently as differentiation and development 
proceeds, differentiated cells gain epigenetic marks dissimilar to those of pluripotent cells 
and cells of various lineages accrue altered patterns (Jaenisch and Bird, 2003; Reik, 2007; 
Remenyi et al., 2004). Epigenetic mechanisms display elasticity in development; at infant 
stages genes that are only essential for later processes are temporarily repressed by histone 
modifications. Such repression is reversed when the genes are required. At the time of 
development, genes necessary for pluripotency are repressed by DNA methylation and 
histone modifications; these genes may also be repressed in germ cells implying that rapid 
reversal of epigenetic modifications may be required following fertilization. This enables 
activation of genes associated with pluripotency in the subsequent generation. Conversely 
DNA methylation-based silencing of imprinted genes and transposons requires stable 
maintenance at all gametic, early embryonic and adult stages (Lande-Diner and Cedar, 2005; 
Matarazzo et al., 2007; Reik, 2007). Surprisingly, without changes in DNA sequence, 
epigenetic modifications are stably retained after numerous cell divisions and generations 
(Kader and Ghai, 2015; Reik, 2007). 
DNA methylation has an essential regulatory function in mammalian development, 
which is to establish the correct pattern of gene expression, and that distinct DNA 
methylation patterns are tightly correlated to specific chromatin structures.  Holliday and 
Pugh (1975) and Riggs (1975) suggested that maintenance of gene expression patterns 
throughout mitosis was due to DNA methylation. Now, with much substantiation and 
investigative studies to support this proposition, one simply cannot dispute the role of DNA 
methylation in gene expression.   
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1.6.1 Differential DNA Methylation and Gene Expression  
Set aside from the greater part of genomic DNA, the methylation profiles of CGIs are 
a major focus of numerous studies; they represent a portion of the epigenome with 
incontestable regulatory potential. CGIs may often be associated with gene promoters and the 
very first exon; however they are also located in gene regions at the 3ʹ end (Takai and Jones, 
2002). CGIs impact gene expression; a common trend observed is increased methylation of 
promoter CGIs leads to decreased expression or inactivation of downstream genes (Figure 
1.5). Research on DNA methylation has exploited the promoter region with studies mainly 
focussing on this area.  The finding that methylation patterns may be tissue-specific 
encouraged several genome-wide studies; researchers are constantly interested in genome-
wide chromosome segments labelled as tissue-specific differentially methylated regions 
(tDMRs) whose methylation configurations fluctuate according to the cell or tissue type. 
tDMRs likewise induce variation in gene expression and regulation, hence enriching the wide 
role of methylation on human genotype and phenotype (Choi et al., 2014; Rakyan et al., 


























Figure 1.5: Regulation of gene expression by DNA Methylation. (A) The CpG island promoter is 
hypomethylated and enables binding of transcription factors, which is necessary for transcription initiation. (B) 
Methylation of the CpG island promoter inhibits binding of transcription factors and results in gene repression 
(Lim and Maher, 2010). 
 
There are two widely accepted theories to the mechanism of gene silencing. First; in 
the presence of methyl groups, DNA methylation dependent transcription factors are 
incapable of gaining access to promoter regions of cognate recognition sites, rendering the 
gene untranscribed and inactive (Kulis et al., 2013; Yu et al., 2013). This concept was 
demonstrated by Macleod and colleagues (1994) who proved that exclusion of the 
transcription factor Sp1 binding sites that flanked a CpG island permitted access of the sites 
to DNA methyltransferases during development, enabling de novo methylation. According to 
the second theory, proteins consisting of a methyl CpG-binding domain (MBD) bind to 
methyl groups, with subsequent recruitment of histone deacetylases, chromatin compression 
and finally, gene inactivation (Dong et al., 2000; Kulis et al., 2013). Classic examples of 
genes in which the methylation status of CpG-dense promoters correlate with gene silencing 
are MASPIN and GATA2 (Mammary Serine Protease Inhibitor and Transcription Factor and 
Gene encoding GATA Binding Protein, respectively) (Kader and Ghai, 2015).  
Mammals are said to use the elevated methylation of CpG-enriched promoters to 
hinder transcription and ensure that genes on the X chromosome, imprinted genes and 
parasitic DNA are silenced (Cocozza et al., 2011; Jones and Takai, 2001). One must also 
consider that even though the greater parts of CGIs are unmethylated during development, 
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only about half the genes are activated in cells or cell types. Other types of silencing 
mechanisms such as the absence of transcription factors are responsible for inactivating the 
remaining genes (Kulis et al., 2013).  
Disease-associated modifications in DNA methylation have been studied extensively 
and they are starting to play an important role as biomarkers (Hesselink et al., 2014; Heyn 
and Esteller, 2012; Laird, 2003; Silva et al., 1999). Their usefulness as biomarkers can be 
attributed to the fact that DNA methylation patterns are stable over time, easy to investigate 
and cell-type specific (Bloushtain-Qimron et al., 2008; Hesselink et al., 2014). DNA 
methylation profiles, especially in cancer cells seem to be partially based on their cell of 
origin. As tumours with different cells of origin may differ in prognostic outcome and 
therapeutic response, biomarkers distinguishing these groups may have predictive value. In 
addition, since DNA methylation alterations usually occur early in disease and are stable 
throughout disease progression, DNA methylation-based markers may be good candidates for 
early disease detection and monitoring disease development. Additionally, DNA methylation 
can be used to detect cancer recurrence (Brennan et al., 2012; Hanahan and Weinberg, 2011; 
Levenson and Melnikov, 2012; Li et al., 2009; Stirzaker et al., 1997). 
Whilst results of most DNA methylation-based studies indicate repressed 
transcription and expression (Rauch et al., 2009; Lam et al., 2012), there are some 
researchers who have not detected a correlation between DNA methylation and expression 
(Grunau et al., 2000), and contrastingly a few have even found enhanced expression due to 
DNA methylation (Archey et al., 1999). Studies that highlight the unpredictable effect of 
DNA methylation on gene expression are discussed in the sections that follow. 
1.6.1.1 Imprinting 
Imprinting refers to the rare but extraordinary situation when alleles of the same gene 
are expressed unequally in a parent-of-origin dependent manner. This means that some genes 
within the diploid genome are only expressed from alleles inherited from the father, whereas 
some others are only expressed from alleles derived from the mother. Although a rather 
infrequent epigenetic phenomenon in humans; genomic imprinting by DNA methylation 
cannot be overlooked for its role in transport, developmental and regulatory processes in 
humans (Hamed et al., 2012; Ishida and Moore, 2013; Tycko and Morrison, 2002).  
26 
 
The first mammalian imprinted genes that were identified are the H19 and Igf2 
(Insulin-like growth factor II) genes. The hypomethylated status of the control region ensures 
H19 expression solely in the maternal allele. Similarly, Igf2 is only expressed in the paternal 
allele (Bell and Felsenfeld, 2000; Kurukuti et al., 2006).  
Hark et al. (2000) and Kurukuti et al. (2006) confirmed that decreased methylation of 
the control region enables binding of CTCF, the Zinc finger protein. This serves as a 
boundary, prohibiting interaction of Igf2 with enhancers located at the 3ʹ end of H19. On the 
other hand, increased methylation of the control region terminates binding of CTCF, hence 
allowing Igf2-enhancer association and enabling paternal expression of Ifg2. These studies, in 
addition to Bell and Felsenfeld (2000) proved that DNA methylation can govern gene 
expression by tempering with enhancer contact to the gene promoter. 
It has been established that aberrant DNA methylation patterns can lead to a diseased 
state, especially wherein global hypomethylation concurs with gene-specific elevated 
methylation, such as cancer (Ehrlich, 2002; Tost, 2010; Yoo and Jones, 2006; Wentzensen et 
al., 2014). The H19 and Igf2 genes are good models of this and have been thoroughly 
researched in this context on numerous occasions (Goa et al., 2002, Guo et al., 2014a; Tost, 
2010). Elevated methylation levels of the DMR (differentially methylated region) directly 
upstream of H19 is linked to anomalous expression of Igf2 and the H19 genes. The DMR of 
H19 facilitates reciprocal expression at the 11p15.5 locus. High methylation of the DMR 
leads to slackened state of imprinting of Igf2 (biallelic as opposed to monoallelic expression), 
resulting in inexpression of H19 in illnesses such as breast cancer (Ehrlich, 2002; Goa et al., 
2002). 
CGIs in general may be deprived of methylation, however this is not the case of the 
female X chromosome and those in the region of imprinted genes; these may contain 
methylated or unmethylated alleles. Minimal research had focussed upon regions throughout 
the genome rather than solely imprinted genes to study allelic differences in methylation. 
This was prior to an analysis of methylation status of 149 CGIs of the human chromosome 
21q (Yamada et al., 2004). The group employed a method termed HpaII-McrBC PCR, based 
on complementary sensitivities of HpaII and McrBC endonucleases. The method identified 
31 hypermethylated CGIs, five of which were located in the 5ʹ promoter region of genes. 
Analysis of expression in these genes demonstrated that three were testis-specific (when 
compared to peripheral blood leukocytes); namely the HSF2BP (Heat-Shock Transcription 
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Factor II Binding Protein), the DKFZp434A171-LIKE gene and PPP1R2P2 (Protein 
Phosphatase 1 Regulatory Inhibitor Subunit 2 Pseudogene II). Full methylation and 
inexpression of HSF2BP and PPP1R2P2 genes were discovered in blood leukocytes. The 
H2B-LIKE (similar to H2B Histone Family Member S) gene demonstrated ubiquitous 
expression, and this was also the case for ADAR2 (double-stranded RNA-specific Adenosine 
Deaminase). The study identified three allele-specific CGIs designated numbers 59, 112 and 
130; former two of which were maternally methylated. CGI-59 exhibited a scattered pattern 
of methylation; one population in leukocytes demonstrated complete unmethylation, the other 
being maternally methylated. CGI-112 was maternally methylated in leukocytes and five 
tissues of placental DNA. Investigation of leukocytes revealed that the differential 
methylation mostly occurred within a tandem repeat sequence; five sequences that were over 
80% identical. The final allele-specific CGI-130 provided the extraordinary factor; 
irrespective of origin, methylation was confined to a C allele. Upon investigation, some C/G 
heterozygotes had a paternally-methylated C allele, whereas others were maternal. Mono-
allelic methylation was also characteristic of those who were homozygous for a G or C allele. 
This was the initial discovery of allele-specific parental-origin-independent methylation 
(Yamada et al., 2004).  
1.6.1.2 Regulation of ncRNAs  
Accompanying the many roles of DNA methylation is the regulation of microRNA 
(miRNA), which are non-coding RNAs (ncRNAs) believed to partake in human growth and 
development, apoptosis, and connected to disease such as cancer. Widely experimented in the 
context of cancer, an inverse correlation exists between variation of DNA methylation 
patterns and miRNA expression, thereby altering expression of the miRNA target genes 


















Figure 1.6: Regulation of non-coding RNAs (ncRNAs) by DNA methylation. Reduced methylation 
of ncRNA-promoters leads to expression of ncRNA and regulation of the ncRNA target genes.  
Regulation occurs in cis or trans, affecting the host gene, or distant target genes respectively. Dark 
lollipops indicate methylation; white indicates unmethylation (Kulis et al., 2013). 
 
The altered expression of miRNA target genes often leads to tumourigenesis 
(Bierkens et al., 2013; Breuckner et al., 2007; He et al., 2015). In colon tissue, MiR-124a 
(human MiR-124-1 stem-loop, microRNA precursor) generally exists in an unmethylated 
state, however is hypermethylated in colorectal tumours. Inactivation of MiR-124 results in 
the phosphorylation and expression of the target oncogene, i.e. Cyclin D Kinase 6. Hence 
RB1, the tumour suppressor gene is inactivated (Lujambio et al., 2007; Taguchi, 2013). Han 
et al. (2007) demonstrated tight regulation of miRNA by DNA methylation. Contrasting of 
miRNA expression patterns of a DNMT1 and DNMT3b double knockout cell line to its 
parental cell line HCT 116 revealed tight controlling of a fraction of the miRNAs by 
methylation. A futile endeavour to revive activation of miRNA by treatment with 5-aza-2-
deoxycytidine (5-aza) or obliteration of DNMT1 shed light that decreased methylation levels 
was inadequate for reinstating miRNA expression (Han et al., 2007). And yet, only a single 
microgram dosage of 5-aza was proven sufficient to reduce methylation levels of all 
promoters analysed by Shen et al. (2007).  
A medical study of Human Papillomavirus (HPV) by Bierkens et al. (2013) found a 
significant association of DNA methylation and miRNA. Upon analysis of DNA from 
vaginal secretions, promoter methylation-mediated silencing of MiR-124-2 (MicroRNA-124-
2), as well as CADM1 (Cell Adhesion Molecule I) and MAL (T-lymphocyte Maturation 
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Associated Protein) genes were found to be associated with cervical carcinogenesis. 
Increased methylation of these genes intensified the severity of cervical disease. 
Control of miRNA by methylation may not always be detrimental. The decreased 
methylation levels of the Let-7a-3 oncogenic miRNA leads to lung adenocarcinoma. Results 
of the study by Breuckner and colleagues (2007) suggested that aberrant methylation patterns 
of Let-7a-3 would be a possible mechanism of suppression of the oncogene and reduced 
expression of the cancer cell line. Similarly, Saito and colleagues (2006) demonstrated that 
activation of the testis-specific MiR-127 from its promoter in cancer cells is reliant on DNA 
demethylation. MiR-127 is a tumour suppressor and treatment with 5-aza led to the down 
regulation of the target proto-oncogene BCL6. This particular testis-specific MiR-127 was 
also analysed, in addition to MiR-142, 338 and 363, by Schilling and Rehli (2008) who 
detected tissue-specific variation in methylation levels of promoters of various tissues and 
miRNAs.  
1.6.1.3 X Chromosome Inactivation  
In mammals, sex is determined by differential inheritance of a pair of dimorphic 
chromosomes: the gene-rich X chromosome and the gene-poor Y chromosome. To balance 
the unequal X chromosome dosage between the XX female and XY male, mammals have 
adopted a unique form of dosage compensation in which one of the two X chromosomes is 
inactivated in the female.  
This highly co-ordinated sequence of events is controlled by X inactivation centre 
(Xic), except for maintenance. Xic contains Xist, a ncRNA gene.  It is assumed that a region 
at the 3ʹ end of the Xist gene is responsible for a counting step in which the number of X 
chromosomes is measured in relation to haploid autosome sets. Thereafter all but one X 
chromosome is committed to inactivation and it has been shown that the genes Xist and Tsix 
participate in regulating this step. Tsix is the second non-translated RNA, transcribed 
antisense to Xist, encoded by the Xic region.  Xist RNA accumulates along the X 
chromosome containing the active Xist gene and proceeds to inactivate almost all of the other 
hundreds of genes on that chromosome (Clerc and Avner, 1998; Lee and Lu, 1999). Tsix 
mRNA has been shown to be a negative regulator of Xist and prevents its abundant 
accumulation on the active X chromosome. Hence, the initiation of silencing relies on Xist 
expression. However, once silencing is established, maintenance of the inactive X is 
apparently independent of further Xic and Xist function. Following this physical deactivation, 
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large parts of the chromosome are silenced by DNA methylation. For random X inactivation 
maintenance, DNA methylation is the key stabilizing factor, as deletion of maintenance DNA 
methyltransferase DNMT1 results in reactivation of the silenced X in the embryo. In addition, 
DNA methylation is also required to stably repress the Xist gene on the active X chromosome 
(Gartler and Goldman, 2001; Lee et al., 1999; Wutz and Jaenisch, 2000). 
  1.6.1.4 Control of Alternate Promoters 
Contradictory to the popular notion that an inverse correlation exists between 
methylated CGIs at promoter regions and gene expression, the concept cannot be applied to 
CpGs situated within the gene itself. DNA methylation blocks transcription initiation at 
promoters, but elongation of genes remain unaffected (Bird, 1995; Kulis et al., 2013).  
Intragenic CpG methylation (which results from elongation-associated nucleosomes such as 
trimethylated H3K36 (H3K36me3) that recruit DNMTs does not affect the transcription and 
expression process (Hahn et al., 2011). Thus, gene bodies with high methylation are still 
transcribed. However, DNA methylation at intragenic CpGs is believed to control use of 
alternative promoters and create diversity in regulation and expression of main transcripts 
(Ayoubi and Van de Ven, 1996; Kulis et al., 2013; Maunakea et al., 2010).  
In a study by Archey et al. (1999)  to decipher whether CpG methylation at the TGF-
β3 (Transforming Growth Factor-β3) gene locus correlates with promoter use, considerable 
variances in CpG methylation of breast and non-breast cancer cell lines were found to be 
restricted to just a small group of CpGs flanking the alternate promoter. In breast cancer cell 
lines, CpGs displayed hypomethylation, whereas non-breast cancer cell lines demonstrated 
approximately complete methylation. Decreased DNA methylation of the intragenic promoter 
of the breast cancer cell lines led to transcriptional activation; generating mRNA with 
enhanced translational potential. 
Alternate promoters of 61 genes of liver, stomach, spleen, brain and testis tissues were 
studied by Cheong and colleagues (2006). Methylation Dependent Restriction Enzyme 
McrBC-PCR with subsequent bisulfite sequencing showed significant differential 
methylation patterns amongst promoters that belonged to the same genes (Cheong et al., 
2006). Additionally, about 62% of the tissue-biased promoters displayed significant variation 
in methylation profiles among the tissues and tended to exhibit greater variation than non-
tissue biased promoters. These tissue-biased promoters displayed greater methylation levels 
in tissues that they were impartial to, than tissues in which they were favourably expressed in 
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(Cheong, et al., 2006). The pattern of differential methylation levels of a specific promoter in 
different genes detected in this study may not be applicable to all promoters. Schilling and 
Rehli (2008) found contrasting results (with a single exception of the SYBL1 gene); copies of 
genes such as VCX (chromosome X) and DAZL (chromosome 3) share practically identical 
promoter methylation with Y chromosome gene homologues, VCY and DAZ, respectively.   
During a genome-wide analysis employing arrays of BAC clones and the MSREs 
NotI and BssHII, Ching and colleagues (2005) discovered that an intragenic island of the 
SHANK3 gene (structural protein in neuronal postsynaptic densities) displays differential 
methylation patterns and tissue-specific expression. Further investigation of methylation in 
SHANK3 and the homologues SHANK1 and SHANK2 in brain cortex, lymphocytes, heart and 
cerebellum revealed numerous differentially methylated CpGs, however only SHANK3 
methylated CpG islands presented promoters displaying high or low methylation with 
silencing and activation respectively.  Majority of the islands were hypermethylated in blood 
lymphocytes but either reduced or completely nil methylation was observed in brain, heart 
and cerebellum. By performing MSRE-Analysis and Methylation-Specific PCR (MSP), CpG 
methylation and expression of SHANK3 was studied in human neuroblastoma lines; these 
were found to demonstrate low methylation and were thus expressed. An Epstein Barr Virus-
transformed line was abundantly methylated and not expressed (Beri et al., 2007). 
Haploinsufficiency of SHANK3 is well-documented for its partaking in dendritic spine 
morphogenesis and is linked to 22q13 deletion syndrome in humans (Ching et al., 2005; 
Roussignol et al., 2005).   
Rauch and colleagues (2009) compared of expression levels in human male CD19+ B 
cells in testis, heart and brain and confirmed that promoter methylation contributes to gene 
silencing. Three genes in the B cells were found to deviate from the 
hypermethylation/inexpression dogma; despite their highly methylated promoters, PARP12, 
MFHAS1 and MSL2L1 were expressed. Upon 5ʹ rapid amplification of cDNA end transcripts 
alternate unmethylated intragenic promoters were detected, not only representative of the role 
of methylation but also highlighting the origin of cell and tissue-specific alternate transcripts 
(Kader and Ghai, 2015; Rauch et al., 2009).  
Shen and colleagues (2007) performed a comprehensive study of promoter-
methylation of over 6000 genes, a great portion of which were rich in CGIs, and detected 
over 200 genes that displayed unusual hypermethylation in normal peripheral blood. This 
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outlined a clear nonconformity to the philosophy that CGI methylation is restricted to 
imprinted genes and X inactivation (Shen et al., 2007). 
1.7 Tissue-Specific Differentially Methylated Regions (tDMRs) and Control of Gene 
Expression  
Tissue-specific gene expression profiling provides vital information about the biology 
of diverse cell types within an organism and interactions among tissues within multicellular 
organisms. It is widely known that tissue-specific methylation patterns are a critical aspect of 
the regulatory mechanisms of tissue-specific gene expression during different phases of 
development (Doi et al., 2009; Ghosh et al., 2010; Schug et al., 2005; Varley et al., 2013). 
tDMRs demonstrate variation in methylation patterns according to tissue/cell/fluid 
type. Since such regions may be unmethylated in particular tissues, yet display varying 
degrees of methylation in others, they provide distinguishing characteristics between the 
tissues (Choi et al., 2014; Schug et al., 2005; Sugimoto et al., 2009). Examples of these 
tDMRs that provide distinguishing characteristics of tissues have been identified by Eckhardt 
et al. (2006) and Shen et al. (2007). tDMRs have been found to play roles in sex-
determination (Naito et al., 1993), phenotypic variations (Heyn et al., 2013; Fraser et al., 
2012), prediction of age, mortality (Fraga et al., 2005; Marioni et al., 2015) as well as 
susceptibility to disease and respective treatments (Stirzaker et al., 1997; Tost, 2010). It is 
assumed that evolutionary dynamics of CpGs where actively functional tDMRs are found in, 
provide indications for a selective signature (Cohen et al., 2011; Huh et al., 2013). Once 
established, DNA methyltransferases ensure that methylation patterns of tDMRs remain 
fixed. This phenomenon was indeed proved by Eckhardt et al. (2006) in a study that 
described methylation profiles at tDMRs to be specific and stable, thus rendering them 
excellent markers for body tissue identification. Hence it is possible to resolve the 
identification of extracted DNA samples using epigenetic markers. Studies based on the roles 
of tissue-specific differential DNA methylation in tissue-specific gene expression are 
discussed below. 
Many researchers have detected an undermethylated trend in male germ-line tissues 
and fluids. Schilling and Rehli (2008) used a self-developed methyl-CpG immune-
precipitation procedure to determine the effect of methylation profiles of CpGs in promoter 
regions of brain, monocytes and testes upon genes expressed in the respective tissues. The 
study confirmed tissue-specific expression as in all cases, the methylation levels were less 
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than 38%. Additionally, even though most of the testes-specific gene promoters displayed 
elevated methylation levels in somatic tissues, a subgroup of four genes deviated from this 
category. This subgroup of genes did not display differential methylation; promoters of these 
genes were hypomethylated in all tissues however, interestingly activated solely in testes. 
Upon correlation of the data with expression patterns; genes that displayed decreased 
methylation results of 20% and 19% in brain and monocytes, respectively were expressed 
specifically in those tissues. Testes-hypomethylated genes, which were the largest group of 
38%, were indeed specifically expressed in testes. 
A thorough investigation of FLJ40201, ANKRD30A, FTMT, SOHLH2, C12orf12, 
INSL6 and DPPA5 genes in assessment of cell and tissue-specific CGI promoter methylation 
was conducted by Shen et al. (2007). Bisulfite pyrosequencing was used to quantitatively 
analyse testes, sperm, blood, breast, liver, colon, fibroblast and skeletal muscle of human 
origin. All promoters demonstrated hypermethylation, with exception of testes and sperm 
tissues. Sperm DNA presented alleles without methylation, and alleles of testes were either 
almost completely hypo- or hypermethylated. FLJ40201, ANKRD30A, SOHLH2, INSL6 and 
DPPA5 genes were specifically expressed in testes and the same genes, with exception of 
SOHLH2, were identified in sperm. To confirm that this group of genes fit into an exclusive 
class of promoter CGI-associated genes that are methylated and therefore silenced in a tissue-
specific manner, final analysis revealed promoter hypomethylation of below 21% for both 
INSL6 and SOHLH2 placental tissue. The specific hypermethylation/inexpression and 
demethylation/derepression of somatic and germ-line promoters respectively was attributed 
to regulatory sequences (Shen et al., 2007). The proposition spurred from previous findings 
that transcription factors, such as male germ-line specific CTCF-paralogous BORIS (Brother 
of the Regulator of Imprinted Sites) may initiate demethylation of cancer-testis antigens 
MAGE-A1 in somatic cells (Kitamura et al., 2007; Schilling and Rehli, 2008; Vatolin et al., 
2005). 
Eckhardt et al. (2006) piloted DNA methylation profiling of specifically human 
chromosomes six, 20 and 22. Forty-three samples consisting of twelve various tissues were 
selected for the study, which reported the methylation status of nearly two million CpG sites. 
The pursuit of tDMRs spotted a minimal portion located in the 5ʹ regions and exons, but a 
third of all non-coding regions were tDMRs. In the attempt to correlate methylation with 
expression: a total of 53 genes were arbitrarily selected. The intragenic tDMRs did not 
display any association with expression and the same could be said for 63% of the 43 genes 
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that were associated with 5ʹ untranslated regions (UTRs). The rest within this category 
demonstrated an indirect correlation. The OSM (Oncostatin) gene reflected an inverse relation 
to expression which was quite interesting as the gene does not contain a CGI in the 5ʹ region.  
Rakyan and colleagues (2008) provided a significant contribution to studies of 
methylation. The group developed the aptly titled Batman program (Bayesian Tool for 
Methylation Analysis) which provides estimates of absolute levels of methylation following 
MeDIP profiling (Down et al., 2008) and performed an all-inclusive genome-wide tDMR 
quest. The methylation profiles that were deciphered by the group, of 13 different somatic 
tissues including blood, placenta, B cells and lung amongst others; sperm, placenta and the 
immortalized EBV-transformed cell line GM06990 were included in the initial ENCODE 
study (ENCODE Project Consortium, 2007; Rakyan et al., 2008). In contrast to observations 
by Eckhardt et al. (2006) who studied three chromosomes, and a chromosome-wide search by 
Weber et al. (2007) this study by Rakyan et al. (2008) found that most promoters that were 
not associated with a CGI displayed unmethylated profiles. An overall negative correlation 
was detected for methylation and expression, for example in tissues wherein expression was 
observed, the transcription start site was not methylated. Comparing their results to previous 
studies with contradictory results led to the unreciprocated query as to why some promoters 
act irrespective of DNA methylation status, and others depend on methylation for regulation. 
For 16 tissues tested, just above 65% of CGIs associated with promoters were also 
unmethylated. Although located throughout the genome, the promoter-associated tDMRs 
were positioned mostly within those with mediocre CpG densities. tDMRs represented 18% 
of the entire genomic region studied, and conforming to results obtained by many other 
research studies, a considerable percentage of all tDMRs were sperm-specific. These 
displayed hypermethylated profiles in all tissues, and low methylation in mature sperm. 
Intragenic tDMRs displayed a positive methylation/expression profile; the ICAM3 
(Intercellular Adhesion Molecule III) gene presented low methylation at the promoter, but 
hypermethylation in expressed tissues (Rakyan et al., 2008). Additional tDMRs to distinguish 
semen from other tissues were identified by Igarashi et al. (2008), who also detected an age-
related linear correlation of DNA methylation in the testes tissues. 
Rienius et al. (2012) and Lam et al. (2012) established that patterns of methylation in 
blood display greater variations between cell populations rather than between individuals. 
Rienius and colleagues (2012) explored whole blood samples as well as its components. 
Variations were found between the low methylated CpGs of the myeloid cell population 
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(monocytes, neutrophils and eosinophils) and the highly methylated lymphoid population (B, 
C, NK cells). In whole blood as well as individual populations, distributions of differentially 
methylated patterns were mostly intragenic. The unmethylated cell populations were 
subjected to gene ontology enrichment analysis to determine cell-specific functions. Even 
though enrichment for the eosinophils was more typical of general cell functions instead of 
specific, the peripheral blood mononuclear cells (PBMCs) demonstrated cell-specific 
enrichment pathways. This included T cells involved in leukocyte and lymphocyte activation 
and NK cells in molecular signalling cascades. Functions of genes exhibiting variation in 
methylation were highlighted more by the cell-specific profiles of methylation of a set of 
genes according to surface expression. For example, membranous expressions of the CD14 
and CD3 genes which demonstrated elevated methylation profiles in the cells that they were 
unexpressed. Strangely, B cells demonstrated overall largest variations in methylation. As the 
B cells evidently epitomize, methylation patterns found in the study were well correlated to 
cell specific functions. They are involved in numerous critical pathways and roles such as the 
humoral immune response, presentation of antigens, and internalization amongst others, 
which estranges them from T cells. Eighty-five percent of genes that were selected during 
inferences to inflammatory diseases such as asthma, atopic dermatitis, inflammatory bowel 
disease, rheumatoid arthritis, and diabetes were differentially methylated. The TNF and LTA 
genes (Tumour Necrosis Factor and Lymphotoxin Alpha, respectively), which are both 
associated with asthma, proved differentially methylated in the promoter regions only. In 
contrast, TCF7L2 (Type 2 Diabetes Candidate Gene Transcription Factor 7-Like II), 
positioned on the 10q25.3 chromosome, exhibited an analogous methylation profile 
throughout the gene however methylation toward the promoter islands tended to decline. 
Some CpG sites of CD14+ monocytes were specifically unmethylated (Rienius et al., 2012). 
A thorough expression study consisting of 13 assays by Prokunina-Olsson et al. (2009) 
proved that the ex7–8 isoform of TCF7L2 is activated specifically in these monocytes with 
lowest levels of expression in activated T cells and B cells.   
A particular example of research that did not find an association between DNA 
methylation and gene expression was by Grunau and colleagues (2000). The group performed 
a detailed methylation analysis of three X linked genes, namely MSSK1 (Muscle-specific 
Serine Kinase), CDM, SLC6A8 (Creatine Transporter) and the pseudogene ψSLC6A8 in eight 
tissues. The MSSK1 gene presented low methylation patterns in prostate, heart and brain and 
intermediate methylation in kidney, muscle, pancreas and lung tissues but was only 
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specifically expressed in muscle and heart.  In spite of overall strong methylation in brain and 
heart, and hypomethylation in the prostate the CDM gene was expressed in all tissues.  
Similar to MSSK1 and CDM, there was no distinct pattern of methylation and gene 
expression in SLC6A8. Hypomethylation was observed in prostate and the additional tissue 
tested, i.e. testis. A fascinating finding was that even though the methylation profiles of liver 
and muscle were nearly indistinguishable, the gene is inhibited in the latter and specifically 
expressed in the former. The autosomal pseudogene ψSLC6A8 was the only gene that showed 
an affiliation between methylation and gene expression. In addition to the nine tissues tested, 
methylation of white cerebral matter from seven more participants were profiled. High 
intensities of methylation were observed in all, except testis which was completely free of 
methylation. High methylation rendered the pseudogene silenced in all somatic tissues, and 
demethylation enabled testis-specific expression. In somatic cells, the pseudogene ψSLC6A8, 
as well as the PDHA-2 and PGK-2 genes (Pyruvate Dehydrogenase (Lipoamide) Alpha II and 
Phosphoglycerate Kinase II, respectively) are all silenced due to methylation, yet 
unmethylated and active in male germ-line cells. A plausible offering was that transcription 
of testis-specific pseudogenes may be a by-product of the transient demethylation during the 
course of spermatogenesis (Ariel et al., 1991; Grunau et al., 2000; Iannello et al., 1997). It is 
conceivable that lack of correspondence with expression would simply be that the studied 
tDMRs may not have been situated in regions that govern expression. Or rather another 
rational explanation, as suggested later by Illingworth and Bird (2009) the intragenic 
methylation status encumbers gene body transcription with subsequent hindering of parent 
genes. 
Recent studies have identified unorthodox non-CpG methylation patterns in the brain 
(Lister et al., 2013), embryonic stem cells (Lister et al., 2009) and germ cells (Kobayashi et 
al., 2013). Schultz et al. (2015) also detected this occurrence in human post-mortem tissue 
samples including lung, pancreas, sigmoid colon and liver. A negative relationship between 
the DMRs and gene expression was observed in MYH10, which is linked to blood vessel 
function. Hypomethylated DMRs in aorta overlapped with aorta-specific enhancers, 
indicating that decreased methylation levels corresponded with tissue-specific functions. 
Non-CpG methylation was most evident in purified glia, brain neurons and H1 embryonic 
stem cells. Non-CpG methylation correlated with positive expression in H1 cells in the study 
by Lister et al. (2009) but both Lister et al. (2013) and Schultz et al. (2015) found a negative 
correlation, thus the function of non-CpG methylation is not known. (Schultz et al., 2015). 
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Such studies of non-CpG methylation and unknown roles in expression and development 
only highlight the poorly understood role of DNA methylation. 
1.8 Tissue-Specific Differentially Methylated Regions (tDMRs) and its Application 
in Forensic Science  
DNA methylation provides a selective signature has been exploited in medical 
laboratories on a very wide scale to target specific tissues and genes for diagnostic and 
therapeutic purposes. Now much effort has been placed on researching tDMRs for forensic 
science applications by various scientists worldwide.  
Analysing the methylation status of DNA is favourable as in addition to 
demonstrating high sensitivity and specificity, simple extraction and purification methods 
may be attuned with novel nucleic acid technologies. Since the methods target only extracted 
DNA, there is no additional consumption of physical material. This is essential in criminal 
cases when sample quantities are limited. Therefore forensic scientists are not faced with 
decisions of which assays to perform for fear of loss of crucial evidence. A major advantage 
of DNA methylation-based assays in forensic sciences is efficiency, convenience and the  
analysis of multiple tissues in a single assay (An et al., 2013; Choi et al., 2014; Frumkin et 
al., 2011; Gunn et al., 2014; Madi et al., 2012). PCR-based techniques are mainly used to 
analyse DNA from biological material. DNA databases are then scanned for matches to DNA 
profiles found at crime scenes. There are countless commercially manufactured DNA systems 
that have been approved for forensic applications (Gunn et al., 2014; Romeika and Yan, 
2013; Vidaki et al., 2013).   
tDMRs may be employed on their own, irrespective of whether the genes they 
represent are expressed or not to differentiate between body fluids, and gene expression 
studies may also be employed to provide indications of sex, age and ancestry informative 
markers. Hence, application of tDMRs in forensics is discussed below. 
1.8.1 Verification of DNA Samples  
It is generally believed that every trace of DNA found at a crime scene is of biological 
origin, although this is not always the case. This is quite disturbing, especially since DNA 
evidence holds such heavy weight in the courtroom. Frumkin et al. (2010) considered the 
ease of fabricating DNA evidence by criminals, since only basic equipment, minimal 
financial expense and no particular expertise would be necessary. There is an alarming 
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possibility that DNA planted at crime scenes may be overlooked during forensic 
investigations. By artificially synthesizing blood, saliva and skin, mock forensic samples 
were generated. A selection of tDMRs, which were known to be methylated or unmethylated 
at particular regions, were analysed in an authentication assay. Methylation profiles of 
artificial DNA were generated using bisulfite conversion followed by PCR amplification, and 
compared to natural human DNA samples. The research revealed that artificially synthesised 
DNA is consistently unmethylated in all loci whereas biological DNA displays methylation in 
some loci and unmethylation in others. This study, using differential methylation, provided a 
mechanism that enables forensic scientists and judicial law to convict the correct criminal, 
rather than one wrongfully accused. Methylation patterns of tDMRs were used to uphold the 
credibility of trace DNA located at crime scenes, which is unquestionably of extreme 
importance in forensic investigations. 
1.8.2 Identification of Forensically Relevant Body Fluids/Tissues by Analysis of 
tDMRs 
In forensics-based research, one of the first fruitful attempts at DNA methylation-
based tissue identification was by Frumkin et al. (2011) leading to successful differentiation 
between blood, saliva, semen and skin samples. The authors selected 16 loci that displayed 
considerable differential amplification patterns and subjected a mere 1 ng of DNA from 
samples to methylation sensitive restriction enzyme PCR (MSRE-PCR) followed by capillary 
electrophoresis. The tissue identification assay was designed such that loci with low degrees 
of methylation were amplified with low efficiency and demonstrated weak signals on the 
resulting electropherogram, and loci with high degrees of methylation conversely displayed 
strong signals. A methylation ratio for each pair of differentially methylated loci was 
calculated, allowing for discrimination between the biological fluids. Precise identification of 
semen was achieved by low methylation levels of the L91762 gene corresponding with 
hypermethylation of the L68346 gene. Methylation levels of L91762 were much higher in 
blood, saliva and skin. A low ratio of L91762/L68346 was again used to differentiate semen 
samples from other tissues. The methylation ratios of L76138/ L26688 genes were higher in 
semen and skin than in blood and saliva. Identification of skin epidermis was confirmed by 
high ratios of methylation in L91762/L68346 as well as L76138/L26688. The assay positively 
identified tissues from a single source, as well as those in mixtures as a combined semen 
assay was also performed. Semen was mixed in varying ratios with urine and saliva, and the 
absence or presence of semen was detected. 
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In a study by Madi et al. (2012) bisulfite modification and pyrosequencing procedures 
were employed to identify new tDMRs. Focus was directed at particular CpG sites in tandem 
as flanking sites may display differing methylation levels. Methylation levels at single CpG 
sites were compared between samples. Various CpG sites of ZC3H12D, FGF7, C20orf117 
and BCAS4 genes were analysed to display differential methylation profiles of semen, blood, 
and saliva and skin tissue. ZC3H12D and FGF7 successfully differentiated semen from other 
fluids. All five CpG sites tested in ZC3H12D displayed high methylation levels ranging from 
82-100% in blood, saliva and skin, but hypomethylation, below 12% in sperm. Presumed 
initially to distinguish skin samples from others; the FGF7 marker enabled identification of 
semen, with hypermethylation relative to blood, saliva and skin. Blood, in particular white 
blood cells, was positively identified by the C20orf117 locus due to hypermethylation.  High 
levels of methylation of CD4+ and CD8+ lymphocytes relative to skin and sperm were 
demonstrated by Eckhardt et al. (2006). The C20orf117 marker showed great prospective for 
the differentiation of blood from other tissues however, one must consider that accurate 
differentiation from skin was inconclusive in the experiment as only one skin sample could 
be amplified due to errors in bisulfite conversions or primer hybridization. Also with this 
marker the methylation of sperm was particularly low compared to other fluids. Based on the 
outcome of the report by Eckhardt and colleagues (2006), Madi et al. (2012) expected a high 
level of methylation for semen in the BCAS4 marker. However this result was not 
reproduced as sperm displayed less than 20% methylation and saliva displayed highest 
methylation; thus this marker was designated for saliva identification. The same group of 
researchers conducted a study in 2013, testing the same tDMRs and body fluids. Analogous 
results were obtained for the markers; and in addition the study determined mean percent 
methylation of nine year old blood samples, and 20 year old blood and semen samples. 
Interestingly, methylation patterns were observed to be unwavering over such long periods of 
time; percent methylation was the same as samples that were recently collected (Antunes et 
al., 2013; Madi et al., 2012).  
In a study by Lee et al. (2012) DNA methylation profiles of blood, saliva, semen, 
vaginal fluid and menstrual blood were generated by a selection of five tDMRs. tDMRs for 
USP49 and DACT1 genes (Ubiquitin-Specific Peptidase 49 and Dapper 1 Isoform II, 
respectively) were selected as semen-specific markers, and tDMRs for PFN3, PRMT2 and 
HOXA4 genes (Profilin III, Protein Arginine N-methyltransferase II and Homeobox A4, 
respectively) were chosen as blood-specific markers as different methylation patterns in 
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blood, spleen and brain tissues were observed in previous reports by Illingworth and 
colleagues (2008). Bisulfite conversion of DNA followed by PCR and sequencing 
demonstrated differentially methylated patterns in all the tested tissues and fluids. DACT1 
and USP49 were unmethylated in over 90% of clones from semen and hypermethylated in 
almost all blood, saliva, vaginal fluid and menstrual blood clones. The methylation profiles of 
tDMRs did not significantly differ in these tissues and fluids, thus they may be used to 
positively identify semen which will aid greatly in sexual assault cases (Lee et al., 2012). The 
VASA tDMR may also be used to identify semen, as it is hypomethylated in testis and 
demonstrates high degrees of methylation in other tissues. Furthermore, it is expressed solely 
in germ cells (Sugimoto et al., 2009). The HOXA4 tDMR displayed high degrees of 
methylation in blood and female saliva, but there was no considerable difference in these 
methylation patterns to allow accurate differentiation. The HOXA4 tDMR was 
hypomethylated in vaginal fluid and menstrual blood, and the PFN3 gene displayed 
methylation of 65% of loci in vaginal fluid whereas more than 80% methylation was 
observed in other tissues and fluids. PRMT2 was hypermethylated in vaginal fluid and 
menstrual blood, and demonstrated great differences between semen/vaginal fluid, and 
semen/menstrual blood. From this data, the authors suggested that low methylation of 
HOXA4 and high methylation of PRMT2, USP49 and DACT1 may be used to confirm the 
presence of vaginal fluid and menstrual blood. For testing pooled DNA of semen and vaginal 
fluid, the combined use of DACT1, USP49, PRMT2 and PFN3 genes may be employed. 
However any issues regarding mixtures of samples, which are often the case in real-life 
situations, may be alleviated by USP49 and DACT1 genes, as methylation patterns are quite 
distinct in semen compared to the other tissues. The same study also tested aged samples 
whereby all tissues and fluids were left at ambient temperatures for 30 days. A methylation-
specific PCR procedure revealed that all unmethylation and methylation patterns remained 
consistent over this period (Lee et al., 2012). 
An et al. (2013) and Choi et al. (2014) studied the same tDMRs USP49, DACT1, 
PFN3 and PRMT2 for body fluid identification. An and colleagues (2013) demonstrated age 
related changes in methylation (discussed below) and methylation profiles of genes within 
blood, saliva, semen, vaginal fluid and menstrual blood. In addition to MSRE-PCR, the study 
also determined methylation profiles using a less common method known as Methylation 
SNaPshot. The method involves a multiplex individual-base extension, designed using in 
silico bisulfite converted genomic reference sequences for specific genes, with subsequent 
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PCR amplification. Using MSRE-PCR, blood and saliva were found to display high 
methylation yields (indicated as peak height ratios of methylation status of tDMRs to 
amelogenin) in DACT1, followed by PFN3, USP49 and lowest methylation in PRMT2. 
Levels of methylation in DACT1 and USP49 were significantly higher than PRMT2 and 
PFN3 for vaginal fluid and menstrual blood. Analogous results for MSRE-PCR and 
methylation SNaPshot were observed as blood and saliva displayed over 90% methylation in 
USP49, DACT1 and PFN3. Similar results to Lee et al. (2012) were achieved for vaginal 
fluid and menstrual blood as high methylation was observed at USP49 and DACT1, and low 
methylation at PFN3. Yet, in contrast to the same study, semen was found to display 
complete unmethylation at the tDMR of PFN3 using both methods (Choi et al., 2014; Lee et 
al., 2012). Choi and colleagues (2014) employed MSRE-PCR and tested the same fluids 
using tDMRs USP49, DACT1, PFN3 and L81528. Vaginal fluid and menstrual blood, 
analogous to the two previously described reports by Lee et al. (2012) and An et al. (2013) 
displayed low methylation levels at PFN3. The L81528 tDMR was selected as a semen-
specific methylation marker; ten out of the 18 non-vasectomised semen samples generated 
amplicons only at this tDMR. Sensitivity tests were conducted by testing varying quantities 
of DNA produced by serial dilutions. Methylation patterns could be generated for saliva and 
semen with just 500 pg or more of DNA and a measly 250 pg of DNA from vaginal fluid was 
sufficient. Aged samples generated identical results to An et al. (2013) as all fluids were 
analysed except for saliva. Mixtures of saliva and semen, in 1:1 and 1:2 ratios were clearly 
distinguished by amplification of L81528. Mixtures of semen and vaginal fluid was also 
distinguishable as profiles were comparable to that of vaginal fluid when using a general 
DNA extraction method, and a differential extraction method facilitated identification of 
vaginal fluid from the resultant supernatant, and semen from the pellet. A single post-coital 
penile sample and three post-coital vaginal samples were tested for an artificial sexual assault 
case. General DNA extraction methods resulted in two of the vaginal fluid and the penile 
samples showing a mixed sample profile by generating low peaks at PFN3, and a semen-
specific L81528 amplicon. Again, the differential extraction method facilitated a display of a 
profile consistent with vaginal fluid, for the third post-coital sample (Choi et al., 2014). From 
the above studies it is clear that additional tDMRs are required for precise discrimination 
between blood and saliva, and vaginal fluid and menstrual blood.  
Wasserstrom et al. (2013) introduced a kit known as DNA-source identifier (DSI-
semen) for confirmation of semen. The study conducted methylation profiling of five genome 
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loci using DNA from blood, saliva, semen, vaginal fluid, and menstrual blood and urine 
samples. The genome loci were located on chromosomes two, four, eleven and 19. All 
samples that were tested were correctly identified with confidence levels above 0.9999. Real 
forensic casework samples were also analysed and all were in complete concordance except 
for one discrepancy; a single sample displayed semen and non-semen components. However, 
further investigation revealed that the assay was more accurate than even the much-relied 
microscopic analysis which did not detect semen at all. Mock casework samples were also 
correctly recognised; vaginal swabs were mixed with varying quantities of semen. In each 
sample the pellet was classified as semen and supernatant as non-semen. This will enable 
scientists to apply the assay for analysis of internal vaginal fluid samples obtained from 
victims of assault. The DSI-semen assay correctly discriminated between semen and male 
urine, rendering it quite a reliable tool. The assay is user-independent, fully automatable and 
operating the software would not require any special training. Furthermore, there is now 
potential for the development of analogous assays for identification other common fluids and 
tissues found at crime scenes, as the only variable would be primers. The same setup, 
reagents and computer software would be employed.  
Park and colleagues (2014a) performed an excellent pyrosequencing analysis of 2986 
differentially methylated CpG sites of blood, saliva, semen and vaginal fluid. Eight markers 
of 20 body fluids each, namely cg08792630 and cg06379435 for blood, cg20691722 and 
cg26107890 for saliva, cg17610929 and cg23521140 for semen, and cg14991487 and 
cg01774894 for vaginal fluid, were examined. Overall, each marker displayed 
hypermethylation for its respective body fluid with significantly reduced methylation in the 
others. To confidently apply the markers in forensic casework, the group tested various 
concentrations of DNA from each fluid, ranging from 5-500 ng. Inaccurate results were 
obtained only when 5 ng was tested and thus the authors suggested a minimum of 10 ng DNA 
to be sufficient for precise distinction of fluids. Although the study provided a great 
contribution to the application of DNA methylation in forensics, the group did experience 
difficulty in differentiation of methylation levels of saliva and vaginal fluid for a few 
samples. To alleviate this, a suggestion of more reliable DNA methylation markers was 





1.8.3 Sex Determination in Forensics 
Gender identification is vital in forensic sciences not only in sexual assault cases to 
distinguish between criminals and victims but also for investigating remains of mass disasters 
and missing persons cases (Butler, 2012). Numerous techniques have been developed over 
the past few years including visualisation of digested DNA on agarose gels as well as PCR-
based methods (Manucci et al., 1994). Currently differential DNA methylation is employed 
on a regular basis for sex-typing in forensics, and even though DNA methylation profiling is 
relatively new, it was reported long ago (Naito et al., 1993). The study introduced DNA 
methylation into forensic sciences by developing a simple procedure for female sex typing 
based on varying methylation pattern of DXZ4, an X chromosome-specific region. The 
DXZ4 sequence showed low degrees of methylation on the inactive X, but hypermethylation 
on the active X chromosome. The protocol was quite sensitive as due to the high copy 
number of DXZ4 in the genome, only a minute amount of DNA was necessary for accurate 
sex typing. The researchers also suggested application for detecting sex-reversed patients 
(Naito et al., 1993; Vidaki et al., 2013).  
The amelogenin system, first introduced by Sullivan and colleagues (1993) is a 
popular sex-differentiating method. It is extremely sensitive and requires only a single set of 
primers to amplify both X and Y chromosomes, providing equal copy numbers of both 
sequences. Manucci et al. (1994) tested only 1 ng of male DNA in a 100-fold excess of 
female DNA from blood, bone and muscle samples and successfully differentiated between 
male and female donors. An et al. (2013) and Choi et al. (2014) also successfully used 
amelogenin in combination with other tDMRs for sex-differentiation and body fluid 
identification. 
Sarter et al. (2005) reported significant sex differences in four autosomal genes of 
blood, (ESR1, MTHFR, CALCA and MGMT) and suggested that sex is at least as strong a 
predictor of methylation in certain genes as is age. However, later on, the study by Eckhardt 
and colleagues (2006) did not find any statistical difference between male and female 
samples.  
The study by Boks et al. (2009) revealed independent links of DNA methylation with 
gender; all X chromosomal probes were extensively more methylated in females than males. 
According to Shen et al. (2008) this pattern of methylation loci on X chromosomes could 
primarily be due to the X inactivation mechanism in females. Numerous autosomal loci of 
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CpGs were also found to display differential methylation in females (Boks et al., 2009), and 
this was also demonstrated previously (El-Maari et al., 2007) signifying that gender-
dependent methylation may not be an uncommon occurrence. Overall, the variation in levels 
of methylation between the two sexes were not too high, but still considerable.  
Zhang and colleagues (2011a) examined LINE1 (Long Interspersed Repeat Sequence) 
of peripheral blood of males and females. This study reported a 1.8% difference in global 
methylation between the two sexes, with females being lower. This is a notable pattern; 
Hsuing et al. (2007), and Zhu et al. (2012) found a 1.17% and 0.8% methylation difference, 
respectively, between males and females with females being lower. In addition to the 
proposed idea that X chromosome inactivation mechanisms diminish the resources necessary 
for methylation of autosomal loci, it is also believed that low degrees of total methylation in 
females may be due to consumption of varying amounts of one-carbon nutrients such as 
methionine and B vitamins, or dietary folate (Shen et al., 2008; Zhang et al., 2011a).  
In the research study by Lee et al. (2012), a tDMR for the HOXA4 gene was 
hypermethylated (above 90%) in male saliva, yet displayed below 53% methylation in female 
saliva. Additionally, low methylation levels of the HOXA4 were generated upon testing 
female menstrual blood, with corresponding high methylation of PRMT2, USP49 and 
DACT1. However, cross-reactivity with other fluids may interfere with results and hence this 
must be considered during application in forensics. Perhaps other confirmatory methods, such 
as use of one or more of the mentioned tDMRs or new markers, may be employed in 
conjunction.  
 
1.8.4 Ancestry Informative Markers of Fluid/Tissue Donor  
Direct genotype–phenotype relations are not easily accounted for since majority of 
variant sites are located in noncoding loci (Kilpinen and Dermitzakis, 2012). Nevertheless, 
genome-wide association studies have endeavoured to establish genetic associations solely 
with differences between populations (Bell et al., 2011; Fraser et al., 2012; Lam et al., 2012); 
diseases (Abdolmaleky et al., 2006; Dunn et al., 2014; Tost, 2010); and the response to 
external stimuli (Jimenez-Chillaron et al., 2012; Terry et al., 2008). In these contexts, the 
epigenetic network is expected to add layers of regulation, suggesting interplay between the 
genotype and epitype in gene regulation and phenotypic variation (ENCODE Project 
Consortium, 2012). Examples for epigenetic differences between individuals are rare and 
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mostly, but not exclusively, confined to the level of DNA methylation (Rakyan et al., 2002). 
With new advances in technology, other than differentiating and finding links between 
individuals based on gender, age and diseases, great progress has been made in determining 
ones ancestry informative characteristics using differential methylation.  
Research of different racial groups has illustrated distinguishable patterns of DNA 
methylation, gene expression and the onset of disease (Adkins et al., 2012; Kuzawa and 
Sweet, 2009). Hypermethylation of the tumour-suppressor gene, PYCARD (~62% vs. ~22% 
in benign controls) was detected in non-Black prostate cancer patients, yet this was not 
observed in Blacks (67% vs. 58% controls) implying that the gene is hypomethylated in non-
tumorous tissues of non-Blacks, however upon the onset of the disease increases to the 
general level that is present in tumorous and non-tumorous tissue of Blacks (Adkins et al., 
2012; Das et al., 2006). Mokarram and colleagues (2009) detected higher levels of 
methylation in three colorectal cancer candidate genes ICAM5, GPNMB and CHD5 
(Intercellular Adhesion Molecule V, Glycoprotein Transmembrane and Chromodomain 
Helicase DNA Binding Protein V, respectively) of Blacks as opposed to Iranians, accounting 
for the higher incidence and mortality rates of Blacks.  
A study quite relevant to discriminating ancestry informative markers which is highly 
applicable to forensic sciences, observed differences in Blacks, Whites and Hispanics in New 
York City birth cohort until mid-life. Blood samples were collected and analysed by [3H]-
methyl acceptance assay which involves incubating DNA with [3H] SAM in the presence of 
SssI prokaryotic methylases. This will methylate unmethylated CpG sites, and is quantified 
followed by statistical analysis relevant to the study. In the birth record, Blacks were found to 
display lower levels of methylation than Whites and Hispanics. This association between 
DNA methylation and the groups did not alter after adjusting life course variables. Other 
factors such as prenatal, early life, adolescent and adult life variables; namely ethnicity, 
prenatal smoke exposure, birth length and weight, smoking, amidst others were considered. 
Exposure to prenatal smoking was associated with considerably elevated levels of DNA 
methylation however insignificant results were obtained for smoke exposure later in life. 
Overall, Blacks demonstrated lowest levels of methylation (Terry et al., 2008).  
Non-Hispanic Blacks, Non-Hispanic Whites and Hispanics were also studied by 
Zhang et al. (2011a) who examined LINE1 (Long Interspersed Nuclear Element) of 
peripheral blood. The correlation of leukocyte DNA methylation to ageing, behavioural and 
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environmental factors between different ethnic groups was also described in this study. 
Analogous to Terry et al. (2008) Blacks displayed lowest percentage methylation of 73.1%, 
Hispanics 74% and Whites 75.3%. Females exhibited lower overall methylation compared to 
males, and obesity similarly demonstrated an inverse relationship with global methylation. 
There were no observed differences in methylation when adjusting for variables such as 
smoking, alcohol, body mass index and education (Zhang et al., 2011a).  
Whilst research studies demonstrating reduced methylation in healthy tissues and 
genes of Blacks (Adkins et al., 2012; Terry et al., 2008; Zhang et al., 2011a) may provide 
significant contributions to long-term disease studies and applications such as forensics, this 
is not a general trend as exemplified by Straughen et al. (2015) who examined Igf1 of the 
mononuclear fraction of umbilical cord blood to model the role of methylation as a mediator 
between birth weight and race. This informative study revealed that higher methylation levels 
in Black neonates accounted for variation of Igf1 expression thus resulting in a substantial 
decrease in birth weight when compared to non-Black counterparts. Studies of methylation in 
Blacks particularly, are unpredictable in different genes and fluids, necessitating further 
exploration to apply the concept of reduced methylation with confidence. 
Elaborate investigations by three groups of researchers have gained insight into 
differential methylation and expression associated with HapMap lymphoblastoid cell lines 
(LCLs) with varying results (Bell et al., 2011; Fraser et al., 2012; Moen et al., 2013). 
In a study aiming to relate genetic variation and differential methylation, Bell and 
colleagues (2011) analysed promoter methylation of 13 236 genes of 77 human LCLs from 
the HapMap Yoruba Collection. Yorubans are an African ethnic group, chiefly of Nigerian 
descent. As most studies have observed, a lower level of methylation was detected near the 
promoter regions of genes as opposed to intergenic regions (Cheong et al., 2006; Schilling 
and Rehli, 2008; Shen et al., 2007). A remarkable number of 11 657 genes displayed a 
negative correlation between DNA methylation and expression; a reduced methylation level 
near transcription start sites was identified with those genes that were highly expressed. The 
group confirmed that methylation and histone modifications are not mutually exclusive in 
regulation of gene expression; a resilient negative correlation was detected between histones 
that target expressed genes and methylation levels. Lack of methylation positively correlated 
with histones involved in activating genes, such as H3K9ac, H3K27ac and H3K4me3. These 
particular histone marks, along with a few others were observed to exhibit lower levels of 
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differential methylation in HapMap Yoruban LCL samples when compared to those of 
European origin by Moen et al. (2013) who profiled differential methylation and implications 
for traits between the two populations. Overall, greater differential methylation was observed 
intergenically rather than at transcription start sites. As exemplified by the STK39 gene 
(Serine Threonine Kinase 39), European samples exhibited higher differential methylation in 
the regions 1 kb upstream of transcription start sites to the first gene body quantile, with 
fairly depleted regions towards the 3ʹ UTRs, whereas the opposite was true for the Yoruban 
population who exhibited elevated differential methylation more towards the 3ʹ UTRs. A 
negative correlation between promoter-methylation of cg27270541 and expression levels was 
eminent for the PLA2G4C (Phospholipase A2, group IVC) gene in the European population, 
contrasting with high expression levels when elevated methylation was detected in the gene 
body (Moen et al., 2013).  
A further step was taken to decipher if genetic variants conveyed inter-individual 
variation in methylation levels and in the resulting expression. The Yoruban LCLs assessed 
by Bell and colleagues (2011) displayed an association between methylation Quantitative 
Trait Loci (meQTL) and gene expression. A substantial number of genome-wide meQTLs 
that were identified demonstrated an indirect relationship between distance and target CpG 
sites, suggestive of a cis-acting pattern. A particular population-specific meQTL noted by 
Moen et al. (2013) was the G allele of rs28544087; associated with higher methylation level 
of cg09307883 in ANAPC2 (Anaphase Promoting Complex Subunit II) in the Yoruban, but 
not European LCLs.  
One hundred and eighty SNPs that were meQTLs demonstrated enrichment for 
expression, for example the single nucleotide polymorphism (SNP) rs8133082, which was a 
meQTL and expression QTL (eQTL) for C21orf56. Located on chromosome 21, the gene is 
hypothesised to serve as a predictor of inter-individual variations upon exposure to DNA 
damaging agents and partakes in the reduced sensitivity of LCLs to N-methyl-N'-nitro-N-
nitrosoguanidine (MNNG), an alkylating agent (Bell et al., 2011; Fry et al., 2008). Initially, 
Bell and colleagues (2011) found ample association between methylation and numerous 
SNPs that were eQTLs for genes with reduced signals; indicative of elevated methylation 
mediating lower gene expression. However, upon re-analysis of the eQTL results and 
considering methylation as the regulator, methylation proved accountable for 10% account 
for the effects of expression associated with SNPs.  
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Nevertheless, the investigation by Moen et al. (2013) accentuated the concept of 
methylation playing a major role; T allele of meQTL rs10779587 exhibited high methylation 
levels of cg01313622, concomitant with reduced expression of FLVCR1 (Feline Leukaemia 
Virus Subgroup C Cellular Receptor I). T allele was less frequent in the Yoruban samples, 
and thus higher expression levels were obtained. A sizable number of meQTLs were linked to 
racial differences in neurological, metabolic and autoimmune disorders. For example, three 
SNPs associated with rheumatoid arthritis, multiple sclerosis and prostate cancer were 
annotated as a meQTL for a CpG located intergenically within LOC285830 (Homo sapiens 
hypothetical LOC285830). All three SNPs demonstrated a higher risk allele frequency in the 
European LCL samples as opposed to Yoruban.  
Additionally, another study based on HapMap LCLs between European and Yoruban 
populations by Fraser et al. (2012), detected an array of differentially methylated CpG sites 
within, as well as between populations. The group employed HumanMethylation27 BeadChip 
arrays followed by pyrosequencing to determine methylation of 27 578 CpG sites near 
transcription start sites of 14 495 genes. The study population comprised of 30 trios 
(consisting of father, mother and offspring) of the Europeans and 30 trios of families of the 
Yorubans. Methylation profiles of approximately 30% of CpG sites, which is over a third of 
the genes examined, differed between the populations. Specifically, 14% of sites differed in 
methylation by an average of over 5%, and 3.9% of sites differed by over 10%. The 
differences were small but somewhat significant, and consistent with findings of Bell and 
colleagues (2011). DNA methylation was liable for little differential gene expression that 
existed between the groups. Delving more into the reasons for observed variances between 
the populations, the group deciphered the role of additive genetic variances to methylation of 
CpG sites, also termed heritability. Measuring the link in methylation levels between the trios 
of parents and offspring revealed transmissible methylation at about 900 CpG sites in the 
Yoruban population, and over 700 in the European LCLs were discovered. This was 
implicative of genetic control of methylated polymorphisms being, albeit less transmissible 
than expression, quite common.  Since failing to establish an analogous pattern of heritability 
between the populations; divergences impacting methylation were further investigated by 
comparing the SNPs linked to methylation of CpG sites in the populations, as genetic and 
environmental interactions may lead to reduced heritability. Eighty-six and 49 mSNPs were 
identified in the Yoruban and European groups respectively which accounted for 36-92% 
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observed differential methylation. Also comparable to the results from Bell and colleagues 
(2011) most of the mSNPs were not in correspondence with eSNPs.  
Furthermore, inconsistencies in allele frequencies between the populations may have 
led to lower heritability. Upon exploring whether population or single SNP genotype were 
dominant contributors of methylation of each site, about 55% of the differentially methylated 
sites exhibited a stronger association with a cis-acting SNP genotype rather than with 
population. This was suggestive of genetic variants being responsible for majority of the 
observed population specificity (Fraser et al., 2012).  
In a study also concentrated on LCLs of blood, Heyn et al. (2013) attempted to 
identify methylation differences between three human populations, and provided a link 
between the methylation and the possible natural phenotypic variation that occurs. Research 
involved LCLs and naive blood of unrelated, healthy African Americans, Caucasian 
Americans and Han-Chinese Americans. In total, 439 CpG sites were found to display 
differential methylation between the three populations. The study associated this differential 
methylation with defining characteristics such as response to various stimuli, disease 
frequencies, sensory perception and appearances. Analysis of differential DNA methylation 
was incorporated into genome-wide association studies; and resulted in a direct relationship 
between differential methylation of CpG sites of the HLA-DPA1 locus. This locus is strongly 
correlated with chronic hepatitis B (HBV) infection. HBV infection risk alleles are usually 
enriched in populations such as Africans or Asians as they have higher frequency of diseases. 
Ten HBV-infection SNPs displayed high correlation with 17 CpG sites in HLA-DPA1. 
Results revealed that the risk alleles were linked to variation in DNA methylation, showing 
high incidence in the African and Asian populations. Risk alleles were related to the high 
degree of methylation of the HLA-DPA1 promoter and hypomethylation of the gene body and 
this is associated with low levels of gene expression (Heyn et al., 2013; Jones, 2012). Gene 
repression of HLA-DPA1 was associated with DNA methylation in these two populations by 
identifying the risk alleles that mediate this phenomenon which spurs variation in 
presentation of cell surface receptors, altered binding of HBV and risk of infection (Heyn et 
al., 2013). This warrants further research into these particular CpG sites; it may be possible 
that they appear specifically in other forensically relevant fluids and tissues.  
It is clear that by only analysing LCLs, no final conclusion could be drawn on the 
effect of methylation upon expression between the European and Yoruban populations, 
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demanding further investigation. Perhaps a panel of methylation-specific markers may be 
chosen with simultaneous analysis of other body fluids in combination with the LCLs. This 
may provide more substantial results. 
Although using differential methylation to distinguish between certain populations 
seems quite promising; it requires much consideration. Due to legal and ethical issues of such 
applications, using these ancestry informative markers requires much consideration. 
Predominantly, the possibility for misapplication as an ancestry informative marking method 
remains an extensive concern as discussed by Koops and Schellekens (2008) and M’charek et 
al. (2012). Such reports emphasize that phenotyping should be allowed for externally 
perceptible traits, such as hair colour and non-sensitive behavioural traits, like left-
handedness or a preference for smoking. It should not be allowed for susceptibilities for 
diseases and for other sensitive information like an inclination toward homosexuality or 
aggressiveness. The intermediate category of not too sensitive traits may be certified, for 
example, for early apparent medical disorders, like albinism or teenage-onset alcoholism. 
Ethnic origin and surname phenotyping are also attuned with fundamental rights, provided 
measures are taken to eliminate the risk of discrimination. Also, informing the suspect of 
forensic phenotyping would be necessary, but it should be left to the suspect to request the 
actual phenotyping results. 
1.9 The Current Status of Forensic Fluid and Tissue Identification  
Forensic analysis of biological fluids is an indispensable tool in the identification of 
suspected perpetrators and the exoneration of innocent individuals in criminal investigations. 
However often in forensic cases, establishing the origin of the body fluid found at a crime 
scene is required. In these specific situations, the presence of a suspect at a crime scene is not 
in dispute. Instead, it is the finding of a specific body fluid such as blood, saliva, or semen 
that can be used to determine that a violent act has taken place. The discovery of such body 
fluids may significantly affect the outcome of a case (Madi et al., 2012). Often merely a 
minute quantity of biological fluid is enough to break a case and ability to identify evidence 
at a crime scene in a non-destructive manner is imperative in order to preserve the sample and 
DNA evidence for further use.  
In particular, body fluids such as blood, saliva, semen and vaginal fluids are often 
found at crime scenes; however others such as sweat and urine also serve as informative 
sources of evidence (Nakazono et al., 2008; Quinones and Daniels, 2011; Virkler and 
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Lednev, 2009; Wickenheiser, 2011). Each of these fluids contains DNA and thus it is 
imperative that great precautionary measures are implemented when handling such crucial 
aspects of investigations. The detection and identification of body fluids in a criminal 
investigation are important in forensic science. Determining whether a body fluid is present 
and later identifying it allows further testing of protein, RNA and DNA components 
(Pandeshwar and Das, 2014; Virkler and Lednev, 2009).  Since the technique that is used 
dictates the levels of purity and integrity for further analysis, a final elaboration is provided 
that will explain the difficulties that one may encounter by employing conventional methods 
to differentiate between the four most forensically relevant human body fluids. 
1.9.1 Conventional Methods Employed to Identify Forensically Relevant Body 
Fluids 
Several presumptive and confirmatory tests have been developed for differentiating 
between saliva, blood, semen and vaginal fluid (Virkler and Lednev, 2009). Presumptive tests 
are used as screening tests but tend to have specificity limitations. Confirmatory tests are 
used for absolute tissue identification and can be useful in reconstructing the events of a 
crime. Confirmatory tests based on proteins and mRNAs are associated with lack of stability 
issues (An et al., 2012; Haas et al., 2009; Zubakov et al., 2008). Existing presumptive and 
confirmatory tests are applicable to only specific biological fluids. The investigator would be 
required to make a choice as to which test to perform, based on which fluid is most likely to 
be identified; necessitating a precise method in which the fluid may be identified irrespective 
of the nature (Virkler and Lednev, 2009).  
  1.9.1.1 Saliva 
A popular presumptive test used for saliva is based on amylase, of which two different 
forms may be found in the human body. Amylase found in saliva, breast milk and 
perspiration is coded by the AMY1 locus on chromosome one, while amylase found in the 
pancreas, semen, and vaginal secretions is coded by the AMY2 locus. Although AMY1 is 
found more in saliva than any other fluid, it can still only give presumptive information since 
it is not exclusive to saliva (Greenfield and Sloan, 2003; Quarino et al., 2005). The starch–
iodine test may also be employed however; competing proteins such as albumin and gamma-
globulin in blood and semen will also break down iodine to form a false positive result 




Methods frequently employed for detection of blood primarily rely on the peroxidase-like 
activity of the haeme unit of haemoglobin in blood. Tests for blood include the Kastle-Meyer 
phenolphthalein test however potential interferences and only probable identification 
represent limitations; and the chemi-luminescence of luminol which has once been reported 
as mutagenic and thus is not recommended due to uncertainty of safety, as well as being 
limited to use only in dark environments (Bevel and Gardner, 2002; Virkler and Lednev, 
2009).  
  1.9.1.3 Semen 
Semen is one of the most prevalent body fluids found during criminal investigations, and 
in sexual assault cases its conclusive identification is usually required to corroborate the 
alleged crime (Romero-Montoya et al., 2011). A common technique is microscopic 
identification of sperm, which may be specific but it impossible to identify sperm cells in 
cases where the evidence is in low amount or quality, due to degradation. Specificity is also 
difficult in bacterially-contaminated samples. Microscopy is expensive, requiring skilled 
personnel, time-consuming and is not amenable to automation. Detecting specific proteins 
found in semen and sperm may also be attempted using the prostate-specific antigen (PSA) 
test but high sensitivity comes with a risk of false positives. In addition, protein-based assays 
might suffer from low sensitivity in relation to DNA-based assays because proteins are 
generally not as stable as DNA under most environmental conditions. Hence a negative PSA 
result might be due to degradation of the protein, and not necessarily indicate absence of 
semen (Virkler and Lednev, 2009; Wasserstrom et al., 2013). Alternative approaches 
developed include mRNA profiling and Raman spectroscopy, which are applicable to other 
fluids as well however limitations include relative instability of mRNA and lack of specificity 
for spectroscopy-based methods (Danaher et al., 2015; Haas et al., 2009; Juusola and 
Ballantyne, 2007). 
1.9.1.4 Vaginal Fluid  
Although not as common at crime scenes as blood, semen, and saliva; vaginal fluid 
evidence can play an important role in sexual assault cases. However, there are not many 
tests available to test for the presence of this fluid mainly because it is not very well defined. 
The constituents can change based on the menstrual cycle of the female, and this makes 
testing for specific components very difficult (Virkler and Lednev, 2009). One test is based 
on the detection of glycogenated epithelial cells using a Periodic Acid-Schiff (PAS). 
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However, since glycogenation varies based on the menstrual cycle; this test is not very 
reliable. Also, some females will likely show no glycogenated cells if they are pre-pubescent 
or postmenopausal, so this technique can easily have false negative results. False positive 
results can emerge from the mouth or urethral tract in males. Moreover, the test uses a large 
amount of sample and will destroy valuable DNA evidence (Greenfield and Sloan, 2003). 
Since citrate and lactate are found in both semen and vaginal fluids; comparisons of 
concentrations of these acids have been made in the past to differentiate between the two 
fluids. However, these carboxylic acids are present, albeit in small amounts, in saliva hence 
limiting use of this relatively simple method (Martin and Cheshire, 1986). 
1.9.2 The Use of Biological Markers  
In addition to difficulties encountered with use of traditional methods, recently 
developed methods also pose various limitations. Whilst great efforts are being made to 
preserve biological fluids for further analysis, there are also issues associated with the 
biological markers that are tested. These are further elaborated. 
1.9.2.1 Protein-based Biomarkers  
Protein-based biomarkers have mainly been employed for the diagnosis and 
treatments of diseases. The detection of medically relevant proteins has long been used as a 
biomarker in the field of diagnosis, for example detection of cardiac troponins serve as 
inference to cardiac disease and carbohydrate deficient transferrine indicates alcoholism 
(Forch et al., 2009). However in forensic contexts, most protein-based techniques are not 
amenable as they are based on presumptive or confirmatory techniques. Such tests depend on 
the stability of target molecules for the tissues of interest, lead to consumption of sample, 
degradation and irreproducibility in laboratories. Protein biomarkers are unstable and have 
been found to undergo rapid decomposition during downstream processing such as autolysis 
and putrefaction. This results in concentrations of proteins being below the detection-limits, 
leading to false results (Mondini et al., 2009; Park et al., 2014a). Protein-based assays rely on 
intact and functional proteins which will not work on degraded and environmentally-
damaged samples. Especially in sexual assault cases, proteins present many drawbacks. To 
date even with many attempts, proteins that are unique to vaginal epithelial cells and buccal 
epithelial cells have not been validated. Whilst semen contains polymorphic protein markers, 
they may not be used in forensic analysis. They are recovered in too small amounts and are 
generally of low quality, making them unreliable. Discrimination power of protein systems 
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are low, so individualization is not promising (Budowle and Daal, 2008; Rifai et al., 2006). 
Cross-reactivity with other tissues and biomolecules also decrease specificity. Furthermore, 
certain proteins require different methods of detection. This means too many chemicals must 
be purchased and various techniques have to be employed; hence eliminating the attention of 
protein markers in forensic laboratories today (Madi et al., 2012; Frumkin et al., 2011). 
1.9.2.2 RNA-based Biomarkers 
Gomes et al. (2013) developed a pentaplex system to identify saliva and skin by 
analysis of two saliva genes STATH and HTN3 (Statherin and Histatin III, respectively) and 
three skin genes LOR, LCE1C and CDS (Loricrin, Late Cornified Envelope 1C and 
Diacylglycerol Synthase (Phosphatidate Cytidyltransferase) 1, respectively). The group 
reported LCE1C as most sensitive. Multiplexing in RNA techniques (Figure 1.7) is limited 
due to dependence on the number of fluorophores (Sijen, 2014). Interpretation of qPCR data 
requires normalization with reference genes. This presents a limitation since reference genes 
differ in expression levels between cell types. Also, most house-keeping genes used as 
controls for normalization and gene expression analysis such as GADPH (Glyceraldehyde-3-
Phosphate Dehydrogenase) exist in the human genome as processed pseudogenes (Juusola 
and Ballantyne, 2007).  
Several markers for vaginal fluids, such as membrane-associated mucins have been 
rendered unreliable due to expression in salivary glands (Liu et al., 2002; Nussbaumer et al., 
2006). Nussbaumer and colleagues (2006) found specificity of KLK (Kallikrein) for semen 
however HBA (Haemoglobin Alpha) was detected in blood but also showed a weak reaction 
in saliva; and MUC4 (Mucin 4) was not specific for vaginal fluid or saliva. Useful mRNA 
markers have been identified for skin (Gomes et al., 2013; Visser et al., 2011), saliva, blood, 
semen (Haas et al., 2014; Zubakov et al., 2011), sweat and urine (Xu et al., 2014). Since a 
marker employed for saliva is also present in nasal mucosa, only a partially specific marker 
for nasal secretion and nasal blood was found by Sakurada et al. (2012). However both the 
specificity and sensitivity vary for all of these candidates. Even though approaches of mRNA 
detection and analysis are constantly being developed, mRNA itself is not stable, being 
vulnerable to variation of temperature and humidity (An et al., 2012). Moreover, tissue-
specific expression of mRNA in humans is not absolute and mRNAs exhibit low levels of 


















Figure 1.7: Commonly employed techniques for body fluid identification using RNA. Procedures entail end-
point PCR which requires capillary electrophoresis for final analysis, or RT-qPCR in which the CT value (cycle 
threshold) is inversely proportional to the amount of RNA in the tested sample.  
 
Hanson and colleagues (2009) introduced miRNA expression analysis into forensics 
by studying over 400 miRNAs of saliva, blood, semen, vaginal fluid and menstrual blood by 
RT-qPCR. Nine miRNAs, namely MiR-412, MiR-372, MiR-205, MiR-451, MiR-135b, MiR-
10b, MiR-124a, MiR-16 and MiR-658 exhibited differential expression in the fluids. Later, 
Zubakov et al. (2010) performed detailed profiling of 718 miRNAs in these body fluids by 
microarrays. Fourteen candidates were identified for potential forensic application however 
when a validation by RT-qPCR was performed, only blood and semen were comparable, but 
still not the same. Inconclusive results were found for saliva, vaginal fluid and menstrual 
blood. Whilst studies exemplify use of miRNA expression to differentiate body fluids, it is 
evident that inconsistent patterns are found when employing different technologies. 
Additional needs to enhance specificity are necessary in miRNA assays since universal 
primers greatly reduce specificity (Baker, 2010). Similar to mRNA assays; since RT-qPCR is 
employed in miRNA detection and quantification, appropriate reference targets are necessary 
for normalization of miRNA expression. These would include stable and abundant expressed 
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small ncRNAs such as snRNAs (small nuclear RNAs that mediate pre-mRNA processing) or 
snoRNAs (small nucleolar RNAs that mediate chemical modification of other RNAs) (Sauer 
et al., 2014; Wang et al., 2013). There is no unanimity in appropriate small RNA genes for 
this purpose. Whilst MiR-16 and snoRNAs SNORD43 and RNU62 are used; MiR-16 is over-
expressed in erythrocytes and haemolysis greatly influences levels in blood. RNU62 is 
unreliable as it synthesised by polymerases different from those that synthesise precursor 
miRNAs (Baker, 2010; Ma et al., 2013b). Not unlike mRNAs, miRNA expression is not fully 
cell-type specific due to background transcription, hence compromising use in forensic 
applications (Sijen, 2014). 
1.9.2.3 Microbial Biomarkers  
Human bodies do not escape the ubiquitous presence of microorganisms. Microbes 
including viruses, fungi, bacteria, protozoa and parasites aid in food digestion and human 
health. They are located outside of, and within the body including hair, skin, the vagina, 
intestines and mouth. Variations of the human microbiome are attributed to illnesses such as 
obesity, periodontitis, vaginosis and inflammatory bowel disease (Jorth et al., 2014). Studies 
have shown that specific microbes may be found in particular human body sites and fluids. 
This is now being exploited profusely for indications of body sites, fluids and tissues such as 
saliva, skin, nasal area, stool and vaginal fluids (Benschop et al., 2012; Huse et al., 2012). 
The specificity of microbial biomarkers is found to be best for vaginal fluids and menstrual 
secretions (Benschop et al., 2012; Choi et al., 2003; Fleming and Harbison, 2010; Giampaoli 
et al., 2012). Akutsu and colleagues (2012) reported PCR detection of 16S-rRNA genes of 
Lactobacillus jensenii and L. crispatus in not only vaginal fluid but also female urine 
samples. The presence of L. gasseri and Gardnerella vaginalis was also found in semen. L. 
gasseri has proven to be unreliable marker, being detected in vaginal fluid (Fleming and 
Harbison, 2010) as well as semen (Akutsu et al., 2012) and furthermore, the use of bacterial 
RNA is a drawback. Primers may target not only the sequence of interest but also any 
species-specific region. In RNA-based assays, sequences must first be transcribed (Sijen, 
2014). Giampaoli and colleagues (2012) described multiplex RT-PCR detection of microflora 
DNA obtained from vaginal and faecal samples. Enterococcus spp. was most prevalent in 
faecal samples. Although strong signals for L. crispatus and L. gasseri were detected in 
vaginal fluid, signals for L. gasseri were also detected for faecal samples.  
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Lactobacilli demonstrate potential as a vaginal fluid marker however, Pavlova and 
Tao (2000) demonstrated that benzo-(a)-pyrene-diol epoxide from smoking disrupts naturally 
occurring Lactobacillus spp. Antibiotics such as erythromycin causes changes in the vaginal 
microbial communities (Choi  et al., 2003; Witkin et al., 2007). Deliberation exists with the 
strategy due to intra-individual variability; bacterial fingerprints may differ from hands of a 
single individual, leading to confusion (Kuczynski et al., 2010). Microbes are easily 
transferred, by touch or contact of another human or surfaces. Vaginal microflora can transfer 
to the male penis or groin (Benschop et al., 2012; Flores et al., 2011). Complexity arises in 
use of microbial markers since the microbiota at a body site does not necessarily relate to 
microbiota from a crime stain. Compositions may vary due to degradation, contamination and 
growth of many airborne species upon release from the human body (Sijen, 2014). Also, 
Dewhirst et al. (2011) showed that approximately 16% of oral microbiota is shared between 
canines and humans; including Mogibacterium timidum, M. diversum, Treponoma 
amylovorum, T. vincenti, three streptococcal species and numerous others. Such findings 















1.10 Scope of the Present Study 
The most prevalent methods to analyse body fluids found at crime scenes are limited 
by lack of specificity and sensitivity, consumption of valuable biological material and are 
largely presumptive. However the precise identification of body fluids found at crime scenes 
provides vital information that can support a link between sample donors and actual criminal 
acts. Reports of whole genome epigenetic analysis indicate that chromosome segments called 
tissue-specific differentially methylated regions (tDMRs) show varying DNA methylation 
profiles according to the type of cell or tissue. Thus, body fluid-specific differential DNA 
methylation is a promising indicator for precise body fluid identification. Even though 
forensic tDMR-based body fluid identification shows much potential, not many tDMRs have 
been confirmed for this purpose. Studies have confirmed tDMRs for semen identification 
however specific tDMRs for blood, saliva and vaginal fluid have yet to be validated. The 
development of new tDMRs is the best way forward for accurate identification of biofluids 
for forensic applications. Accordingly, novel tDMRs were searched for based on the analysis 
of differential gene expression in human tissues and its correlation with DNA methylation. 
The tDMRs were targeted to develop primers for use in Methylation-Specific Restriction 
Enzyme (MSRE-PCR) for efficient identification of saliva, blood, semen and vaginal fluid. 
The identification of additional body fluid tDMRs is expected to spur the improvement of 
promising body fluid identification methods for forensic applications.  
Additionally, researchers have provided resounding evidence of differential DNA 
methylation between population groups. Therefore, it is worthwhile to validate previously 
documented tDMR-based markers on the South African population. For this, methylation 
profiles of four previously reported tDMRs in saliva obtained from Blacks, Indians, Whites 
and Coloureds in South Africa were evaluated, to determine if there is differential 
methylation of targeted tDMRs among ethnic groups. Significant differences could assist 







1.10.1 Hypotheses tested  
It is hypothesized that the identification of new tissue-specific differentially 
methylated regions (tDMRs) in human body fluids would allow the development of markers 
to differentiate between body fluids. 
It is further hypothesized that DNA methylation profiles of saliva, using selected 
tissue-specific differentially methylated regions (tDMRs) for USP49, DACT1, L81528 and 
PFN3 genes differ among the diverse South African population and thus may be of 
significance in forensic casework. 
1.10.2 Aims  
a) To identify novel tissue-specific differentially methylated regions (tDMRs) which could 
be used as specific markers for body fluid identification and thus aid in the reconstruction 
of crime scenes. 
 
b)  To infer variation between four ethnic groups of South Africa based on differential DNA 
methylation profiles of four previously reported tDMRs in saliva.  
1.10.3 Objectives  
The following objectives were established to achieve the stated aims: 
a) To mine gene expression and DNA methylation databases for identification of 
differentially methylated regions in forensically significant body fluids: saliva, blood, 
semen and vaginal fluid.  
b)  To design PCR primers targeting tissue-specific differentially methylated regions. 
c) To test the selected methylation-targeted primers by MSRE-PCR, on DNA derived from 
human body fluids (saliva, blood, semen, vaginal fluid). 






1.10.4 Experimental Design 
In order to achieve the stated objectives, the research was divided into the relevant 
chapters described below. A precise description of each phase will be described in the 
chapters which will include all rationale, challenges experienced and deviations from 
reported methods. 
 Chapter Two 
This chapter focuses on collection of DNA methylation information of CpG islands 
(CGIs) of tissue-specific differentially expressed genes, followed by the design of PCR 
primers that target the differentially methylated CGIs. Bioinformatics data acquisition and 
primer design was followed by testing selected methylation-targeted primers on DNA derived 
from human body fluids (saliva, blood, semen and vaginal fluid) by Methylation-Sensitive 
Restriction Enzyme-PCR (MSRE-PCR) to identify specific primers that allow the 
differentiation of the body fluids. 
 Chapter Three  
This chapter investigated the methylation profile of saliva within various ethnic 
groups of the South African population. Previously reported tDMR-based markers for 
identification of saliva, were used to screen the diverse South African population. 
 Chapter Four 
The final chapter, comprising the general discussion and conclusion, places the 
present research study in perspective, providing an overview of the main objectives and 
findings reported in each of the chapters of the dissertation. Possible limitations or 
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DNA methylation is an epigenetic mark of paramount importance as it plays a vital 
role in development and differentiation by control of gene expression via alterations in 
chromatin structure. Studies of whole-genome methylation have reported that chromosome 
segments known as tissue-specific differentially methylated regions (tDMRs) present varying 
methylation profiles according to tissue or cell type which also induce tissue-specific 
variation in gene expression and regulation. Therefore, tDMRs can be targeted to develop 
markers for body fluid identification, which would be especially useful in forensic casework 
where the identification of biological materials is in dispute. The present study aimed to 
develop new DNA methylation-specific markers using a bioinformatics approach based on 
the analysis of differential gene expression in human tissues and its correlation with DNA 
methylation. The objective was to target the identified tDMRs to design PCR primers for 
efficient identification of body fluids. 
Tissue-specific gene expression is mostly associated with hypomethylation of gene-
based CpG islands (CGIs), and low or no expression level is associated with 
hypermethylation. Thus, to identify new tDMRs, a total of 1833 genes which were over-
expressed in only a single body fluid, were identified from surrogate tissues of four body 
fluids, namely; saliva, blood, semen and vaginal fluid. CpG methylation information of 
normal tissues (non-target tissues) was mapped to genes and heavily methylated CGIs were 
targeted for primer design. Sixty-three CGI sequences were selected and analysed for 
specificity in the human genome, and a total of four CGIs were targeted to design PCR 
primers. Methylation profiles of the tDMR-based primers in saliva, blood, semen and vaginal 
fluid was determined by Methylation-Sensitive Restriction Enzyme PCR (MSRE–PCR). Two 
potential body fluid-specific tDMRs were identified: a tDMR of the HPCAL1 gene was 
identified as a potential blood-specific hypomethylation marker, and a tDMR of the PTPRS 
gene was identified as a potential vaginal fluid-specific hypermethylation marker. 
Currently, only a few tDMR-based markers have been reported to identify body 
fluids, most of which require validation. To enhance the specificity and robustness of DNA 
methylation-based identification, identification of novel markers is required. The described 
method of identification and analysis of tDMRs represents an efficient and reliable technique 
to identify biological fluids and tissues found at crime scenes, and the two novel body fluid 
specific tDMRs will be of great assistance in accurate identification and differentiation 
between forensically relevant biological fluids. 
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2.1  Introduction 
DNA methylation is a significant epigenetic alteration that plays a key role in gene 
expression and regulation (Ghosh et al., 2010; Kurukuti et al., 2006; Varley et al., 2013). 
Changes in DNA methylation are most frequently associated with cytosines at CpG 
dinucleotides. However, recent research has described non-CpG methylation in human 
embryonic stem cells and in differentiated mammalian cell types including human skeletal 
muscle and brain (Pinney, 2014; Guo et al., 2014b). Although CpG sites are mainly 
methylated across the mammalian genome (Gutierrez-Arcelus et al., 2013), there are distinct, 
mostly unmethylated CG-rich regions called CpG islands (CGIs), which have a G+C content 
greater than 50%. CGI methylation in promoters and first exon regions are strongly 
associated with reduced gene expression (Bird, 2002; Ginno et al., 2012; Lienert et al., 2011). 
However, positive correlations between intragenic DNA methylation and gene expression 
have been reported (Irizarry et al., 2009; Lister et al., 2009; VanderKraats et al., 2013). CGI 
methylation is also important for tissue-specific gene regulation. Certain tissue-specific genes 
or regions of a gene are methylated in the tissues in which they are not expressed, but 
unmethylated in tissues where they are expressed (De-Smet et al., 1999; Weber et al., 2007). 
These tissue-specific differentially methylated regions (tDMRs) are currently seen as 
potential biomarkers particularly in the field of cancer research for disease detection, 
progression and therapeutic intervention (Kulis et al., 2012; Mikeska and Craig, 2014; 
Rawson and Bapat, 2012; Yoo and Jones, 2006). 
 The amplifiable and stable nature of methylated DNA enables simple transfer of a 
methylation-based diagnostic test from laboratory settings to diagnostic situations. tDMR-
based biomarkers are sensitive, specific, readily detectable, and unaffected by varying 
methods of collection and analysis (Mikeska and Craig, 2014). Since methylation profiles 
underpin the regulatory landscape for externally-visible cellular expression programs; 
scientists have shifted focus from unstable and unreliable protein and RNA biomarkers to 
differentially methylated regions (Kit et al., 2012; Levenson, 2010). Indeed the risk of 
heterogeneity, along with the necessity for preservation of tissues, and need for normalization 
of derived data has limited the use of other biomolecules such as mRNA and miRNA as 
biomarkers (Tost, 2010). 
Scientists are striving to develop methods to identify and characterise CGIs and 
methylation patterns that associate with genes and phenotypes. For this, computational 
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programs based solely on DNA methylation have been developed. Recent research has 
focused on the identification of differentially methylated regions (DMRs) predominantly in 
the context of diseased and healthy tissues between populations. Early studies for tDMR 
identification used the Students t-test or the Wilcoxin Rank Sum Test (WRST) with 
normalization between population groups (Dyson et al., 2014; Wang et al., 2012). Expression 
analysis was performed by the univariate test (Hsiao et al., 2014). Also, the Analysis of 
Variance model (ANOVA) has been developed for detection of aberrant methylation in 
diseased samples (Dyson et al., 2014); as well as ‘sliding window’ technique for DMR 
analysis (Hackenberg et al., 2010; Jones and Takai, 2003; Ponger and Mouchiroud, 2002). 
Wang and Leung (2004) developed a Java-based application known as CpGIE to identify 
CGIs made up of ~200 bp, a G+C content of 55%, CpG observed/expected (o/e) ratio of 0.65, 
as specified by Takai and Jones (2002). 
Bioinformatics-based methods have also been created to identify DMRs. Slieker and 
colleagues (2013) identified 3533 tDMRs in peripheral tissues including hair follicles, blood, 
buccal swabs and saliva; and 5382 tDMRs in internal tissues comprising of liver, pancreas, 
muscle, fat, spleen and omentum by use of the R package 
IlluminaHumanMethylation450k.db. Upon searching for gene expression data from the 
TiGER (Tissue-specific Gene Expression and Regulation) database, they discovered that 
tDMRs mapping to genes with tissue-specific expression were hypomethylated in the tissue 
in which the gene was over-expressed and hypermethylated in tissues showing no expression, 
indicative of a negative relationship between DNA methylation and gene expression. When 
ENCODE data was mapped onto transcription factor binding sites, enrichment of tDMRs was 
observed. FOXA2 transcription factor was active in pancreas, liver and hair follicles and was 
hypomethylated in these tissues.  The tDMRs were also enriched in alternative transcription 
sites. Nearly 50% of both the peripheral tissue and the internal organ datasets mapped to an 
alternative transcription event (Cheong et al., 2006; Kulis et al., 2013; Slieker et al., 2013). 
Software programs mainly employed for analysis and visualization of Illumina array 
data have also been developed to identify new DMRs (Aryee et al., 2014; Chen et al., 2012; 
Wang et al., 2012). These include Minfi (Aryee et al., 2014), DMRforPAIRS (Rijlaarsdam et 
al., 2014), QDMR (Zhang et al., 2011b), BSmooth (Hansen et al., 2012), DMRcate (Peters et 
al., 2015) and methyAnalysis (Du and Bourgon, 2015). The methods are useful to explore 
methylation mechanisms further but are restricted to Infinium arrays which are time-
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consuming and expensive. Issues exist with normalization, development and understanding of 
intricate algorithms (Frommer et al., 1992; Levenson, 2010).  
Screening of novel tDMR-based biomarkers requires a dependable and accurate 
method of identification and analysis. Most approaches are based on bisulfite conversion 
followed by Methylation-Specific PCR, which is sensitive and cost-effective but highly 
stringent assays are necessary to avoid false positives. Bisulfite treatment provides detailed 
methylation profiling of abundant and homogenous samples. However, in a medical or 
forensic situation the DNA is most often heterogeneous and rarely available in high amounts 
or purity. Epigenotyping arrays such as Infinium enables single-base resolution and high 
coverage yet comes with the drawbacks of cross-reactivity, expense and vulnerability to 
genetic variations (Dedeurwaerder et al., 2013; Kit et al., 2012). Pyrosequencing, as 
employed by Madi and colleagues (2012) offers quantitative methylation status of CpGs, but 
is compromised by mediocre sensitivity, high cost and high error rate (Tost and Gut, 2007). 
Whole-genome bisulfite sequencing (WGBS) is limited by incomplete bisulfite conversion 
and DNA degradation. Moreover, hydroxymethyl-cytosine is indistinguishable from methyl-
cytosine, leading to false positives. Thus, the technique is neither informative nor reliable 
(Bock, 2012; Levenson, 2010; Munson et al., 2007). Methods based on pre-treatment with 
methyl-cytosine specific proteins and antibodies such as MeDIP-seq, MethylCap Sequencing 
and MBD-isolated Genome Sequencing (MIGS) present  limits of low resolution, elevated 
levels of background signals, and degrees of CpG and DMR methylation levels that bias the 
techniques (Bock et al., 2010; Down et al., 2008; Harris et al., 2010).  
To evade bisulfite conversion and intricate algorithms, researchers have turned to the 
robust, reliable method of Methylation Sensitive Restriction Enzymes (MSRE) (Choi et al., 
2014; Melnikov et al., 2005). MSRE-based treatments are cost-effective, relatively simple 
and easy to perform. Most analysis methods do not require special instrumentation (Kit et al., 
2012; Melnikov et al., 2005). MSRE treatment followed by PCR and electrophoresis presents 
advantageous features over bisulfite pre-treatment methods; however has not been used to a 
large extent in gene expression-based research. The method enables numerous regions to be 
analysed in a single reaction by multiplexing, whilst simultaneously reducing the amount of 
template DNA required (Choi et al., 2014).  
DNA methylation and tDMR-based markers demonstrate paramount potential in 
forensic casework. Relating methylation profiles of tDMRs and their corresponding 
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phenotypic effects on various body fluids collected at crime scenes would be extremely 
useful in discriminating between unknown body fluids. Accurate identification of biological 
material is crucial, as results could either make or break a case. However, to date, not many 
tDMRs have been confirmed for this purpose. Whilst tDMR-based markers, targeting CpGs 
of genes such as L81528 (Choi et al., 2014), FGF7 and ZC3H12D (Madi et al., 2012) have 
been developed for semen identification, validated markers do not exist for other forensically 
significant body fluids such as epithelia, saliva, blood and vaginal fluid. Accurate 
differentiation between saliva and blood has presented difficulty for numerous researchers 
(An et al., 2013; Frumkin et al., 2011; Lee et al., 2012; Liu et al., 2010). Frumkin et al. 
(2011) tested methylation ratios of various loci to differentiate body fluids and detected 
similar methylation patterns for blood and saliva in L76138/L26688. Similarly An and 
colleagues (2013) found hypermethylation for both body fluids using the PFN3 gene, and Lee 
et al. (2012) experienced difficulty upon employing the HOXA4 tDMR.  
Thus far, inconclusive results have been obtained for other body fluids. The BCAS4 
marker was found to be hypermethylated in semen by Eckhardt et al. (2006) however Madi et 
al. (2012) found saliva to be similarly hypermethylated. Madi and colleagues (2012) also 
declared C20orf117 inconclusive in differentiating between blood and epithelial skin cells. 
More recent research by Choi et al. (2014) has only been able to classify samples as blood-
saliva or semen-vaginal fluid due to similar methylation levels. The group proposed that 
PFN3 may be able to identify vaginal fluid however the marker has yet to be validated. 
Additionally, Park and colleagues (2014a) experienced difficulty in finding stable markers to 
differentiate saliva and vaginal fluid.  
Being a relatively novel tool, DNA methylation-based cell-type and body fluid 
inference still requires much work. DNA collected from crime scenes are typically in low 
concentrations and amounts and there is no room for error, false positives or wastage of 
valuable evidential, genetic material (Gomes et al., 2011; Sijen, 2014; Virkler and Lednev, 
2009). Body fluid identification by tDMR analysis targets DNA, thus there is no additional 
consumption of evidence. Multiplex systems for PCR analysis uses standard capillary 
electrophoresis platforms, which are compatible with STR-typing techniques. The 
identification and development of new tDMRs will enable accurate identification of biofluids 
for forensic applications (Choi et al., 2014; Frumkin et al., 2011; Park et al., 2014a). 
67 
 
The present study centres mainly on the identification of tDMRs in four forensically 
significant body fluids, namely; saliva, blood, semen and vaginal fluid. The objective was to 
target the identified tDMRs to design PCR primers for efficient identification of body fluids 
by MSRE-PCR. The approach followed for the identification of differential DNA 
methylation is based on bioinformatics analysis of differential gene expression in human 






















2.2  Materials and Methods 
2.2.1 Data Acquisition 
Bioinformatics data collection and analysis was performed in correspondence with Dr 
Dyfed Lloyd Evans. Gene expression data of normal surrogate tissues of four human body 
fluids, namely saliva (surrogate tissues: salivary glands and tongue), blood, semen (surrogate 
tissue: prostate) and vaginal fluid (surrogate tissues: uterus and cervix) were mined.  
Gene Expression Data were obtained from the following databases: 
 Tissue-specific Gene Expression and Regulation (TiGER) expression database 
(http://bioinfo.wilmer.jhu.edu/tiger/). 
TiGER (Tissue-specific Gene Expression and Regulation) is a database for generating 
comprehensive information about human tissue-specific gene regulation, including both 
expression and regulatory data. The database contains tissue-specific expression profiles for 
UniGene genes, combinatorial regulation for interacting transcription factor (TF) pairs, and 
cis-regulatory modules (CRMs) for tissue-specific genes (Liu et al., 2008).  
Identification of differentially expressed genes: Any gene with a minimum of 10-fold 
enrichment in any single surrogate tissue of interest as compared to all other tissues was 
deemed to be up-regulated in that particular tissue. 
 Human BodyMap 2.0 data was downloaded from EnsEMBL 
(http://www.ensembl.org). 
EnsEMBL is a database comprising of numerous species genomes including humans, 
other vertebrates as well as model organisms. Specifically, RNASeq data from Illumina’s 
Human BodyMap project was obtained from EnsEMBL. The data entails 16 human tissue 
types including kidney, adrenal, adipose, brain, liver, heart, lymph, breast, skeletal muscle, 
lung, testes, prostate, colon, ovary, white blood cells and thyroid (Cunningham et al., 2015). 
Identification of differentially expressed genes: Differentially expressed genes were 
determined by using the DEGseq R package:  
(https://www.bioconductor.org/packages/release/bioc/html/DEGseq.html) (Wang and Wang, 
2015).  
 GXA (Gene Expression Atlas) (http://www.ebi.ac.uk/gxa/home). 
Comprising both microarray and RNASeq data, the GXA provides information on gene 
expression patterns under various biological conditions. The Expression Atlas provides 
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information on gene expression patterns under different biological conditions. Gene 
expression data is re-analysed to detect genes showing interesting baseline and differential 
expression (Petryszak et al., 2014). 
Differentially expressed genes were determined by using DEGseq R package. 
 Human Gene Expression (HuGE) dataset 
(http://zlab.bu.edu/HugeIndex/HugeIndex/HugenIndexCompendiumSupplement.shtml).  
The HuGE Index is a comprehensive mRNA expression database that contains expression 
data of thousands of genes in normal human tissues and organs. The expression data was 
achieved from use of high-density oligonucleotide array technology (Haverty et al., 2002). 
 Serial Analysis of Gene Expression (SAGE) data from NCBI Gene Expression 
Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/). 
The GEO is an international public repository that archives and freely distributes 
microarray, next-generation sequencing, and other forms of high-throughput functional 
genomics data submitted by researchers (Barrett et al., 2013). 
From the above databases, gene expression data was integrated and genes specifically up-
regulated or over-expressed in surrogate tissues of interest but were not expressed or 
marginally expressed in other tissues were selected for further study.  
 
2.2.2 Methylation Data Acquisition 
Methylation states for selected genes were obtained from the datasets stated below, 
together with methylation positions, and custom scripts were written to map these 
methylation states to the CpG islands (CGIs). 
 ENCODE data was downloaded from EnsEMBL (http://www.ensembl.org). 
The ENCODE (Encyclopaedia of DNA Elements) Consortium is a comprehensive list of 
functional elements of the human genome. These elements include those that act at RNA and 
protein levels, as well as regulatory elements involved in cell-control and circumstances 
wherein a gene is activated (ENCODE Project Consortium, 2012). 
 NGSmethDB (http://www.methdb.net/). Human DNA methylation datasets with 
3-pass verification were downloaded. 
The NGSmethDB databases comprise information of methylated cytosines in human 
DNA. The database contains many types of data, including that obtained from HPLC and 
sequencing. Comprehensive background information is obtained from NGSmethDB 
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including the sample origin, phenotypes and expression of related genes (Grunau et al., 
2001). NGSMethDB data was based on an old version of the human genome assembly 
(hg18). As a result, the entire dataset was remapped onto the latest human genome assembly 
(GRCh38) coordinate system, enabling the integration of ENCODE and NGSMethDB data. 
  
 2.2.3 Data Integration and Exclusion of Differentially Expressed Genes Present 
in More than One Surrogate Tissue 
Gene expression data from various sources mentioned above were integrated to 
generate a single dataset. Since the data sources use varying transcript and gene identifiers, 
these were mapped to stable EnsEMBL identifiers using both the HGNC 
(www.genenames.org) and EnsEMBL APIs (Application Program Interfaces).  
Genenames.org is a repository of official human gene nomenclatures, gene families 
and associated resources including access to genomic, proteomic and phenotypic information. 
All of the nomenclature in the database has been approved by the HUGO Gene 
Nomenclature Committee (HGNC) (Gray et al., 2015). Using common, stable identifiers 
enabled tissue specific expression data to be mapped onto the corresponding human gene set.  
Based on EnsEMBL IDs, genes found to be over-expressed in more than one 
surrogate tissue were excluded from further study (this occurs as most expression data is 
based on transcript rather than gene sequences).  
 
2.2.4 Elimination of Genes with No Evidence of Protein Synthesis  
Even if an mRNA signal does increase, it is still possible for no additional protein to 
be expressed in a particular tissue (this is known as mRNA sequestration), therefore to 
confirm that the genes were functional, RNA expression profiles were compared with protein 
expression data derived from GeneCards. GeneCards is a compendium of genomic, 
transcriptomic, proteomic, genetic, clinical and functional information of both annotated and 
predicted human genes. It may be obtained from the Human Gene Expression database 
(Belinky et al., 2015).  
Using an exclusive link for each gene (http://www.genecards.org/cgi-
bin/carddisp.pl?<gene>) known as the gene card summary, the remaining genes were 
checked for their protein expression. All genes that could not be confirmed as protein coding, 
RNA encoding genes, pseudogenes and non-coding RNAs were removed from the study. 
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Genes which showed high protein expression in concert with high transcript expression were 
selected for further evaluation.  
2.2.5 Genes and Genome Data 
Genome regions corresponding to over-expressed transcripts were obtained from the 
EnsEMBL online databases using custom scripts developed against EnsEMBL APIs 
(http://www.ensembl.org). 
 
2.2.6 Mapping CpG Island and Methylation Information  
Using codes developed against the EnsEMBL Core API, the genes identified above 
were used to query the EnsEMBL databases. Co-ordinates of CpG Islands (CGIs) associated 
with the genes, as well as exons and UTRs were obtained. ENCODE and NGSMethDB data 
were also mapped to the gene co-ordinates.  Genes without association with CGIs were 
eliminated at this stage. The methylated CpG dinucleotides were mapped onto the genomic 
co-ordinates of the remaining genes. The methylation signal was averaged across the length 
of the CGIs on which they were located. 
For each CGI, methylation data were integrated and expressed as mean, median and 
minimum-maximum values of the methylation states across the CGI. Genes in which CGIs 
presented a mean, median and minimum-maximum methylation percentage above 75% were 
targeted. These genes had methylation profiles above 75% (in tissues where typical gene 
expression was normal or low) but were specifically over-expressed in one of the surrogate 
tissues of the four forensically relevant body fluids.  
2.2.7 Final Selection of Candidate Tissue-Specific Differentially Methylated 
Regions 
The targeted CGIs of selected genes which were highly methylated in tissues other 
than saliva, blood, semen and vaginal fluid were pasted into NEBcutter V2.0, 
(http://nc2.neb.com/NEBcutter2/) to ensure the CGIs contained the HhaI restriction site 
(GCGC). The CGI sequences which lacked these sites were removed from the list of 
candidate genes. This step was to ensure that the designed primers targeting the CGIs would 
flank the HhaI recognition site during Methylation-Sensitive Restriction Enzyme Polymerase 
Chain Reaction (MSRE-PCR).  
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The sequences of these remaining CGIs that correspond to the genes of interest and 
had the HhaI restriction site were BLASTed against the human genome assembly GRCh38. 
This was to ensure that unique CGIs were targeted to design the primers. CpG sequences 
mapping to a single chromosomal location were selected, whilst those mapping to several 
locations on human chromosomes were discarded. 
2.2.8 Primer Design for PCR  
To determine the methylation status of the selected CGIs, primers flanking the HhaI 
recognition sites (GCGC) were designed using the Primer3Plus program 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi//). The unmethylated 
artificial DNA control was obtained by PCR amplification of the 481-bp portion of the 
pCR®2.1 TOPO® vector (Invitrogen, Carlsbad, CA, USA) (An et al., 2013; Choi et al., 
2014; Appendix A).  
2.2.9 Sample Collection  
Body fluid samples (saliva, blood, semen and vaginal fluid) for analysis of designed 
primers were obtained from the principal investigator and a male member of her family, 
according to methods specified by the Biomedical Research Ethics Committee of UKZN 
Westville. Saliva was collected in a 15 ml sterile tube and 200  L aliquots were stored frozen 
at -20  C until DNA was extracted. Blood was obtained in sterile tubes containing 
ethylenediamine tetraacetic acid (EDTA, an anticoagulant), and 200  L aliquots were stored 
frozen at -20  C until DNA was extracted. Semen was obtained in sterile Eppendorf tubes and 
stored frozen at -20  C until DNA extraction. Vaginal fluid was obtained using sterile cotton 
swabs and dried at room temperature for approximately two hours, followed by DNA 
extraction. 
2.2.10 DNA Extraction and Quantification 
DNA was extracted from each aliquot of blood and saliva using a Quick-g DNA 
MiniPrep Kit (ZymoResearch); from semen using a QIAamp® DNA Mini Kit (QIAGEN, 
Germany) and DNA from vaginal fluid was extracted using a QIAamp® DNA Investigator 
Kit (QIAGEN) according to the manufacturer’s instructions. Extracted DNA was quantified 
using a spectrophotometer (Nanodrop ND-2000, Thermo Fisher Scientific Inc, Waltham, 
MA, USA).  
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2.2.11 Restriction Enzyme Treatment  
MSRE-PCR was developed to amplify HhaI recognition sites (GCGC) of the selected 
CGIs. Prior to conducting the PCR; approximately 100 ng of saliva, blood, semen and 
vaginal fluid DNA was restricted separately with HhaI in a 10  L reaction containing  1  L 
of CutSmart Buffer (New England Biolabs, Ipswitch, MA, USA) and HhaI (New England 
Biolabs, Ipswitch, MA, USA) at various concentrations of 10 U, 2 U and 0.2 U. Different 
incubation and inactivation temperatures and times were attempted for successful restriction 
(37  C for 16 hours; 37  C for 1 hour; 37  C for 30 minutes; and heat inactivation at 80  C for 20 
minutes as well as 65  C for 20 minutes). The control reaction, to ensure successful restriction, 
also consisted of restricting 100 ng of the unmethylated artificial DNA template using the 
same concentrations of HhaI as for body fluids. All restrictions were performed in triplicate. 
2.2.12 MSRE-PCR  
PCR amplification was carried out in a 20  L reaction volume containing 10  L of 
enzyme-digested DNA, 2.0 U of AmpliTaq Gold® DNA Polymerase (Applied Biosystems), 
1  L of Gold ST*R 10× Buffer (Promega, Madison, WI, USA) and 0.3  M each primer 
(Table 2.8; Table 2.9). PCR cycling was conducted on a BIORAD T100™ Thermal Cycler 
under the following HotStart conditions: 95˚C for 11 minutes, 28 cycles of 94˚C for 20 
seconds, varying annealing temperatures (Table 2.8) for 60 seconds, and 72˚C for 30 seconds 
and final extension at 72˚C for 60 minutes. The amplification products were analysed by 
agarose gel electrophoresis using 2% agarose gel, stained with 10 mg/ml ethidium bromide at 
80 V for 1 hour. 
The stated PCR cycling conditions known as HotStart PCR were used as AmpliTaq 
Gold® DNA Polymerase (Applied Biosystems) is provided in an inactive state and is only 
activated upon heat. Whilst typical PCR cycling reactions consist of an initial denaturation 








2.3 Results  
 2.3.1 Tissue-Specific Gene Expression Data  
 A total of 1833 genes were found to be over-expressed in the surrogate tissues of 
saliva, blood, semen and vaginal fluid. The distribution of these genes in the different body 
fluids are shown in Table 2.1, indicating that majority of these genes were found to be 
specifically over-expressed in saliva (31.8%) and blood (28.8%). Table 2.2 shows the top 10 
over-expressed genes in each of the forensically significant body fluids. 
Table 2.1: Over-expressed genes in surrogate tissues of saliva, blood semen and vaginal 
fluid. 
Body Fluid Number of Over-expressed 
Genes 
Percent Distribution of 
Over-Expressed Genes 
Saliva 583 31.8% 
Blood 528 28.8% 
Semen 352 19.2% 
Vaginal Fluid 370 20.2% 
Total 1833 - 
 
Table 2.2: The top 10 over-expressed genes in each of the forensically significant body 
fluids. 
Body Fluid EnsEMBL ID Gene Name Expressed Sequence Tag 
(EST)-Enrichment 
Saliva ENSG00000225930 DKFZP434L187 92.598 
 ENSG00000092758 COL9A3 66.814 
 ENSG00000169248 CXCL11 53.569 
 ENSG00000017483 SLC38A5 49.807 
 ENSG00000198464 ZNF480  45.061 
 ENSG00000073282 TP73L 43.041 
 ENSG00000169752 NRG4 41.595 
 ENSG00000166535 A2ML1 40.992 
 ENSG00000169474 SPRR1A 40.992 
 ENSG00000241794 SPRR2A 39.284 
Blood ENSG00000133742 CA1 66.412 
 ENSG00000262827 FCAR 63.037 
 ENSG00000223609 HBD  62.519 
 ENSG00000206047 DEFA1 61.841 
 ENSG00000172232 AZU1  61.461 
75 
 
 ENSG00000159339 PADI4  61.287 
 ENSG00000169385 RNASE2 59.535 
 ENSG00000262383 LILRA3  56.909 
 ENSG00000124469 CEACAM8  55.282 
 ENSG00000101425 BPI 54.929 
Semen ENSG00000100373 UPK3A 25.523 
 ENSG00000124233 SEMG1 24.110 
 ENSG00000159182 PRAC 23.928 
 ENSG00000124157 SEMG2 23.615 
 ENSG00000263639 MSMB 23.226 
 ENSG00000167751 KLK2 22.775 
 ENSG00000229637 PRAC2 22.043 
 ENSG00000163810 TGM4 21.665 
 ENSG00000167749 KLK4 20.206 
 ENSG00000167332 OR51E2 20.109 
Vaginal Fluid ENSG00000205810 KLRC3 44.514 
 ENSG00000205809 KLRC2 44.514 
 ENSG00000178226 PRSS36 41.334 
 ENSG00000177138 FAM9B 33.067 
 ENSG00000158483 FLJ10661 30.061 
 ENSG00000186523 FAM86B1 30.061 
 ENSG00000123388 HOXC11 30.061 
 ENSG00000170577 SIX2  29.334 
 ENSG00000130720 FIBCD1  28.934 
 ENSG00000117148 ACTL8 27.556 
 
2.3.2 Exclusion of Differentially Expressed Genes Present in More than One 
Surrogate Tissue 
 Comparisons of RNA and protein expression identified 179 genes that were over-
expressed in more than one surrogate tissue. Together with the tissues the genes are over-
expressed in, these 179 genes are shown in Table 2.3. The removal of the genes yielded 1654 







Table 2.3: Genes over-expressed in more than a single surrogate tissue and corresponding 
tissues in which they were over-expressed.  
 
EnsEMBL ID Body Fluid/s EnsEMBL ID Body Fluid/s 
ENSG00000011600 
 










Saliva, vaginal fluid ENSG00000108405 
 
Blood, semen 






































































































Semen, vaginal fluid ENSG00000162078 
 
Saliva,  lachrymal 
ENSG00000136689 
 























































































Blood, saliva ENSG00000229035 
 































 2.3.3 Elimination of Genes with Unconfirmed Protein Products  
Since not all transcribed RNAs are translated into proteins, 190 genes for which 
protein products could not be confirmed were removed (Table 2.4). Thereafter, 1464 genes 








Table 2.4: Genes over-expressed in surrogate tissues of saliva, blood, semen and vaginal 
fluid that could not be confirmed as protein coding. 
 





















































































































































































ENSG00000183688 Blood ENSG00000266109 
 
Semen 


























































































Saliva  ENSG00000186205 
 
Vaginal fluid 



































































































































Saliva  ENSG00000100300 
 
Vaginal fluid 










Saliva  ENSG00000064545 
 
Vaginal fluid 











































 2.3.4 Methylation Data 
CpG Island (CGI) methylation information was obtained for the remaining 1464 
genes in tissues which displayed low-to-normal gene expression. A total of 952 genes 
outlined in Table 2.5, have CGIs positioned within them and were therefore included in the 
study. The genes which did not have any CGIs positioned within them and were excluded 
from further analysis are outlined in Table 1, Appendix A. 
 
Table 2.5: List of genes harbouring CGIs.  
ENSG00000155545 ENSG00000145860 ENSG00000170802 ENSG00000196353 
ENSG00000178226 ENSG00000176597 ENSG00000162040 ENSG00000132205 
ENSG00000069011 ENSG00000136490 ENSG00000050628 ENSG00000100266 
ENSG00000215440 ENSG00000109255 ENSG00000161798 ENSG00000082175 
ENSG00000185947 ENSG00000100359 ENSG00000167130 ENSG00000140564 
ENSG00000111328 ENSG00000107077 ENSG00000125965 ENSG00000181577 
ENSG00000161992 ENSG00000136161 ENSG00000198464 ENSG00000115963 
ENSG00000164221 ENSG00000242110 ENSG00000198863 ENSG00000107554 
ENSG00000088205 ENSG00000089639 ENSG00000092758 ENSG00000184825 
ENSG00000173581 ENSG00000046604 ENSG00000145592 ENSG00000125347 
ENSG00000135636 ENSG00000174851 ENSG00000134516 ENSG00000152359 
ENSG00000172244 ENSG00000183242 ENSG00000103174 ENSG00000204842 
ENSG00000164164 ENSG00000101333 ENSG00000179111 ENSG00000173535 
ENSG00000065268 ENSG00000148110 ENSG00000198001 ENSG00000143147 
ENSG00000167004 ENSG00000100461 ENSG00000163660 ENSG00000103126 
ENSG00000158019 ENSG00000170961 ENSG00000123609 ENSG00000005073 
ENSG00000158715 ENSG00000130707 ENSG00000134574 ENSG00000144724 
ENSG00000119559 ENSG00000141298 ENSG00000107738 ENSG00000165502 
ENSG00000185024 ENSG00000196943 ENSG00000185215 ENSG00000128641 
ENSG00000106780 ENSG00000170581 ENSG00000130119 ENSG00000077782 
ENSG00000140332 ENSG00000149554 ENSG00000174564 ENSG00000112234 
ENSG00000166451 ENSG00000174292 ENSG00000112062 ENSG00000119760 
ENSG00000241399 ENSG00000157540 ENSG00000145934 ENSG00000130300 
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ENSG00000083307 ENSG00000125257 ENSG00000168875 ENSG00000149177 
ENSG00000068650 ENSG00000114209 ENSG00000152822 ENSG00000122335 
ENSG00000097007 ENSG00000104267 ENSG00000111186 ENSG00000168461 
ENSG00000134201 ENSG00000155657 ENSG00000188372 ENSG00000188130 
ENSG00000048140 ENSG00000205133 ENSG00000186205 ENSG00000075290 
ENSG00000062282 ENSG00000185088 ENSG00000161055 ENSG00000005381 
ENSG00000171055 ENSG00000114779 ENSG00000106714 ENSG00000121671 
ENSG00000101624 ENSG00000151617 ENSG00000184381 ENSG00000144668 
ENSG00000075218 ENSG00000170485 ENSG00000135698 ENSG00000165097 
ENSG00000180739 ENSG00000109743 ENSG00000160145 ENSG00000103245 
ENSG00000184056 ENSG00000164284 ENSG00000125967 ENSG00000166938 
ENSG00000158417 ENSG00000156482 ENSG00000188419 ENSG00000060138 
ENSG00000132604 ENSG00000065621 ENSG00000021762 ENSG00000166006 
ENSG0000007278 ENSG00000203747 ENSG00000149489 ENSG00000166509 
ENSG00000120899 ENSG00000158470 ENSG00000137709 ENSG00000124251 
ENSG00000136937 ENSG00000182858 ENSG00000266714 ENSG00000137841 
ENSG00000162676 ENSG00000167034 ENSG00000038219 ENSG00000080815 
ENSG00000096070 ENSG00000182796 ENSG00000074370 ENSG00000113013 
ENSG00000177200 ENSG00000196652 ENSG00000148300 ENSG00000070371 
ENSG00000172197 ENSG00000167202 ENSG00000198496 ENSG00000169174 
ENSG00000151726 ENSG00000008283 ENSG00000108669 ENSG00000169599 
ENSG00000107159 ENSG00000165527 ENSG00000117691 ENSG00000144339 
ENSG00000104856 ENSG00000153179 ENSG00000064115 ENSG00000179583 
ENSG00000082293 ENSG00000182318 ENSG00000150867 ENSG00000133067 
ENSG00000152229 ENSG00000140993 ENSG00000105427 ENSG00000167705 
ENSG00000180340 ENSG00000156427 ENSG00000151835 ENSG00000198604 
ENSG00000162493 ENSG00000058866 ENSG00000151702 ENSG00000047648 
ENSG00000168092 ENSG00000068831 ENSG00000158483 ENSG00000088247 
ENSG00000072195 ENSG00000169213 ENSG00000068878 ENSG00000038002 
ENSG00000113296 ENSG00000198729 ENSG00000253293 ENSG00000113119 
ENSG00000169020 ENSG00000184708 ENSG00000169621 ENSG00000182400 
ENSG00000104960 ENSG00000134215 ENSG00000077063 ENSG00000182162 
ENSG00000125845 ENSG00000130720 ENSG00000175264 ENSG00000175938 
ENSG00000184307 ENSG00000184956 ENSG00000114480 ENSG00000059378 
ENSG00000122585 ENSG00000198382 ENSG00000122592 ENSG00000076928 
ENSG00000173545 ENSG00000099953 ENSG00000141574 ENSG00000070031 
ENSG00000184012 ENSG00000128652 ENSG00000009413 ENSG00000121316 
ENSG00000187605 ENSG00000140279 ENSG00000198211 ENSG00000196357 
ENSG00000104047 ENSG00000156983 ENSG00000117525 ENSG00000197622 
ENSG00000130803 ENSG00000197561 ENSG00000146205 ENSG00000142347 
ENSG00000142765 ENSG00000136378 ENSG00000108932 ENSG00000135655 
ENSG00000168071 ENSG00000262209 ENSG00000121742 ENSG00000103257 
ENSG00000196428 ENSG00000140577 ENSG00000153113 ENSG00000138780 
ENSG00000008869 ENSG00000167815 ENSG00000244274 ENSG00000171517 
ENSG00000171462 ENSG00000157613 ENSG00000112699 ENSG00000077420 
ENSG00000076662 ENSG00000186523 ENSG00000145569 ENSG00000115163 
ENSG00000133704 ENSG00000204160 ENSG00000152256 ENSG00000084693 
ENSG00000148803 ENSG00000000938 ENSG00000110934 ENSG00000117280 
ENSG00000165501 ENSG00000126822 ENSG00000123179 ENSG00000198315 
ENSG00000001167 ENSG00000036549 ENSG00000133028 ENSG00000106003 
ENSG00000167658 ENSG00000173480 ENSG00000103222 ENSG00000198951 
ENSG00000118197 ENSG00000035664 ENSG00000197965 ENSG00000140945 
ENSG00000171840 ENSG00000043355 ENSG00000171174 ENSG00000104064 
ENSG00000225921 ENSG00000185761 ENSG00000145331 ENSG00000186635 
ENSG00000183166 ENSG00000178038 ENSG00000169981 ENSG00000131591 
ENSG00000109184 ENSG00000230989 ENSG00000145916 ENSG00000103381 
ENSG00000170540 ENSG00000153094 ENSG00000149488 ENSG00000110075 
ENSG00000121691 ENSG00000136231 ENSG00000176788 ENSG00000183943 
ENSG00000105538 ENSG00000130741 ENSG00000101773 ENSG00000165879 
ENSG00000032219 ENSG00000134283 ENSG00000119986 ENSG00000182230 
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ENSG00000131351 ENSG00000128268 ENSG00000105835 ENSG00000178449 
ENSG00000169851 ENSG00000179361 ENSG00000124243 ENSG00000124614 
ENSG00000137193 ENSG00000169083 ENSG00000184922 ENSG00000115380 
ENSG00000103343 ENSG00000174669 ENSG00000005302 ENSG00000118849 
ENSG00000101596 ENSG00000170577 ENSG00000148655 ENSG00000109881 
ENSG00000010017 ENSG00000267645 ENSG00000196628 ENSG00000187583 
ENSG00000154553 ENSG00000101336 ENSG00000066427 ENSG00000110400 
ENSG00000131018 ENSG00000019186 ENSG00000171135 ENSG00000040608 
ENSG00000132773 ENSG00000006611 ENSG00000139289 ENSG00000085719 
ENSG00000214160 ENSG00000167580 ENSG00000175575 ENSG00000182566 
ENSG00000006016 ENSG00000049319 ENSG00000142197 ENSG00000128040 
ENSG00000137699 ENSG00000136819 ENSG00000180818 ENSG00000145113 
ENSG00000139190 ENSG00000185721 ENSG00000124164 ENSG00000197261 
ENSG00000183570 ENSG00000176386 ENSG00000137273 ENSG00000135372 
ENSG00000198554 ENSG00000108443 ENSG00000158615 ENSG00000057704 
ENSG00000101654 ENSG00000127989 ENSG00000146733 ENSG00000150760 
ENSG00000186340 ENSG00000099812 ENSG00000112541 ENSG00000172006 
ENSG00000106031 ENSG00000015285 ENSG00000136286 ENSG00000187079 
ENSG00000115756 ENSG00000225930 ENSG00000136877 ENSG00000166923 
ENSG00000170425 ENSG00000089195 ENSG00000104976 ENSG00000182580 
ENSG00000179104 ENSG00000117151 ENSG00000124193 ENSG00000108055 
ENSG00000005961 ENSG00000167693 ENSG00000096696 ENSG00000183091 
ENSG00000167513 ENSG00000135604 ENSG00000115750 ENSG00000112146 
ENSG00000177105 ENSG00000168769 ENSG00000058056 ENSG00000064270 
ENSG00000166974 ENSG00000173511 ENSG00000184076 ENSG00000149499 
ENSG00000123146 ENSG00000173442 ENSG00000223414 ENSG00000005020 
ENSG00000167799 ENSG00000115361 ENSG00000130635 ENSG00000137414 
ENSG00000134901 ENSG00000174125 ENSG00000128585 ENSG00000026103 
ENSG00000187735 ENSG00000100311 ENSG00000185567 ENSG00000104447 
ENSG00000182481 ENSG00000150281 ENSG00000128713 ENSG00000155849 
ENSG00000102554 ENSG00000197361 ENSG00000136718 ENSG00000042286 
ENSG00000169896 ENSG00000116478 ENSG00000152078 ENSG00000174579 
ENSG00000053747 ENSG00000110324 ENSG00000249859 ENSG00000134046 
ENSG00000066336 ENSG00000168476 ENSG00000162129 ENSG00000145819 
ENSG00000106351 ENSG00000185345 ENSG00000204271 ENSG00000163067 
ENSG00000118898 ENSG00000110375 ENSG00000146457 ENSG00000064012 
ENSG00000113719 ENSG00000174206 ENSG00000134698 ENSG00000125657 
ENSG00000102362 ENSG00000156931 ENSG00000105122 ENSG00000173546 
ENSG00000187840 ENSG00000214021 ENSG00000144909 ENSG00000124466 
ENSG00000170178 ENSG00000124440 ENSG00000141655 ENSG00000183688 
ENSG00000090339 ENSG00000198858 ENSG00000198088 ENSG00000174562 
ENSG00000115138 ENSG00000180071 ENSG00000164920 ENSG00000196767 
ENSG00000162526 ENSG00000141380 ENSG00000136536 ENSG00000028137 
ENSG00000124766 ENSG00000183762 ENSG00000117143 ENSG00000140836 
ENSG00000030304 ENSG00000187266 ENSG00000172432 ENSG00000221866 
ENSG00000140519 ENSG00000095261 ENSG00000128709 ENSG00000171097 
ENSG00000160191 ENSG00000120457 ENSG00000144674 ENSG00000254087 
ENSG00000021355 ENSG00000140396 ENSG00000165533 ENSG00000130038 
ENSG00000138162 ENSG00000137198 ENSG00000211456 ENSG00000167700 
ENSG00000115306 ENSG00000165102 ENSG00000122644 ENSG00000134419 
ENSG00000156017 ENSG00000166133 ENSG00000166710 ENSG00000171700 
ENSG00000168209 ENSG00000146676 ENSG00000156273 ENSG00000130592 
ENSG00000124831 ENSG00000138180 ENSG00000048740 ENSG00000158406 
ENSG00000100599 ENSG00000111913 ENSG00000198736 ENSG00000182287 
ENSG00000196358 ENSG00000174775 ENSG00000121749 ENSG00000137857 
ENSG00000160703 ENSG00000181222 ENSG00000133401 ENSG00000168310 
ENSG00000151657 ENSG00000142156 ENSG00000171307 ENSG00000074657 
ENSG00000074319 ENSG00000163357 ENSG00000197548 ENSG00000143815 
ENSG00000173530 ENSG00000169752 ENSG00000183597 ENSG00000113448 
ENSG00000166501 ENSG00000158711 ENSG00000119121 ENSG00000144029 
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ENSG00000049759 ENSG00000104413 ENSG00000129933 ENSG00000139874 
ENSG00000130844 ENSG00000100350 ENSG00000159202 ENSG00000173171 
ENSG00000204219 ENSG00000172530 ENSG00000197045 ENSG00000148842 
ENSG00000131389 ENSG00000119231 ENSG00000156113 ENSG00000101868 
ENSG00000143761 ENSG00000117148 ENSG00000130775 ENSG00000160796 
ENSG00000163795 ENSG00000078061 ENSG00000141404 ENSG00000169855 
ENSG00000185009 ENSG00000109775 ENSG00000198900 ENSG00000149212 
ENSG00000107625 ENSG00000166477 ENSG00000183878 ENSG00000116815 
ENSG00000119714 ENSG00000160712 ENSG00000100285 ENSG00000104979 
ENSG00000124383 ENSG00000135838 ENSG00000071054 ENSG00000035928 
ENSG00000081277 ENSG00000141480 ENSG00000101096 ENSG00000137809 
ENSG00000118855 ENSG00000123329 ENSG00000181274 ENSG00000008516 
ENSG00000105426 ENSG00000100416 ENSG00000079482 ENSG00000196422 
ENSG00000157570 ENSG00000106078 ENSG00000167996 ENSG00000198000 
ENSG00000159842 ENSG00000101425 ENSG00000169180 ENSG00000187664 
ENSG00000140368 ENSG00000107551 ENSG00000092036 ENSG00000168386 
ENSG00000111790 ENSG00000184937 ENSG00000159648 ENSG00000119684 
ENSG00000104154 ENSG00000134202 ENSG00000136867 ENSG00000132906 
ENSG00000006194 ENSG00000164647 ENSG00000159461 ENSG00000243766 
ENSG00000132570 ENSG00000132507 ENSG00000063169 ENSG00000108306 
ENSG00000130755 ENSG00000100985 ENSG00000217555 ENSG00000186642 
ENSG00000180447 ENSG00000015475 ENSG00000182568 ENSG00000154229 
ENSG00000182022 ENSG00000101236 ENSG00000178935 ENSG00000165689 
ENSG00000145088 ENSG00000117411 ENSG00000103855 ENSG00000122420 
ENSG00000143537 ENSG00000135069 ENSG00000184470 ENSG00000254806 
ENSG00000151651 ENSG00000112208 ENSG00000011198 ENSG00000184281 
ENSG00000116747 ENSG00000160753 ENSG00000163069 ENSG00000105656 
ENSG00000131759 ENSG00000132334 ENSG00000146410 ENSG00000114115 
ENSG00000187778 ENSG00000077943 ENSG00000089154 ENSG00000069275 
ENSG00000198755 ENSG00000147889 ENSG00000138346 ENSG00000075643 
ENSG00000139880 ENSG00000105204 ENSG00000103202 ENSG00000182257 
ENSG00000108264 ENSG00000179029 ENSG00000163637 ENSG00000113231 
ENSG00000203685 ENSG00000136167 ENSG00000167419 ENSG00000172572 
ENSG00000147065 ENSG00000150893 ENSG00000008130 ENSG00000177663 
ENSG00000175643 ENSG00000089248 ENSG00000155506 ENSG00000066468 
ENSG00000128714 ENSG00000123388 ENSG00000076242 ENSG00000141002 
ENSG00000158042 ENSG00000130733 ENSG00000113648 ENSG00000127191 
ENSG00000107187 ENSG00000204138 ENSG00000206560 ENSG00000017797 
ENSG00000115761 ENSG00000064687 ENSG00000077157 ENSG00000099341 
ENSG00000198108 ENSG00000162714 ENSG00000165816 ENSG00000164032 
ENSG00000117115 ENSG00000151503 ENSG00000101255 ENSG00000131969 
ENSG00000169567 ENSG00000050767 ENSG00000185811 ENSG00000012061 
ENSG00000091536 ENSG00000176390 ENSG00000110328 ENSG00000165752 
ENSG00000117713 ENSG00000083454 ENSG00000177192 ENSG00000131873 
ENSG00000140406 ENSG00000168077 ENSG00000100983 ENSG00000173068 
ENSG00000135363 ENSG00000181444 ENSG00000213390 ENSG00000175054 
ENSG00000124225 ENSG00000159733 ENSG00000173214 ENSG00000179151 
ENSG00000091831 ENSG00000141524 ENSG00000107262 ENSG00000172789 
ENSG00000168010 ENSG00000008382 ENSG00000085982 ENSG00000128283 
ENSG00000139865 ENSG00000100802 ENSG00000138735 ENSG00000167880 
ENSG00000167173 ENSG00000109572 ENSG00000123364 ENSG00000259112 
ENSG00000154025 ENSG00000172987 ENSG00000105483 ENSG00000120158 
ENSG00000103544 ENSG00000173575 ENSG00000170456 ENSG00000159231 
ENSG00000129657 ENSG00000114626 ENSG00000075073 ENSG00000166592 
ENSG00000144554 ENSG00000090470 ENSG00000088543 ENSG00000007541 
ENSG00000120616 ENSG00000125457 ENSG00000171444 ENSG00000029534 
ENSG00000112996 ENSG00000160255 ENSG00000147324 ENSG00000133627 
ENSG00000117614 ENSG00000196655 ENSG00000100504 ENSG00000072401 
ENSG00000104043 ENSG00000180370 ENSG00000112964 ENSG00000171862 
ENSG00000130590 ENSG00000165312 ENSG00000168067 ENSG00000127616 
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ENSG00000137642 ENSG00000178403 ENSG00000102034 ENSG00000108591 
ENSG00000145808 ENSG00000157554 ENSG00000111432 ENSG00000088387 
ENSG00000180758 ENSG00000163798 ENSG00000119699 ENSG00000123700 
ENSG00000088386 ENSG00000167114 ENSG00000100393 ENSG00000175106 
ENSG00000109180 ENSG00000150051 ENSG00000115524 ENSG00000198918 
ENSG00000182463 ENSG00000161513 ENSG00000125691 ENSG00000133961 
ENSG00000159788 ENSG00000107968 ENSG00000175356 ENSG00000100314 
ENSG00000187866 ENSG00000149269 ENSG00000143578 ENSG00000177548 
ENSG00000198924 ENSG00000105676 ENSG00000102879 ENSG00000138376 
ENSG00000172845 ENSG00000005513 ENSG00000172936 ENSG00000169509 
ENSG00000187741 ENSG00000163497 ENSG00000144535 ENSG00000170370 
ENSG00000171729 ENSG00000162302 ENSG00000108474 ENSG00000062038 
ENSG00000171763 ENSG00000116741 ENSG00000168765 ENSG00000171777 
ENSG00000221829 ENSG00000007038 ENSG00000049239 ENSG00000144063 
ENSG00000197299 ENSG00000107018 ENSG00000083223 ENSG00000129534 
ENSG00000129451 ENSG00000144468 ENSG00000132849 ENSG00000165474 
ENSG00000090889 ENSG00000133805 ENSG00000187210 ENSG00000143801 
ENSG00000164941 ENSG00000102539 ENSG00000109805 ENSG00000088826 
ENSG00000159184 ENSG00000087460 ENSG00000170571 ENSG00000163975 
ENSG00000133392 ENSG00000076944 ENSG00000034713 ENSG00000173110 
ENSG00000171608 ENSG00000158717 ENSG00000169826 ENSG00000151715 
ENSG00000133302 ENSG00000106591 ENSG00000145824 ENSG00000136630 
ENSG00000136040 ENSG00000106038 ENSG00000139132 ENSG00000150361 
ENSG00000015133 ENSG00000254470 ENSG00000136522 ENSG00000156026 
ENSG00000089159 ENSG00000115271 ENSG00000114738 ENSG00000100030 
ENSG00000135312 ENSG00000124171 ENSG00000068024 ENSG00000154102 
ENSG00000143669 ENSG00000102854 ENSG00000143768 ENSG00000140044 
ENSG00000138696 ENSG00000134996 ENSG00000170265 ENSG00000135441 
ENSG00000148572 ENSG00000143476 ENSG00000168556 ENSG00000182307 
ENSG00000129474 ENSG00000114026 ENSG00000170615 ENSG00000179008 
ENSG00000104738 ENSG00000113387 ENSG00000104093 ENSG00000165912 
ENSG00000164078 ENSG00000129514 ENSG00000088992 ENSG00000139842 
ENSG00000176170 ENSG00000102921 ENSG00000128965 ENSG00000182132 






  2.3.5 Mapping CpG Island and Methylation Information 
After finding the 952 genes in which CGIs were located, the mean, median and min-
max methylation levels for each of the CGIs were calculated (based on a merged ENCODE 
and NGSMethDB dataset).  CGIs of 50 genes which displayed a mean, median and min-max 
methylation level above 75% (heavily methylated and low-to-normal expression in non-target 
tissues) but over-expression in saliva, blood, semen and vaginal fluid were selected 
(methylation levels are listed in Table 2, Appendix A). The genes where CGIs displayed a 
methylation level below 75% are presented in Table 3, Appendix A. Since multiple CGIs 
within certain genes displayed high methylation, all of these CGIs were included. Table 2.6 
outlines the genes with CGIs displaying above 75% methylation and the body fluids in which 
those genes are over-expressed. 
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Table 2.6: Genes displaying methylation levels above 75% (hypermethylation) in tissues with low-to-normal expression, the body fluid it is over-
expressed in and the number of CGIs selected from the gene. 
EnsEMBL ID Gene    
Abbreviation 
Name of Gene Body Fluid Number of CGIs 
selected  
ENSG00000135636 DYSF Dysferlin Blood 1 
ENSG00000172244 C5orf34 Chromosome 5 open reading frame 34 Vaginal fluid 1 
ENSG00000065268 WDR18 WD repeat domain 18 Vaginal fluid 1 
ENSG00000082293 COL19A1 Collagen, type XIX, alpha 1 Blood  1 
ENSG00000160145 KALRN Kalirin, RhoGEF kinase Semen 1 
ENSG00000107077 KDM4C Lysine (K)-specific demethylase 4C Blood 3 
ENSG00000155657 TTN Titin Saliva  1 
ENSG00000174564 IL20RB Interleukin 20 receptor beta Vaginal fluid 1 
ENSG00000145934 TENM2 Teneurin transmembrane protein 2 Saliva 2 
ENSG00000196353 CPNE4 Copine IV Semen 1 
ENSG00000100266 PACSIN2 Protein kinase C and casein kinase substrate in neurons 2 Saliva 2 
ENSG00000128641 MYO1B Myosin IB Saliva 1 
ENSG00000130300  PLVAP Plasmalemma vesicle associated protein Saliva  1 
ENSG00000149596  JPH2 Junctophilin 2 Saliva 1 
ENSG00000006459  KDM7A Lysine (K)-specific demethylase 7A Semen 1 
ENSG00000188419  CHM Choroideremia (Rab escort protein 1) Semen 1 
ENSG00000187605  TET3 Tet methylcytosine dioxygenase 3 Blood  1 
ENSG00000130803  ZNF317 Zinc finger protein 317 Saliva 1 
ENSG00000146205  ANO7 Anoctamin 7 Blood 1 
ENSG00000088247  KHSRP KH-type splicing regulatory protein Semen 1 
ENSG00000167658  EEF2 Eukaryotic translation elongation factor 2 Saliva  1 
ENSG00000136231  IGF2BP3 Insulin-like growth factor 2 mRNA binding protein 3 Saliva  1 
ENSG00000183570 PCBP3 Poly(rC) binding protein 3 Blood 4 
ENSG00000115756 HPCAL1 Hippocalcin-Like 1 Vaginal fluid 1 
ENSG00000064012 CASP8 Caspase 8, apoptosis-related cysteine peptidase Blood 1 
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ENSG00000030304 MUSK Muscle, skeletal, receptor tyrosine kinase Saliva 1 
ENSG00000115306 SPTBN1 Spectrin, beta, non-erythrocytic 1 Saliva 1 
ENSG00000196358 NTNG2 Netrin G2 Blood  1 
ENSG00000165102 HGSNAT Heparan-alpha-glucosaminide N-acetyltransferase Saliva  1 
ENSG00000197548 ATG7 Autophagy related 7 Blood  1 
ENSG00000119121 TRPM6 Transient receptor potential cation channel, subfamily M, member 6 Blood 1 
ENSG00000113448 PDE4D Phosphodiesterase 4D, cAMP-specific Semen  1 
ENSG00000101868 POLA1 Polymerase (DNA directed), alpha 1, catalytic subunit Semen  1 
ENSG00000105426 PTPRS Protein tyrosine phosphatase, receptor type, S Saliva  2 
ENSG00000124225 PMEPA1 Prostate transmembrane protein, androgen induced 1 Semen  1 
ENSG00000091831 ESR1 Estrogen receptor 1 Vaginal fluid 1 
ENSG00000015475 BID BH3 BH3 interacting domain death agonist Blood 1 
ENSG00000101096 NFATC1 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 2 
Semen  1 
ENSG00000079482 OPHN1 Oligophrenin 1 Saliva  2 
ENSG00000063169 GLTSCR1 Glioma tumor suppressor candidate region gene 1 Semen  3 
ENSG00000184470 TXNRD2 Thioredoxin reductase 2  Vaginal Fluid 1 
ENSG00000050767 COL23A1 Collagen, type XXIII, alpha 1 Blood  1 
ENSG00000159733 ZFYVE28 Zinc finger, FYVE domain containing 28 Saliva  1 
ENSG00000109572 CLCN3 Chloride channel, voltage-sensitive 3 Saliva  1 
ENSG00000127191 TRAF2 TNF receptor-associated factor 2 Vaginal Fluid 1 
ENSG00000206560 ANKRD28 Ankyrin repeat domain 28 Blood 1 
ENSG00000090889 KIF4A Kinesin family member 4A Vaginal fluid 2 
ENSG00000083223 ZCCHC6 Zinc finger, CCHC domain containing 6 Blood 1 
ENSG00000068024 HDAC4 Histone deacetylase 4 Blood  2 




2.3.6 Final Selection of CGIs for Primer Design 
The heavily methylated CGIs of the selected genes were BLASTed against the human 
genome assembly to ensure that the CGIs mapped to a single location in the human genome 
(Table 4 and Figure 2-11, Appendix A) and were also checked for the presence of HhaI 
restriction site. Finally, out of 50 genes, 10 candidate genes met the above criteria and were 
selected for primer design (Table 2.7).  
Table 2.7: Candidate genes selected for primer design and chromosomal locations of 
targeted CGIs. 




Name of Gene 
ENSG00000135636 Chromosome 2 DYSF 
 
Dysferlin 





ENSG00000196353 Chromosome 3 CPNE4 
 
Copine IV 
ENSG00000091831 Chromosome 6 ESR1 
 
Estrogen Receptor 1 
ENSG00000170265 Chromosome 7 ZNF282 
 
Zinc Finger Protein 2 
ENSG00000136231 Chromosome 7 IGF2BP3 
 
Insulin-like Growth Factor 2 
mRNA Binding Protein 3 
 
ENSG00000030304 Chromosome 9 MUSK 
 
Muscle, Skeletal, Receptor 
Tyrosine Kinase 
 
ENSG00000167658 Chromosome 19 EEF2 
 
Eukaryotic Translation 
Elongation Factor 2 
 




Receptor Type S 
 
ENSG00000124225 Chromosome 20 PMEPA1 
 
Prostate Transmembrane 
Protein, Androgen Induced 1 
 
 
The sequences of all the candidate tDMR-based primers along with their specific 

















Temperature       
Reverse primer 
Melting 
Temperature      
          
            






GCATAAATCACCCTGGTTGG GGAAAATGGAGAGGAGTCCC 55 56 50 599 
HPCAL1 
 
GCCTTCTTGGTGGTCCATAA TGTCTTGCAGGTGTAGTCGC 56 59 51 178 
CPNE4 
 
CGCCTGACTGGTTTTCGTAT GAACCCGTATGGGAGGTGA 56 58 51 554 
ESR1 
 
ACGGGTGACTTCTGCATTTC GACAGCTTTGAAGAGGGCAG 56 57 51 568 
ZNF282 
 
CTATCTCCCCAGGTGACAGC CGAGAAGAGCTTCAACTGCC 58 58 53 504 
IGF2BP3 
 
CATCACCAAGTCCCTGTACG GTTCTTTCGCCTTTCAGCAC 56 55 50 584 
MUSK 
 
GAACAGCTCCGGTCTACAGC TCTGTAGGCTCCACCTCTGG 59 60 54 528 
EEF2 
 
TCAGCACACTGGCATAGAGG CACCTCGCCTTTATCGATGT 58 56 51 565 
PTPRS 
 
CATAACCCACAAACCGCTCT GATGCTGTAACGTGTGGTGG 56 57 51 517 
PMEPA1 
 
CTGATGCCCGAGTTACTGCT CGTGTGCAGAGAGCAGAGAG 58 59 53 580 
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Upon initial analysis of the status of methylation of the targeted CGIs in saliva, 
blood, semen and vaginal fluid by MSRE-PCR, only four candidate genes (HPCAL1, 
ZNF282, PTPRS and PMEPA1) showed differential methylation profiles and thus were 
selected for further analysis. 
Table 2.9:  PCR primers and concentrations used for amplification of potential tDMRs.  
Marker Forward primer sequences 
(5'→3') 
Reverse primer sequences 
(5'→3') 
Conc 
 μM  
Amplicon 
size (bp) 
HPCAL1 GCCTTCTTGGTGGTCCATAA GCGACTACACCTGCAAGACA 0.3 178 
ZNF282 CTATCTCCCCAGGTGACAGC GGCAGTTGAAGCTCTTCTCG 0.3 503 
PTPRS CATAACCCACAAACCGCTCT CCACCACACGTTACAGCATC 0.3 516 
PMEPA1 CTGATGCCCGAGTTACTGCT CTCTCTGCTCTCTGCACACG 0.3 579 
 
2.3.7 Optimisation of the HhaI Restriction Reaction 
Optimisation of the restriction reaction was performed under different conditions. 
High concentrations of HhaI enzyme such as 10 U and 2 U hindered complete digestion, 
evident by the presence of a band for the unmethylated artificial DNA template (481-bp 
portion of the pCR®2.1 TOPO® vector) even after restriction (results not shown). Increasing 
the incubation time from 37  C for 30 minutes to 37  C for 16 hours and 37  C for 1 hour did 
not increase the efficiency of restriction (results not shown). Heat inactivation at 80  C for 20 
minutes showed similar results as heat inactivation at 65  C for 20 minutes. However, efficient 
digestion was obtained by using 0.2 U of enzyme, 37  C for 30 minutes for incubation and 








2.3.8 Body Fluid Identification using MSRE-PCR  
2.3.8.1 HPCAL1 Gene-based Primer Set 
The expected product size of the amplicon was 178 bp. Amplification was observed in 
saliva (Lane 2), semen (Lane 4) and vaginal fluid (Lane 5) but not in blood (Lane 3) (Figure 
2.1). This implies that the target region is hypermethylated in saliva, semen and vaginal fluid 
and was not cleaved by HhaI; but it is hypomethylated in blood. The absence of a band at 481 
bp in Lane 10 (restricted unmethylated artificial DNA template, size 481 bp) proves 
successful digestion. Thus, the primer set could be used as a potential tDMR to differentiate 


















Figure 2.1: MSRE-PCR based methylation profiling of body fluids using the HPCAL1-based primer 
set. Lane 1 - GeneRuler™ Low Range DNA Ladder. Lane 2 – Saliva DNA (100 ng/ųl); Lane 3; Blood 
DNA (100 ng/ųl); Lane 4 – Semen DNA (100 ng/ųl); Lane 5 – Vaginal fluid DNA (100 ng/ųl). Lanes 
6-9 – Unrestricted control of saliva, blood, semen and vaginal fluid respectively. Lane 10 – Restricted 
unmethylated artificial DNA template (481-bp portion of the pCR®2.1 TOPO® vector); Lane 11 – 
Unrestricted control of the unmethylated artificial DNA template.  

















2.7.8.2 PTPRS Gene-based Primer Set 
The expected product size of the primers was 516 bp. Amplification was not observed 
in saliva (Lane 2), blood (Lane 3) and semen (Lane 4) but amplification was observed in 
vaginal fluid (Lane 5) (Figure 2.2).  Clear distinct bands were obtained. This implies that the 
region is potentially hypermethylated in vaginal fluid and thus was not cleaved by HhaI; but 
it is potentially hypomethylated in saliva, blood and semen. Thus, the primer set could be 














Figure 2.2: MSRE-PCR based methylation profiling of body fluids using the PTPRS-based primer 
set. Lane 1 - GeneRuler™ 100 bp DNA Ladder. Lane 2 – Saliva DNA (100 ng/ųl); Lane 3; Blood 
DNA (100 ng/ųl); Lane 4 – Semen DNA (100 ng/ųl); Lane 5 – Vaginal fluid DNA (100 ng/ųl). Lanes 












2.3.8.3 ZNF282 Gene-based Primer Set 
The expected product size of the primers was 503 bp. Clear bands were not observed 
at 503 bp. However, amplification was observed in saliva (Lane 2) and vaginal fluid (Lane 5) 
but not in blood (Lane 3) and semen (Lane 4) (Figure 2.3). Non-specific amplification was 















Figure 2.3: MSRE-PCR based methylation profiling of body fluids using the ZNF282-based primer 
set. Lane 1 - GeneRuler™ 100 bp DNA Ladder. Lane 2 - Saliva DNA (100 ng/ųl); Lane 3; Blood 
DNA (100 ng/ųl); Lane 4 – Semen DNA (100 ng/ųl); Lane 5 – Vaginal fluid DNA (100 ng/ųl). Lane 6 
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2.3.8.4 PMEPA1 Gene-based Primer Set 
The expected product size was 579 bp. Amplification was not observed in saliva 
(Lane 2) and semen (Lane 4) but amplification was observed in blood (Lane 3) and vaginal 
fluid (Lane 5) (Figure 2.4). A single distinct band was not observed for this primer set at 579 
bp. Faint bands were obtained for vaginal fluid. The results indicate potential 
hypermethylation in blood and vaginal fluid and potential hypomethylation in saliva and 















Figure 2.4: MSRE-PCR based methylation profiling of body fluids using the PMEPA1-based primer 
set. Lane 1 - GeneRuler™ 100 bp DNA Ladder. Lane 2 – Saliva DNA (100 ng/ųl); Lane 3; Blood 
DNA (100 ng/ųl); Lane 4 – Semen DNA (100 ng/ųl); Lane 5 – Vaginal fluid DNA (100 ng/ųl). Lanes 
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Vaginal Fluid Blood 
600 bp  
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2.4  Discussion 
 The aim of the present study was to identify tissue-specific differentially methylated 
regions (tDMRs) in four forensically significant body fluids: namely saliva, blood, semen and 
vaginal fluid. tDMRs exhibit different DNA methylation profiles according to tissue or cell 
type (An et al., 2013; Choi et al., 2014; Lee et al., 2012; Rakyan et al., 2008). The basis 
behind identification of potential tDMRs was to design PCR primers targeting the 
differentially methylated regions, to differentiate between the four fluids by Methylation-
Sensitive Restriction Enzyme PCR (MSRE-PCR). Body fluid identification is achieved by 
analysing the DNA methylation status of tDMRs. 
Research studies have provided resounding evidence for a correlation between DNA 
methylation and gene expression (Kulis et al., 2013; Schilling and Rehli, 2008). Differential 
expression of genes in different tissues may be regulated by DNA methylation. tDMRs have 
been associated with tissue-specific expression of genes and also show hypomethylation 
specifically in the tissue expressing those genes (De-Smet et al., 1999; Slieker et al., 2013; 
Weber et al., 2007). 
Based on this knowledge, the approach for the identification of tDMRs was entirely 
based on information acquired from bioinformatics databases on DNA methylation and gene 
expression in the human genome. Other methods employed to identify tDMRs include 
Methylation Specific Karyotyping (MSDK) (Hu et al., 2006; Bloushtain-Qimron et al., 
2008), MethylCap Sequencing and MBD-isolated Genome Sequencing (MIGS) (Harris et al., 
2010), Whole Genome Bisulfite Sequencing (WGBS), pyrosequencing (Edwards et al., 2010; 
Madi et al., 2012; Park et al., 2014a), base resolution methylomes genome sequencing 
(MethylC-Seq) (Schultz et al., 2015) and epigenome-typing arrays such as Infinium 
HumanMethylation BeadChip (Dedeurwaerder et al., 2013). Major advantages of 
bioinformatics approaches compared to others are that it is relatively simple and low-cost 
since databases are freely available online, and very importantly it provides high resolution 
screening for tDMRs throughout the genome.  
The initial steps of the study involved bioinformatics data mining to obtain a list of 
candidate genes that were over-expressed in surrogate tissues representing four body fluids of 
interest; namely saliva, blood, semen and vaginal fluid. Other than blood, gene expression 
data does not exist for the body fluids of interest. Therefore surrogate tissues that represented 
primary cell or fluid sources for the fluids of interest were selected. Salivary glands and 
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tongue were chosen for saliva; prostate gland for semen and vaginal and cervical tissues for 
vaginal fluid. 
As genes showing under-expression or low expression could be due to factors other 
than DNA methylation, only over-expressed genes were specifically targeted. It is also not 
possible, in many databases, to differentiate between genes that were studied but 
demonstrated no expression and genes that were not analysed. It was assumed that the over-
expression was more likely to be associated with low intragenic methylation levels compared 
to hypermethylation in other tissues.  
Once genes that were over-expressed in the specific body fluids were identified 
(1833), genes that were found to be up-regulated in more than one of the body fluids were 
removed. This was to obtain genes that were specifically over-expressed in only one of the 
body fluids. Genes for which substantial data was unavailable for protein expression or 
association was not found between transcript expression and translation were eliminated.  
This was done because the aim was to target functional genes and their expression, and proof 
of a protein product reinforces that gene expression data is correct. After the exclusion of 
these genes, 1464 genes remained for further analysis. 
 Corresponding CGI Island (CGI) methylation information was obtained for these 
remaining 1464 genes. Obtaining methylation states in normal tissues enabled identification 
of the genes containing highly methylated CGIs. It is likely that this methylation is associated 
with low expression in normal tissues. Genes displaying CGIs with a mean and median 
methylation of above 75% were categorized as hypermethylated. Not only were promoter-
associated CpGs analysed; but also those located across the entire gene. Hypermethylated 
CGIs which were unique to specific regions in the human genome and had a HhaI restriction 
site were selected for primer design. 
As a result, a total of ten genes harboured CGIs which could be differentially 
methylated between the four forensically relevant tissues of interest and were selected for 
primer design. Methylation-Sensitive Restriction Enzyme PCR (MSRE-PCR) was used for 
the analysis of DNA methylation status of the targeted CGIs (potential tDMRs) in saliva, 
blood, semen and vaginal fluid.  
 Significant tissue-specific differential DNA methylation patterns between saliva, 
blood, semen and vaginal fluid were apparent upon methylation analysis using four gene-
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based primer sets; HPCAL1 (Hippocalcin-Like 1), ZNF282 (Zinc Finger 282), PTPRS 
(Protein Tyrosine Phosphatase) and PMEPA1 (Prostate Transmembrane Protein). In this 
study, two potential tDMRs showing differential DNA methylation between the four body 
fluids of interest were identified. These were blood-specific and vaginal fluid-specific 
markers.  
The HPCAL1 gene-based CGI was initially presumed to show hypomethylation in 
vaginal fluid, as it was over-expressed in vaginal fluid. However from the results of MSRE-
PCR, the marker displayed blood-specific hypomethylation, and hypermethylation, indicated 
by bright bands on the agarose gel, was evident in other fluids. The HPCAL1 gene is found 
on chromosome two and encodes a protein which is a member of a neuron-specific calcium-
binding protein family that is typically found in the brain and retina. It is assumed to be of 
significance for neuronal signalling in the central nervous system and also plays a role in 
calcium-dependent regulation of rhodopsin phosphorylation (Burgoyne, 2007). Blood-
specific hypomethylation of HPCAL1 instead of vaginal fluid could be because of mix up of 
cervical tissue with uterine tissue of the wall of the cervix during gene expression studies. 
Uterine tissue is very rich in blood vessels so there is a possibility that over-expression of 
HPCAL1 was actually associated with blood. Over-expression yet hypermethylation in 
vaginal fluid could also be because of the presence of alternate promoters. DNA methylation 
at intragenic CpGs is believed to control use of alternative promoters and create diversity in 
regulation and expression of main transcripts (Ayoubi and Van de Ven, 1996; Kulis et al., 
2013).  When used in conjunction with other markers, the HPCAL1 may aid in forensic 
identification of blood. Frumkin et al. (2011) detected inconclusive methylation ratios 
between L76138/L26688 loci for blood and saliva. Similarly Lee et al. (2012) and An et al. 
(2013) detected similar methylation between blood and saliva for HOXA4 and DACT1 
markers respectively. Ma et al. (2013a) showed promising results for blood identification. Six 
blood-specific differentially methylated fragments, termed BL 1-6 were identified. Two were 
potential blood-specific hypomethylation markers and four were potential hypermethylation 
markers. The ELOVL2 marker was also studied to be a potential marker for blood by Zbiec-
Piekarska et al. (2015). 
The PTPRS gene-based CGI was presumed to show hypomethylation in saliva. 
However it displayed hypomethylation not only in saliva, but also in blood and semen. 
Successful differentiation of vaginal fluid from other tested fluids was achieved using the 
marker as it was found to be hypermethylated. The marker may be useful in future forensic 
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assays for identifying vaginal fluid since currently only a single tDMR; PFN3 exists for this 
purpose. Moreover, the PFN3 marker requires further validation (Choi et al., 2014). Also, 
current methods using miRNA markers such as those tested by Zubakov et al. (2010) are 
incapable of differentiating vaginal fluid and saliva. The PTPRS gene is located on 
chromosome 19. PTPs are well-known as signalling molecules that partake in cellular 
processes such as growth, proliferation and mitosis. It is of great significance in oncogenic 
transformation; illnesses associated with PTPRS include ureteroceles and pineal gland cancer 
(Belinky et al., 2015). 
The PMEPA1 gene-based CGI showed hypomethylation in semen and saliva. Vaginal 
fluid and blood were hypermethylated. Further investigation of this marker is necessary for 
conclusive results since the results were not reproducible. Perhaps once the HPCAL1 and 
PTPRS markers are validated they may be used in a multiplex reaction with PMEPA1 for 
accurate differentiation between blood and vaginal fluid. The PMEPA1 gene is situated on 
chromosome 20 and encodes a protein that harbours a Smad interacting motif. The gene is 
androgen and transforming growth factor β-inducible. Via interaction with Smad proteins, 
PMEPA1 inhibits the androgen receptor and transforming growth factor β signalling 
pathways. Importantly, it negatively regulates prostate cancer cell growth (Li et al., 2008).  
To our knowledge, this unique panel of genes targeted to design primers have not 
been previously used for identification of tDMRs or differentiation of forensically significant 
body fluids. Recent studies on the use of tDMRs for identification of body fluids have shown 
variable methylation levels in saliva, blood, semen and vaginal fluids (Igarashi et al., 2008; 
Madi et al., 2012; Schilling and Rehli, 2008; Smith et al., 2014). The unique feature of the 
present study is the identification of potential methylation sites that demonstrate presence or 
absence of methylation, as opposed to varying degrees of methylation levels. This approach 
simplifies identification of body fluids considerably, since quantification of methylated CpGs 
is rendered unnecessary. Assessment of DNA methylation status using MSRE-PCR is less 
time-consuming and labour-intensive than bisulfite conversion (Melnikov et al., 2005; Rein 
et al., 1997).  Samples of low quality and concentrations may be tested and because analysis 
is performed by the universal method of electrophoresis, the requirement for special training 
is circumvented. Furthermore, it is highly advantageous due to compatibility with current 
STR typing (An et al., 2013).   
99 
 
The results of this study will complement previous forensics-based research in the 
development of novel tDMRs for body fluid identification. Since tDMR-based markers such 
as L81528, USP49, ZC3H2D and FGF7 have been developed and validated for semen (An et 
al., 2013; Choi et al., 2014; Madi et al., 2012), there is much potential for development of 
tDMR markers for other fluids. As such, two potential hypermethylated tDMRs each for 
blood, saliva, semen and vaginal fluid were identified by Park et al. (2014a), six potential 
blood-specific markers were identified by Ma et al. (2013a) and now the present study has 
identified potential blood-specific and vaginal fluid-specific tDMRs. These results are 
promising and pave the way for application of differential DNA methylation for body fluid 
identification in forensic sciences.  
Regarding the observed lack of sync between the expression dataset and the MSRE–
PCR results, it can be said that the surrogate tissues used for each body fluid may be 
associated with a small amount of cell debris from surrounding body fluid that can induce 
cross-talk. So even though expression levels are validated and can be confirmed, and their 
association with hypermethylated CpGs and tDMRs can also be confirmed, the link between 
surrogate tissue and targeted bodily fluid may not be as direct as anticipated. This is clear 
from cervical tissue, where the rich blood supply to this tissue led to the discovery of blood-
associated markers rather than the expected vaginal fluid markers. Despite these drawbacks, 
the method presented here still offers the most rapid approach to discovering new tissue-
specific differential methylation markers. 
It is evident that the analysis of DNA methylation and tDMR-based biomarkers in 
forensic sciences would be favourable. There is considerable potential for identification of 
body fluids and tissues by employing DNA methylation assays, but there are a few factors to 
consider first. When selecting a particular CpG site to analyse, it is vital to examine several 
samples to certify that the site does not demonstrate low levels of inter-individual variation. 
Also, it must be established that the site is not influenced by external stimuli or is age-
dependent. Future research will involve quantification of methylation and validation of the 
potential tDMRs identified in this study by different profiling methods such as Methylation-
Specific PCR (Beri et al., 2007; Lee et al., 2012) or the development of multiplex assays such 
as methylation SNaPshot (An et al., 2013). Also, the identified potential tDMRs should be 
tested on a larger sample size comprising individuals of varying age groups. Identification of 











METHYLATION PROFILING OF SALIVA 
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 Forensic DNA analysis is an indispensable tool which aids in the identification of 
suspected perpetrators and exoneration of innocent persons in criminal investigations, 
identification of the dead or missing, and identification of human remains in mass disasters 
both by natural causes and by criminal intent. While current methods for human identification 
include the use of short tandem repeats (STRs) and single nucleotide polymorphisms (SNPs), 
certain disadvantages such as allele drop-ins and drop-outs pose a hindrance and too high 
numbers of markers (50-200) are required for powerful discrimination. Moreover, STR and 
SNP markers only provide inference of persons who are already known to the investigating 
authorities. DNA methylation-based markers show potential as an alternative tool for forensic 
human identification. Studies of genome-wide DNA methylation have discovered numerous 
differentially methylated regions (tDMRs) that differ in levels of methylation in various cell 
types and tissues. Furthermore while studies of genetic variation between human populations 
have shown that methylation levels of tDMRs differ between human populations; to our 
knowledge differentiation of ethnic groups by differential DNA methylation for forensic 
application has not been studied in South Africa. Therefore based on analysis of a 
forensically significant fluid, saliva, the present study aimed to determine if there is 
differential methylation of previously reported tDMR-based markers between ethnic groups 
of South Africa.          
 For DNA methylation-based screening of the diverse SA population, saliva was 
collected from 80 healthy individuals, male and female, belonging to the Black, Indian, 
White and Coloured ethnic groups. A multiplex MSRE-PCR assay was used to determine the 
methylation levels of four tDMRs of the USP49, DACT1, L81528 and PFN3 genes. The 
Coloured group displayed the highest methylation levels for all selected tDMRs and lowest 
methylation levels were evident for the Black ethnic group. Two tDMRs; DACT1 and 
L81528 displayed significant variations between the four ethnic groups; with p = 0.02 and p 
= 0.03, respectively. The significant differences in DNA methylation levels could potentially 
assist forensic analysts in future, not only to accurately identify saliva but also to narrow 
down the search of sample donors. This assists in identification of human remains in mass 
disasters, as well as linking donors to crimes or exonerating them with confidence. However, 





3.1  Introduction 
Forensic analysis and identification of body fluid samples found at crime scenes is 
essential for crime scene reconstruction. The accurate identification of cell types and fluids 
are especially necessary when activities leading to deposition of the person’s biological 
material are disputed. Biological evidence for assessment at crime scenes are mainly in the 
form of saliva traces, blood stains, semen, vaginal fluid, organ tissue such as brain or kidney 
as well as skin shreds (Sijen, 2014). However, conventional presumptive and confirmative 
tests for identifying these fluids, including identification of phosphatase in semen, haeme in 
blood and amylase in saliva lack sensitivity and specificity, result in false positives and lead 
to degradation of what little sample is collected (Haas et al., 2009; Quarino et al., 2005; 
Virkler and Lednev, 2009). It is necessary to explore novel strategies that aid in identification 
of body fluids. Core aspects in forensics are the necessity to develop markers not only for 
identification of body fluids, but also to gain inference to the origin and donor of the fluid. 
This is especially important to reveal identities of perpetrators or victims, which can direct 
conviction or exoneration, respectively. 
 Determining clues of the donor, in particular their racial/ethnic group is vastly 
researched by detection of genetic variants within and among human populations. Some 
researchers state that genetic variations account for a modest amount of differences between 
populations while others showed that individuals of different populations are more 
genetically similar than individuals from a single population (Rosenberg et al., 2002; Tang et 
al., 2005; Witherspoon et al., 2007).  Nevertheless, the prospect of genetic variation between 
populations is gaining momentum as it is advantageous to know if individuals within a 
population are more or less susceptible to diseases and who will most likely benefit from 
therapeutic interventions (Ku et al., 2010; Lohmueller et al., 2003; Risch et al., 2002; Wilson 
et al., 2001). It has recently become evident that mRNA and miRNA expression profiles, 
short tandem repeats (STRs), single nucleotide polymorphisms (SNPs) and DNA methylation 
may be reliably used to categorize humans into population groups (Bryc et al., 2010; 
D’Amato et al., 2008; Heyn et al., 2013; Rawlings-Goss et al., 2014; Rosenberg et al., 2002).  
MiRNA-based biomarkers have been developed for several diseases including 
diabetes, asthma, breast, prostate and lung cancers as well as leukaemia (Berezikov, et al., 
2005; Breuckner et al., 2007; He et al., 2015; Rawlings-Goss et al., 2014; Taguchi, 2013). 
Studies have provided evidence of differing miRNA profiles between African Americans and 
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European Americans in lung cancers and in early stages of breast cancer (Heegaard et al., 
2012; Zhao et al., 2010). Rawlings-Goss and colleagues (2014) found common SNPs in 
miRNA sequences between Hadza and Sandawe populations, and between Hadza and 
Kalahari San individuals of Africa. A large number of population differentiated miRNA (pd-
miRNA) alleles between Africans and Asians were found, while only a few between Asians 
and Europeans were identified.  A lower frequency of the hsa-mir-196a-2 T allele at SNP 
rs11614913 in Africans was found compared to non-Africans (Rawlings-Goss et al., 2014). 
This particular variant is linked to a higher risk of oesophageal cancers in European males but 
lower risk for breast and gastric cancers in Chinese populations (Ryan et al., 2010). Higher 
mortality rates have been reported for renal cell carcinoma and prostate and testicular-germ 
cancers in Africans compared to Europeans or Asians (Chornokur et al., 2012; Sun et al., 
2011). Studies of Alzheimer’s found that high expression of MiRNA-34a and MiRNA-125b 
is significant in brain synaptogenesis and amyloidogenesis (Cui et al., 2010; Zhao et al., 
2013). This could explain onset and severity of Alzheimer’s amongst African American, 
Caucasian American and Hispanics. Interestingly, African Americans and Hispanics have a 
higher incidence and severity of Alzheimer’s when compared to Caucasians (Lukiw, 2013; 
Reitz et al., 2013).  
STRs which are regions of DNA that contain a variable number of tandemly repeated 
short sequence motifs (Kayser and Kniff, 2011) were examined by Rosenberg et al. (2002) to 
verify a  relationship between patterns of genetic variation and different populations. The 
group was able to cluster 1056 individuals into Europeans and Asians west of the Himalayas, 
sub-Saharan Africans, inhabitants of New Guinea and Melanesia, Native Americans and East 
Asians. In South African research, D’Amato et al. (2008) genotyped nine Y-STR loci and 
identified high levels of genetic diversity in a Mixed Ancestry group (Coloureds) and 
minimal variation in a Xhosa population. The same group of researchers (D’Amato et al., 
2009) found high discriminatory capacity of DYS447, DYS437, DYS448, and 18 other Y-
STR markers for forensic human identification in South Africa (D’amato et al., 2009). By 
genotyping STR markers from the AmpFlSTR Identifiler kit against from eight Mexican 
Amer-Indian populations, Rangel-Villalobos and colleagues (2013) found that D18S51, 
D19S433, FGA, and D21S11 were the most informative loci to decipher genetic variation 
between various populations of the North Mexican Region and West Regions.  
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Variation of diets and climates as well as exposure to disease has resulted in high 
levels of diversity in genotypic and phenotypic characteristics of populations in Africa (Bryc 
et al., 2010; Campbell and Tishkoff, 2008; Tishkoff et al., 2010). In evaluating this diversity 
Tishkoff and colleagues (2010) genotyped SNPs and found high levels of genetic diversity 
within Africa and African American populations. Middle Easterns and Africans shared a high 
number of alleles and private alleles were found in between African Khoesan (SAK) San and 
Xun/Khwe groups of South Africa. Possibly due to genetic drift, Oceanic and Native 
American populations displayed highest proportions of genetic variation amongst their 
populations. Within Africa, two SAK populations clustered together and were most distant 
from other populations suggesting that these populations had the highest number of diverged 
genetic lineages (Tishkoff et al., 2010).  Bryc et al. (2010) also genotyped SNPs and found 
significant differences within West African populations. Africans were clearly distinguished 
from Europeans, and African Americans demonstrated highly variable levels of West African 
and European ancestry. A Fulani population was genetically distinct from Yoruba, Igbo and 
Brong groups, however, the Yoruba and Igbo groups were indistinguishable even when 
comparing over 300 000 markers.  
While studies have shown that SNPs and miRNAs play significant roles in variation 
of gene expression between HapMap Lymphoblastoid cell lines (LCLs) obtained from 
Yorubans and Caucasians (Altshuler et al., 2010; Huang et al., 2011; Stranger et al., 2007), 
recent research has also found significant differential DNA methylation between populations 
using LCLs (Bell et al., 2011; Fraser et al., 2012; Moen et al., 2013). Fraser et al. (2012) and 
Moen et al. (2013) both evaluated European and Yoruban populations. Over 4300 
differentially methylated CpG sites within and between populations were found by Fraser and 
colleagues (2012), and over 36 500 were identified by Moen et al. (2013). The FLJ32569 and 
STK39 (Serine Threonine Kinase 39) genes were differentially methylated between the 
populations whereas there was little variation in AP4S1 (Adaptor-Related Protein Complex 4, 
Sigma 1 Subunit). A higher degree of methylation-SNP (mSNP) associations were found for 
the Yorubans than Europeans. Several mSNPs were associated with cardiovascular diseases, 
metabolic, autoimmune and neurological disorders. Five mSNPs linked with cholesterol, 
cardiovascular and coronary artery disease were found in APOA5 (Apolipoprotein A-V) and a 
lower risk allele frequency was observed in Europeans, however mSNPs associated with 
rheumatoid arthritis, multiple sclerosis and prostate cancer demonstrated a higher risk allele 
frequency in the European LCLs as opposed to Yorubans (Cullen, 2000; Moen et al., 2013).  
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The HLA-DPA1 locus which is correlated with chronic hepatitis B (HBV) infection is 
abundant in Africans or Asians as they have higher frequency of diseases. Heyn and 
colleagues (2013) and Jones (2012) found that hypermethylation of the HLA-DPA1 promoter 
conjoined with intragenic hypomethylation is associated with decreased gene expression. 
This alters cell surface receptor presentation for HBV-binding and thus, higher risk of 
infection in these populations.  
In prostate cancer research, Enokida and colleagues (2005) demonstrated that 
methylation levels of GSTP1 (π-class Glutathione S-transferase) were significantly higher in 
African Americans when compared to Caucasians and Asians. Kwabi-Addo et al. (2010) 
examined the methylation status of prostate cancer-related genes; GSTP1, AR, RARβ2, 
SPARC, TIMP3, and NKX2-5 in African American and Caucasian American populations. The 
study also found higher methylation levels of the genes in African Americans compared to 
Caucasians, which may potentially contribute to the racial differences that are observed in 
prostate cancer pathogenesis.  
Terry and colleagues (2008) and Zhang et al. (2011a) measured DNA methylation of 
peripheral blood samples between Blacks, Whites and Hispanics and found that Whites 
displayed highest levels of methylation, followed by Hispanics, while Blacks displayed 
lowest methylation levels.  
At present, body fluid analysis is frequently employed in identification of individuals 
following vehicle accidents, victims and criminals of armed conflicts, situations of criminal 
acts and disasters (Goodwin et al., 2009). For this, body fluid-specific mRNA and miRNA 
markers were identified (Juusola and Ballantyne, 2007; Nussbaumer et al., 2006; Park et al., 
2014b), but RNA is highly unstable and susceptible to degradation, fluctuating pH and UV 
light (Liu et al., 2002; Park et al., 2014a).  After many years of forensic STR- and SNP-
typing, analysts found that PCR amplicon sizes of STRs included in kits are too large which 
lead to genotyping failures and degraded samples (common in forensic laboratories) cannot 
be genotyped. Stutter artefacts due to strand slippage in PCR compromise analysis and not 
every STR locus varies between individuals (Butler, 2012; Gill, 2002; Kayser and Kniff, 
2011; Parson and Steinlechner, 2001). Whilst SNPs have been considered as potential 
replacements of STRs due to ability to analyse degraded samples and generation of smaller 
PCR amplicons (Dixon et al., 2005; Sanchez et al., 2006), allele drop-ins and drop-outs pose 
a hindrance and too many SNP markers are required for powerful discrimination (Amorim 
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and Periera, 2005; Gill et al., 2004). Very importantly, STRs and SNPs cannot be used to 
identify those individuals that are not known to investigating authorities (Butler et al., 2007; 
Kayser and Kniff, 2011).  
In contrast, profiles of tissue-specific differentially methylated regions (tDMRs) show 
potential for the identification of unknown individuals since phenotypic differences between 
twins (Fraga et al., 2005), clues to donors ethnicity and diets have been estimated by tDMR 
profiling (Terry et al., 2008; Lam et al., 2012). Analysts are able to confidently estimate age 
of fluids, time of fluid deposition as well as differentiation of sex (An et al., 2013; Bockland 
et al., 2011). tDMRs of EDARADD (EDAR Associated Death Domain) and ELOVL2 (Fatty 
Acid Elongase II) genes from blood and teeth were validated to accurately estimate age of 
donors (Bekeart et al., 2015; Garagnani et al., 2012).  
Analysis of tDMRs is cost-effective, reproducible, robust, sensitive and specific, and 
only requires low amounts of template DNA (Choi et al., 2014; Frumkin et al., 2011; Sijen, 
2014). tDMR-based markers are not influenced by fluctuating temperatures, varying methods 
of collection and handling, transport and storage. Multiplexing enables rapid analysis of large 
amounts of samples within a short time period (An et al., 2013; Choi et al., 2014; Frumkin et 
al., 2011; Park et al., 2014a).  Since it is evident that epigenetic variation does account for 
differences in human populations, the aim of the present study was to determine if the diverse 
South African population shows differences in DNA methylation. MSRE-PCR and capillary 
electrophoresis was used due to rapidity, ease of use and can easily be implemented in real 
casework due to compatibility with STR-typing methods (An et al., 2013; Choi et al., 2014; 
Frumkin et al., 2011). Unlike bisulfite treatment, MSRE-PCR enables analysis of 
heterogenous mixtures as well as multiplexing; thereby reducing the number of 
amplifications and overall costs. In addition to sequence specificity, fluorescent primers 
enable closed-tube detection of numerous targets within a single reaction which eliminates 
chances of cross-contamination. The only factor be cautious of is efficient digestion of the 
template DNA, therefore the use of an unmethylated control is recommended (Frumkin et al., 
2011). Since PCR is followed by the universally well-known method of capillary 






For the present study, the methylation profile of saliva obtained from four ethnic 
groups in South Africa was evaluated, to determine if there is differential methylation of 
targeted tDMRs among ethnic groups. Significant differences in DNA methylation among 



























3.2  Materials and Methods  
 3.2.1 Sample collection  
Approximately 5 mL of saliva was collected in sterile 15 mL tubes from 80 healthy 
volunteers (with no chronic disorders). Participants included males and females, from four 
ethnicities (Blacks, Indians, Whites and Coloureds). The saliva samples were stored frozen at 
-20  C until DNA extraction. To ensure anonymity, each donor was designated a number 
code. The collection tube was numbered and labelled according to gender and ethnicity of 
donor. The ages of participants used for the study is presented in Table 3.1. The donors 
provided signed informed consent after the goals of the study were described (Appendix B). 
Additionally, each participant was requested to provide written disclosure of their 
ethnicity/race, age and gender in the form of a questionnaire (Appendix B). The study was 
conducted according to the methods specified by the Biomedical Research Ethics Committee 
of the University of Kwa-Zulu Natal (Westville Campus).   
3.2.2 DNA Extraction and Quantification 
DNA was extracted from 200  L aliquots of saliva using a Quick-g DNA MiniPrep 
Kit (ZymoResearch) according to the manufacturer’s instructions. Extracted DNA was 
quantified using a spectrophotometer (Nanodrop ND-2000, Thermo Fisher Scientific Inc, 
Waltham, MA, USA). The concentration of saliva DNA of each participant is listed in Table 












Table 3.1: Demographics for study participants. 
Ethnic group Gender Number of Participants 
(n)  
Age Range  
(years)  
Black Male 11 Below 30 n=6 
  30-50 n=5 
Female 10 Below 30 n=7 
   30-50 n=3 
Indian  Male 9 30-50 n=8 
  Above 50 n=1 
Female 10 Below 30 n=10 
White  Male 12 Below 30 n=5 
  30-50 n=6 
  Above 50 n=1 
Female 8 Below 30 n=5 
   30-50 n=3 
Coloured  Male 10 30-50 n=10 
 Female 10 Below 30 n=4 
   30-50 n=5 
   Above 50 n=1 
Black participants can belong to any one, or be a mixture of the four major ethnic groups living in South Africa 
including the Nguni, Sotho, Shangaan-Tsonga and Venda groups. The Black participants were part of the Nguni 
languages (Zulu, Xhosa, Swati and Ndebele). All Indian participants had Indian grandparents and parents. 
Whites refer to individuals having only European ancestry. Coloureds of South Africa are said to be the 
outcome of admixture which is mating between individuals from reproductively isolated ancestral populations, 
therefore having mixed ancestry. 
 
3.2.3 Selection of tDMR Markers and Primer Design for PCR 
For DNA methylation-based differentiation of four ethnic groups, four tDMRs for 
DACT1, USP49, L81528 and PFN3 genes were selected as markers. tDMRs for DACT1, 
USP49 and PFN3 genes have been reported to  display varying amplification in saliva (An et 
al., 2013; Choi et al., 2014; Lee et al., 2012) and L81528 shows no amplification in saliva as 
it was reported to be a semen-specific hypermethylation marker  (Choi et al., 2014; Frumkin 
et al., 2011). To ensure that the markers would be applicable in Methylation-Sensitive 
Restriction Enzyme PCR (MSRE-PCR), primers developed by Choi et al. (2014) that flank 
the HhaI recognition sites (GCGC) of the four tDMRs were used (Table 3.2). Amplicon sizes 
were smaller than 150 bp and the forward or reverse primer were labelled with FAM 
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(Fluorescein), a fluorescent dye (Choi et al., 2014). Amelogenin was used as a sex-typing 
marker. Primers for the amplification of an amplification control, was designed and 
synthesised. The artificial DNA templates of the amplification control for PCR success was 
obtained by PCR amplification of the 481 bp portion of the pCR®2.1 TOPO® vector 
(Invitrogen, Carlsbad, CA, USA) (An et al., 2013; Choi et al., 2014). The USP49, DACT1, 
L81528, PFN3 and Amelogenin markers were labelled with FAM, and the amplification 
control was labelled with NED. 
Table 3.2: Multiplex PCR primers for amplification of tDMRs. Adapted from Choi et al. (2014) with 
minor modifications. 
Marker Forward primer sequences (5'→3') Reverse primer sequences (5'→3') Conc 
 μM  
Amplicon 
size (bp) 
USP49 GTAGCAGGTGTTGCCCAGGTT FAM-CCCTCCCTACCTCACGCAGA 1.0 107 
DACT1 FAM-CACTCCTCCCCTGCTGTCTA GATAAACTGGCTTGACCA 0.70 118 
L81528 FAM-CTTCTGGGGCGACTACCTG AGTCAGCCTCATCCACACTGA 0.40 128 
PFN3 CCTGGCAGCCTCTAGACTCA FAM-GGGCCAAATAAACTGTGACC 0.20 137 
Amelogenin CCCCTTTGAAGTGGTACCAGAG FAM-
GCATGCCTAATATTTTCAGGGAATAA 
0.25 81; 84 
Amplification 
Control 
CTGTTCTTCTAGTGTAGCCGTAGTT NED-CAACCCGGTAAGACACGACT 0.15 131 
 
 3.2.4 HhaI Enzyme Restriction Reaction 
Multiplex PCR was developed to amplify HhaI recognition sites (GCGC) of the 
tDMRs of USP49, L81528, DACT1 and PFN3 genes. Amelogenin is devoid of a restriction 
site. Approximately 100 ng of DNA from each participant was digested with HhaI in a 10  L 
reaction containing 1  L of CutSmart Buffer (New England Biolabs, Ipswitch, MA, USA) 
and 0.2 U of the HhaI restriction enzyme (New England Biolabs, Ipswitch, MA, USA). To 
ensure complete digestion, the unmethylated artificial DNA template (481 bp portion of the 
pCR®2.1 TOPO® vector) was restricted. Additionally, each sample was run with an 
unrestricted control reaction. Herein the enzyme was not added therefore the reaction simply 
contained 100 ng of DNA and 1  L of CutSmart Buffer (New England Biolabs, Ipswitch, 
MA, USA). All digestions were incubated at 37  C for 30 minutes with subsequent heat 
inactivation at 65  C for 20 minutes on a BIORAD T100™ Thermal Cycler (An et al., 2013; 
Choi et al., 2014). 
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3.2.5 Multiplex MSRE-PCR 
Multiplex PCR was carried out in a 96 well plate, in 20  L reaction volumes that 
contained 10  L of enzyme-digested DNA and undigested DNA controls, 2.0 U of AmpliTaq 
Gold DNA Polymerase, 1  L of Gold ST*R 10× Buffer (Promega, Madison, WI, USA) and 
the stated primer concentrations (Table 3.2). PCR was conducted under the following 
HotStart conditions: 95˚C for 11 minutes, 28 cycles of 94˚C for 20 seconds, 59˚C for 60 
seconds, and 72˚C for 30 seconds and final extension at 60˚C for 60 minutes on a BIORAD 
T100™ Thermal Cycler (Choi et al., 2014). 
To prepare samples for analysis, a mix containing 1  L of amplification products, 20 
 L of Hi-Di formamide and 0.2  L of GeneScan™-500 LIZ® internal lane size standard was 
denatured at 95˚C for 5 minutes followed immediately by 3 minutes on ice (An et al., 2013; 
Choi et al., 2014). These preparation steps were essential as the amplification products were 
run on an ABI 310 genetic analyser (Applied Biosystems) (Figure 3.1) according to 
manufacturer’s instructions.  
The electropherograms were analysed using GeneMapper ID Software 5 (Applied 































Figure 3.1: An internal view of the ABI 310 Genetic Analyser. A single capillary is located between 
the gel block and the inlet electrode. The capillary is filled with polymer solution through the gel 
block. A heat plate is used to raise the temperature of the capillary to a specified temperature. Samples 
are placed in an autosampler tray that moves up and down to insert the sample onto the capillary and 












3.2.6 Statistical Analyses  
To determine whether the tDMRs showed a significant difference in DNA 
methylation profiles of saliva between the four ethnic groups, ANOVA (Analysis of 
Variance) was carried out using SAS Software Version 9.2 (SAS Institute Inc., Cary, NC, 
USA). Comparison of methylation status of each tDMR, for each ethnic group, was 
performed by calculating the peak height ratios/tDMRs. Differences were statistically 
significant when p values were less than 0.05. To test for normality of data, Shapiro-Wilk, 
Kolmorogorov-Smirnov Cramer-von Mises and Anderson-Darling tests were carried out. All 
tests confirmed that the data followed a normal distribution. The decision to utilize analysis 
of variance (ANOVA) to analyse the data was therefore justified. The methylation status is 
shown as peak height ratios of each of four tDMRs to Amelogenin for each sample in MSRE-
PCR. For men, the peak height of Amelogenin was calculated by the sum of two peak heights 
















3.3  Results  
3.3.1 Individual DNA Methylation Profiling using MSRE-PCR 
 MSRE-PCR was conducted on saliva DNA from 80 individuals. From a total of 80, 
amplification was observed only for 42 samples; comprising of 9 Blacks, 10 Indians, 15 
Whites and 8 Coloureds. The non-amplified samples which did not show any amplification in 
the restricted as well as unrestricted controls were eliminated from further analysis. 
 Figure 3.2 represents an example of the multiplex MSRE-PCR results of HhaI-treated 
saliva DNA. The figure depicts a restricted profile (A) followed by a control unrestricted 
profile (B). The sequence of Amelogenin, the sex-typing marker, is devoid of the HhaI site 
and will thus generate peaks following MSRE-PCR for every sample. The electropherograms 





































Figure 3.2: Methylation profile of saliva obtained from a Black Male by multiplex MSRE-PCR. Samples were run on an 
Applied Biosystems 310 Genetic Analyser and analysed by GeneMapper ID Software 5. A – Restricted DNA. B – Unrestricted 
DNA (Control). The grey bars represent bins assigned to the peaks. The allele/loci calls and peak heights are shown at the 








3.3.2 Calculation and Comparison of Methylation Levels of Selected tDMRs 
between Four Ethnic Groups  
Methylation status of each tDMR was calculated as a peak height ratio of each 
sample. The peak height ratios for each individual in each ethnic group are listed in Table 3.3 
– Table 3.6 Peak height ratios revealed a distinct variation of methylation levels for all four 
tDMRs between the four ethnic groups. The DACT1 tDMR displayed the highest 
methylation status between all four tDMRs. The methylation status of the tDMRs in saliva of 
the Coloured population was highest between the four ethnic groups (Table 3.6), whereas the 
lowest methylation status of the tDMRs was found in the Black population group (Table 3.3). 
A graphical representation of the mean peak height ratio for each tDMR in each ethnic group 
is shown in Figure 3.3. 
Table 3.3: The peak height ratio (%) for each marker depicting the methylation status in 
every individual in the Black ethnic group. 
Sample 
Number 








3 1706 0 20.57 0 0 
4 6822 26.68 88.33 3.35 29.27 
5 3906 0 11.11 0 0 
11 7039 20.88 130.39 25.87 39.8 
12 6029 3.67 21.06 0 0 
14 3325 14.41 151.16 7.64 61.62 
15 6652 6.98 69.14 8.75 18.08 
17 5474 3.54 27.3 0 0 
18 1105 0 0 0 0 
Average/Mean  4673.11 8.46 57.67 5.07 16.53 
 
Table 3.4: The peak height ratio (%) for each marker depicting the methylation status in 
every individual in the Indian ethnic group. 
Sample 
Number 








24 2279 0 0 0 0 
29 4497 12.63 77.21 2.58 18.61 
30 13154 20.83 82.81 24.22 18.83 
31 4727 2.34 13.81 0 0 
31 8887 11.63 65.01 1.64 3.5 
33 743 0 76.04 0 21.93 
34 9819 13.14 78.81 1.92 13.71 
37 8281 26.84 105.34 51.72 36.01 
38 11674 27.44 112.88 40.11 35.99 
40 742 0 54.58 0 19.14 
Average/Mean 6480.3 11.49 66.65 12.22 16.77 
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Table 3.5: The peak height ratio (%) for each marker depicting the methylation status in 
every individual in the White ethnic group. 
Sample 
Number 








41 12437 28.25 84.5 9.01 24.41 
42 432 0 56.25 0 36.11 
43 2594 17.66 111.6 17.81 45.41 
44 5036 24.5 90.48 24.46 28.69 
45 5428 5.6 43.28 0 3.78 
46 10050 19.4 89.29 22.03 29.52 
47 8687 15.72 100.71 15.16 34.76 
48 9084 7.38 37.12 3.76 7.55 
49 7493 20.47 110.09 59.76 36.02 
53 5223 31.05 117.9 62.44 37.81 
56 3879 13.22 90.92 8.89 19.93 
57 6796 0 3.39 0 0 
58 8413 31.58 140.68 13.65 49.64 
59 2677 9.82 127.53 28.05 29.59 
60 8240 20.13 113.86 7.56 32.68 
Average/Mean 6431.27 16.32 87.84 18.17 27.73 
 
Table 3.6: The peak height ratio (%) for each marker depicting the methylation status in 
every individual in the Coloured ethnic group. 
Sample 
Number 








61 3635 29.38 134.97 42.28 62.17 
64 10280 25.27 120.56 43.02 44 
71 7375 18.87 92.5 5.44 14.54 
72 5869 29.9 127.3 55.14 44.73 
74 4678 7.2 54.44 4.15 6.54 
75 6096 35.16 136.63 46.7 47.55 
76 6101 18.95 122.41 39.91 45.44 
77 12635 17.15 86.88 29.29 26.78 


























Figure 3.3: Methylation status of the USP49, DACT1, L81528 and PFN3 tDMRs in saliva DNA of all four ethnic groups. 
Methylation status is indicated as (mean) peak height ratios of each of four tDMRs to Amelogenin for each sample in MSRE-
PCR. For men, peak height of Amelogenin was calculated by the sum of two peak heights. Blacks, n=9; Indians, n=10; 
Whites, n=15; Coloureds, n=8. All four tDMRs are display highest methylation in the Coloured population and lowest 





































3.3.3 Statistical Analyses  
ANOVA was performed to determine if there was any significant difference in 
methylation status of the four tDMRs in saliva of four ethnic groups. Methylation profiles of 
each tDMR was analysed for each race. Effect of age and gender on methylation status was 
also analysed. All ANOVA results followed a normal distribution. Normality plots are 
shown in Appendix B. 
3.3.3.1 USP49 tDMR-based Marker 
The statistical analysis of the methylation status of the USP49 tDMR demonstrated 
that the marker did show slight variation between the four ethnic groups (p = 0.05) (Table 
3.7). The Coloured group displayed the highest methylation level and the Black groups 
displayed minimum methylation levels (Figure 3.4).  
Table 3.7: Analysis of variance to test the effect of race and age on methylation status of the 
USP49 tDMR. 
Source DF Type III SS Mean Square F Value Pr > F 
Race 3 869.71 289.90 2.82 0.05 
Age 2 388.04 194.02 1.89 0.17 
Race*Age 5 355.93 71.18 0.69 0.63 
 
The age of individuals did not have any significant effect on the methylation status of 
USP49, however an increased methylation level was observed in subjects between 30-50 
years of age when compared to subjects below 30 years of age (Figure 3.5). Interaction of 
race and age did not have any significant effect (data not shown). There was no significant 





















Figure 3.4: Box-Whisper plot depicting the effect of ethnicity on methylation status of the USP49 tDMR across four ethnic 















Figure 3.5: Distribution of methylation levels for the USP49 tDMR across three age groups. 1 - <30 years; 2 – 30-50 years; 



































3.3.3.2 DACT1 tDMR-based Marker 
The statistical analysis of the methylation status of the DACT1 tDMR demonstrated 
that the marker showed significant variation between the four ethnic groups (p = 0.02) (Table 
3.8). The Coloured group displayed the highest methylation level and the Black group 
displayed minimum methylation levels (Figure 3.6).  
Table 3.8: Analysis of variance to test the effect of race and age on methylation status of the 
DACT1 tDMR. 
Source DF Type III SS Mean Square F Value Pr > F 
Race 3 17733.31 5911.10 3.89 0.02 
Age 2 5952.50 2976.23 1.96 0.13 
Race*Age 5 8411.68 1682.33 1.11 0.38 
 
Distribution of methylation levels for the DACT1 tDMR across all four ethnic groups 
and ages are represented in Figures 3.6 and Figure 3.7 respectively. Even though a 
significant variation in methylation levels was observed across all races, the largest 
difference of methylation was observed between Coloureds and Blacks (Figure 3.6), and a 
consistent level of methylation of the DACT1 tDMR in subjects <30 years and between 30-
50 years of age was observed (Figure 3.7). Interaction of race and age, as well as gender, did 

























Figure 3.6: Box-Whisper plot depicting the effect of ethnicity on methylation status of the DACT1 tDMR across four 
ethnic groups. Races 1-4 represent Blacks, Indians, Whites and Coloureds respectively. Significant variations were 
















Figure 3.7: Distribution of methylation levels for the DACT1 tDMR across three age groups. 1 - <30 years; 2 – 30-50 




































3.3.3.3  L81528 tDMR-based Marker 
The statistical analysis of the methylation status of the L81528 tDMR demonstrated 
that the marker showed significant variation between the four ethnic groups (p = 0.03) (Table 
3.9). Similar to USP49 and DACT1, the Coloured group displayed the highest methylation 
level and the Black group displayed minimum methylation levels (Figure 3.8).  
Table 3.9: Analysis of variance to test the effect of race and age on methylation status of the 
L81528 tDMR. 
Source DF Type III SS Mean Square F Value Pr > F 
Race 3 2976.08 992.03 3.27 0.03 
Age 2 1181.18 590.59 1.94 0.16 
Race*Age 5 1262.19 252.44 0.83 0.54 
 
Distribution of methylation levels for the L81528 tDMR across all four ethnic groups 
and ages are represented in Figure 3.8 and Figure 3.9, respectively. Methylation levels for 
this marker across all age groups did not significantly differ (Figure 3.9). Similarly, the 



























Figure 3.8: Box-Whisper plot depicting the effect of ethnicity on methylation status of the L81528 tDMR across four 
ethnic groups. Races 1-4 represent Blacks, Indians, Whites and Coloureds respectively. Significant variations between all 
four ethnic groups were observed for the marker, but the largest differences between the Black and Coloured populations 















Figure 3.9: Distribution of methylation levels in the L81528 tDMR across three age groups. 1 - <30 years; 2 – 30-50 




































3.3.3.4 PFN3 tDMR-based Marker 
The statistical analysis of the methylation status of the PFN3 tDMR demonstrated 
that the marker did show slight variation between the four ethnic groups (p = 0.05) (Table 
3.10). The Coloured group displayed the highest methylation level and the Black groups 
displayed minimum methylation levels (Figure 3.10).  
Table 3.10: Analysis of variance to test the effect of race and age on methylation status of 
the PFN3 tDMR. 
Source DF Type III SS Mean Square F Value Pr > F 
Race 3 2266.35 755.45 2.78 0.05 
Age 2 1046.00 523.00 1.92 0.16 
Race*Age 5 1398.62 279.72 1.03 0.42 
 
Distribution of methylation levels for the PFN3 tDMR across all four ethnic groups 
and ages are represented in Figure 3.10 and Figure 3.11, respectively. A consistent level of 
methylation of the PFN3 tDMR in subjects <30 years and between 30-50 years of age was 
observed (Figure 3.11). Interaction of race and age, as well as gender, did not have an effect 


























Figure 3.10: Box-Whisper plot depicting the effect of ethnicity on methylation status of the PFN3 tDMR across four 















Figure 3.11: Distribution of methylation levels in the PFN3 tDMR across three age groups. 1 - <30 years; 2 – 30-50 years; 



































3.4 Discussion  
 Predominantly for medical research purposes, studies have proven that variations in 
human populations exist at the genetic and epigenetic level (Lukiw, 2013; Reitz et al., 2013; 
Ryan et al., 2010; Tang et al., 2005). South Africa is a multi-ethnic country comprising of 
various races, religions and traditions. While variation in outward appearances is apparent, 
little is understood of the extent of these variances at the epigenetic level. Thus, the present 
study was undertaken to explore this epigenetic variation in the context of tissue-specific 
DNA methylation. The aim was to determine if the methylation profile of tissue-specific 
differentially methylated regions (tDMRs) in saliva differs between four ethnic groups in 
South Africa, namely; Blacks, Whites, Indians and Coloureds. The analysis of these tDMR-
based biomarkers may be of relevance in surveying phenotypic and ethnic traits for forensic 
applications.  
The approach to screen the diverse South African population first began by collecting 
a forensically significant body fluid from study subjects. The body fluid of choice, saliva; 
was selected as advantages lie in ease of access and handling, non-invasive collection 
techniques, as well as no cost involvement (Pandeshwar and Das, 2014; Rajshekar et al., 
2013). Saliva was collected from 80 healthy individuals (with no history of any chronic 
disorder). As volunteers were from different age groups, the effect of age on methylation 
status of the selected tDMRs was also investigated. To facilitate the differentiation of the four 
ethnic groups using the saliva DNA, a multiplex PCR assay was used to detect the 
methylation status of tDMRs. Four tDMRS from the USP49, DACT1, L81528 and PFN3 
genes were selected. These markers have been previously reported to differ between 
forensically significant fluids including saliva, blood, semen and vaginal fluid (An et al., 
2013; Choi et al., 2014; Lee et al., 2012). Two tDMRs for the DACT1 and USP49 genes 
display semen-specific hypomethylation (An et al., 2013; Choi et al., 2014; Lee et al., 2012) 
therefore they should ideally be hypermethylated in saliva. Another semen-specific 
hypermethylation marker; L81528 was included (Choi et al., 2014; Frumkin et al., 2011). 
This tDMR should ideally display hypomethylation in saliva. The PFN3 tDMR was chosen 
as a vaginal fluid and menstrual blood-specific hypomethylation marker (An et al., 2013; Lee 
et al., 2012). This marker would similarly be hypermethylated in saliva. The multiplex assay 
used was based on Methylation-Sensitive Restriction Enzyme PCR (MSRE-PCR). The 
methylation-sensitive enzyme used for restriction was HhaI.  
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Methylation profiling of saliva indicated a distinct variation in the methylation status 
of the four tDMRs; especially between the Coloured and Black ethnic groups. All four tDMR 
markers displayed highest methylation levels in the Coloured ethnic group. The methylation 
level/status of all tDMRs for all study subjects was graphically represented as peak height 
ratios. A trend in methylation levels is apparent; the tDMRs of the Coloured population 
displayed highest methylation levels, followed by Whites, Indians and Blacks. The Coloured 
population of South Africa is said to be the outcome of admixture, which is mating between 
individuals from reproductively isolated ancestral populations; in this case the admixture of 
various ethnic groups namely Khoi-San, Xhosa, and descendants from European, South East 
Asian, Indian and Middle East immigrants (D’Amato et al., 2008). Notably, the Black 
population shows the lowest methylation levels for all four tDMRs.  Similar results were 
observed by Terry et al. (2008) and Zhang et al. (2011a), who compared DNA methylation 
levels of blood DNA obtained from Hispanics, Whites and Blacks and found lowest levels of 
methylation in the Black populations. In this regard, there have been reports of similar 
methylation patterns between saliva and blood (Frumkin et al., 2011; Liu et al., 2010; 
Philibert et al., 2008; Thompson et al., 2013). 
In the present study, the DACT1 tDMR marker displayed the highest peak height 
ratio, followed by PFN3, L81528 and USP49 which displayed the lowest average/mean peak 
height ratio (between the four markers) of 22.74% in the Coloured population. Other studies 
have also reported high methylation of the DACT1 tDMR in saliva. The DACT1 tDMR was 
also found to display highest methylation followed by USP49 and PFN3 in saliva obtained 
from 34 Korean males and females in the study by Choi and colleagues (2014). An and 
colleagues (2013) found highest peak height ratio for the DACT1 tDMR followed by PFN3, 
USP49 and PRMT2 tDMRs; and Lee et al. (2012) found approximately 97% methylation for 
the DACT1 tDMR.  
ANOVA analysis showed that methylation levels for the USP49 and PFN3 tDMRs 
did not differ significantly across all races (p = 0.05). However, the distribution plot showed 
a marked difference between the Coloureds and Black groups. There were no significant 
variations between the Indian and White populations for these markers therefore they would 
not be good candidates to differentiate between these two populations. Choi and colleagues 
(2014) have reported the PFN3 marker to generate significant methylation yields in saliva 
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DNA in their study, wherein 34 study participants were involved. Similarly Lee et al. (2012) 
found methylation levels above 80% for the PFN3 marker in saliva. 
The DACT1 (p = 0.02) and L81528 (p = 0.03) markers displayed significant variation 
in methylation levels across all four ethnic groups. Since the L81528 tDMR is a semen-
specific hypermethylation marker (Choi et al., 2014) either complete unmethylation or 
hypomethylation should be observed in saliva. Consistently low, yet varying methylation 
levels was observed across all races and ages. A significant variation in methylation levels 
were observed across all four races (p = 0.03), and analogous to USP49 and DACT1, largest 
differences in methylation levels between the Coloured and Black populations were observed. 
There was no significant effect of age and gender on the methylation profile of saliva 
for the ethnic groups. A larger sample size would shed more light on the effect of age on 
methylation levels of tDMRs. An et al. (2013) used Methylation Snapshot and found that, in 
saliva, there was a significant difference in methylation levels between young (below 30 
years) and elderly males (above 50 years) for the DACT1 tDMR (p = 0.008). 
Promising results were found in this study for two markers, DACT1 and L81528 as 
both these markers displayed significant variations between the Coloured and Black ethnic 
groups. The analysis of DNA extracted from saliva has been proven to be informative in 
medical as well as forensic research (Pandeshwar and Das, 2014; Malamud and Rodriguez-
Chavez, 2011; Tabak, 2001). Once deemed as merely a digestive juice, researching salivary 
biomarkers is widely acclaimed due to non-invasive methods of collection and hence 
compliance of study subjects, as well as providing good quantities of sound quality DNA for 
large amounts of applications. Minimum volumes of 0.1 ml have been sufficient for excellent 
quality DNA despite being subjected to processing and storage during shipping, and when 
stored without refrigeration for up to eight months (Abraham et al., 2012; Nunes et al., 2012; 
Rogers et al., 2007). However, detecting methylation status of the tDMRs in other body 
fluids, such as blood, semen, vaginal fluid and menstrual blood obtained from the four ethnic 
groups will further introduce more accuracy and precision in the analysis. 
The optimisation of multiplex PCR was initially a challenging task. Numerous factors 
were taken into consideration, such as primer concentration and thermocycling conditions. 
However, the method facilitated rapid amplification of the four tDMRs of interest as well as 
the sex-typing marker Amelogenin in a single reaction. Multiplexing in forensic DNA 
investigations would be advantageous since only a limited amount of template DNA would 
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be needed for a detailed analysis of samples. Overall costs are reduced, time is saved and the 
added use of fluorescent primers supported detection of numerous targets within a single 
reaction which eliminates chances of cross-contamination. The multiplex MSRE-PCR used in 
the present study for differentiation of ethnic groups based on methylation levels of tDMRs 
was designed to use a standard capillary electrophoresis platform; which is compatible with 
STR-typing methods. The method ensures forensic applicability, high sensitivity, specificity 
and reliability. Developments in novel technologies for analysis of DNA methylation enable 
easy compatibility with current STR-typing methods which makes the method more 
attractive. Analysis of DNA methylation status in tDMRs, especially DACT1 and L81528, 
may be potentially implemented in differentiation of ethnic groups in real forensic casework. 
However, further quantification of the methylation status of the tDMRs and testing in a larger 






































4.1  Research in Perspective 
 Human biological traces, such as saliva, blood, semen, vaginal fluid and menstrual 
blood have the potential to serve as strong evidence to place a suspect or victim at a crime 
scene. For forensic investigations, activities leading to the deposition of an individual’s 
biological material are increasingly disputed. Therein, the identification of the biological 
material could be essential in order to determine that a violent act has indeed taken place, as 
well as to determine the circumstances leading to deposition of the biological material, which 
may have resulted in injury or death. 
Traditional presumptive and confirmative methods developed for differentiation of 
body fluids, such as identification of phosphatase in semen, haeme in blood and amylase in 
saliva lack sensitivity, are applicable to a few types of body fluids and result in consumption 
of evidential material (Haas et al., 2009; Quarino et al., 2005; Virkler and Lednev, 2009). 
Following the introduction of DNA/RNA co-extraction techniques in forensics, RNA 
analysis became a routine application (Alvarez et al., 2004; Haas et al., 2014).  Numerous 
body fluid-specific mRNA and miRNA markers have been identified (Juusola and 
Ballantyne, 2007; Nussbaumer et al., 2006; Park et al., 2014b), but RNA itself is highly 
unstable and susceptible to degradation by ribonucleases, fluctuating pH, moisture and UV 
light (Liu et al., 2002; Park et al., 2014a). Whereas mRNA and miRNA markers are sensitive 
to a certain extent, there are issues in applying these markers for routine applications. These 
include normalization in analysis, susceptibility to environmental degradation and expression 
not being fully cell-type specific (Ma et al., 2013b; Sijen, 2014; Vennemann and 
Koppelkamm, 2010). DNA is highly regarded as a biological source for forensic 
identification profiling due to high stability and insusceptibility to external factors such as 
fluctuations in pH, temperature and humidity (An et al., 2012; Frumkin et al., 2011). 
Currently, identification of body fluids based on differential DNA methylation is an area of 
much interest because tissue-specific differentially methylated regions (tDMRs) exhibit 
different DNA methylation profiles according to tissue or cell type (An et al., 2013; Choi et 
al., 2014; Lee et al., 2012; Rakyan et al., 2008). 
There is a dire need for the identification of new tDMRs and development of novel 
markers to increase specificity and sensitivity of DNA methylation-based profiling. Thus, the 
main aim of the present study was to identify new tDMRs for forensically significant body 
fluids (saliva, blood, semen and vaginal fluid). The search for novel tDMRs was based on 
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information acquired from bioinformatics databases on DNA methylation and gene 
expression in the human genome. Over-expressed or up-regulated genes in body fluids of 
interest were identified. Numerous studies have demonstrated that gene expression is 
regulated by DNA methylation (Choi et al., 2014; Kulis et al., 2013; Rakyan et al., 2008). 
Hence, it was proposed that genes over-expressed in a single body fluid are likely to be 
hypomethylated in that tissue, and hypermethylated in normal tissues. As gene expression 
data was only available for blood, gene expression data from surrogate tissues for saliva 
(surrogate tissues: salivary glands and tongue), semen (surrogate tissue: prostate) and vaginal 
fluid (surrogate tissues: uterus and cervix) was obtained. Differential DNA methylation 
markers are persistent, resulting in cellular differentiation with specific expression of those 
specific genes (Eckhardt et al., 2006; Jones and Takai, 2001). The present study sought to 
exploit this characteristic; using unique methylation levels of differentiated cells to identify 
them. The underlying principle behind identifying potential tDMRs in these body fluids was 
to target the differentially methylated regions to design PCR primers to differentiate between 
the four fluids. 
Numerous researchers have reported experimental methods for identification of 
tDMRs including Whole Genome Bisulfite Sequencing (WGBS), pyrosequencing (Madi et 
al., 2012; Park et al., 2014a), base resolution methylomes genome sequencing (MethylC-Seq) 
(Schultz et al., 2015) and epigenome-typing arrays such as Infinium HumanMethylation 
BeadChip (Dedeurwaerder et al., 2013). However, the present study describes a completely 
bioinformatics-based search for novel tDMRs which is relatively simple and low-cost since 
databases are freely available online, and very importantly it provides high resolution 
screening for tDMRs throughout the genome. After intricate screening of genes and their 
associated potential tDMRs in surrogate tissues, four genes and their heavily methylated 
CGIs were selected for primer design. These genes were HPCAL1 (Hippocalcin-Like 1), 
ZNF282 (Zinc Finger 282), PTPRS (Protein Tyrosine Phosphatase) and PMEPA1 (Prostate 
Transmembrane Protein). 
For studying DNA methylation profiles of identified potential tDMRs in four body 
fluids of interest, Methylation-Sensitive Restriction Enzyme PCR (MSRE-PCR) using a 
methylation-sensitive enzyme, HhaI was employed. MSRE treatment followed by PCR and 
capillary electrophoresis presents advantageous features over bisulfite pre-treatment methods; 
however it has not been used to a large extent in gene expression-based research. Most 
research focuses on bisulfite conversion since it has been deemed the standard method of 
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methylation analysis (Madi et al., 2012; Park et al., 2014a), however, these studies have not 
taken into account the high error rates, unreliability, low sensitivity and specificity. To 
surpass these limitations, MSRE-PCR was selected.  
The HPCAL1 gene-based primer enabled successful differentiation of blood from 
saliva, semen and vaginal fluid. HPCAL1 displayed hypomethylation in blood relative to 
other fluids. The HPCAL1 gene encodes a protein which is a member of a neuron-specific 
calcium-binding protein family that is typically found in the brain and retina. Not only is the 
gene important for neuronal signalling in the central nervous system and calcium-dependent 
regulation of rhodopsin phosphorylation (Burgoyne, 2007), but also recently Wang and 
colleagues (2014) found that HPCAL1 is involved in Alzheimer’s Disease. Currently, only a 
few promising markers for identification of blood have been reported. Frumkin et al. (2011), 
An et al. (2013) and Lee et al. (2012) have reported difficulty in differentiation between 
blood and saliva. Additionally, the ELOVL2 marker was also studied to be a potential marker 
for blood by Zbiec-Piekarska et al. (2015). The HPCAL1 gene-based marker will aid in 
providing accurate differentiation of blood in forensic casework.  
The PTPRS gene-based CGI was specifically hypermethylated in vaginal fluid and 
hypomethylated in saliva, blood and semen.  PTPs are well-known as signalling molecules 
that partake in cellular processes such as growth, proliferation and mitosis. They are 
important in control of cellular phosphotyrosine levels and have also been implicated in 
neural development, and importantly, axon growth and guidance (Aricescu et al., 2002). It is 
of great significance in oncogenic transformation; illnesses associated with PTPRS include 
ureteroceles and pineal gland cancer (Belinky et al., 2015), and it has been proposed that 
SNPs in the PTPRS gene is associated with ulcerative colitis (Muise et al., 2007). 
Particularly, vaginal fluid-specific markers are of utmost importance in one of the most 
common genital cancers in females, which is endometrial cancer (Doufekas et al., 2014; Fiegl 
et al., 2004; Jones et al., 2013). The PTPRS gene-based primer shows great potential in 
forensic applications for specific identification of vaginal fluid but also in medical research, 
seeing as it is involved in many diseases. The other two gene-based markers, ZNF282 and 
PMEPA1, were not specific for single fluids.  
The second aim of the study was to decipher whether the tissue-specific methylation 
status of previously documented tDMRs (An et al., 2013; Choi et al., 2014; Lee et al., 2012) 
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differ in saliva of four ethnic groups of South Africa; which could enable scientists to narrow 
down the forensic search to a particular ethnic group. 
Mainly for medical research purposes, numerous studies have investigated genetic 
variation amongst populations by employing protein, mRNA, miRNA, STR and SNP 
markers (Bryc et al., 2010; Chornokur et al., 2012; D’Amato et al., 2009; Lukiw, 2013; 
Tishkoff et al., 2010). However in forensics, human identification based on population 
variation has disregarded protein and RNA-based markers due to instability, insensitivity and 
susceptibility to environmental insults. To identify human remains from vehicle accidents, 
victims and criminals of armed conflicts, situations of criminal acts and disasters (Goodwin et 
al., 2009), forensic analysts have mainly used STR and SNP markers. However, it has come 
to light that sizes of PCR amplicons of forensic STRs included in kits are still too large, allele 
drop-ins and drop-outs pose a limitation, markers are required in high numbers for accurate 
identification and STRs and SNPs cannot identify those individuals that are not captured on a 
national database. Recent studies have targeted variation in DNA methylation to differentiate 
between populations (Fraser et al., 2012; Heyn et al., 2013; Moen et al., 2013). DNA 
methylation-based markers are stable, reproducible, sensitive and specific (Choi et al., 2014; 
Frumkin et al., 2011; Sijen, 2014).  
For investigation of DNA methylation status of four previously reported tDMRs; 
USP49, DACT1, L81528 and PFN3 between Blacks, Indians, Whites and Coloureds, saliva 
was collected from 80 healthy volunteers. These tDMRs have been previously reported to 
differ between forensically significant fluids including saliva, blood, semen and vaginal fluid 
(An et al., 2013; Choi et al., 2014; Lee et al., 2012). MSRE-PCR was employed to detect the 
methylation status of the tDMRs, using the methylation-sensitive enzyme, HhaI. Even though 
DNA was isolated from all saliva samples under similar conditions, the quality of DNA 
ranged from very high to very poor. From a total of 80 samples, 42 amplified and the final 
analysis was based on them.  
Two tDMRs; namely DACT1 (p = 0.02) and L81528 (p = 0.03) displayed significant 
differences in methylation levels between the Coloured and Black populations. Amplification 
yield (based on peak height ratios) for all the four tDMRs was highest in the Coloured 
population, followed by Whites, Indians and Blacks. This implies that the methylation level 
of the four tDMRs in saliva from the Coloured ethnic group was higher when compared to 
the other ethnic groups. Blacks showed the lowest methylation levels for all four tDMRs. 
136 
 
Variation in DNA methylation levels between ethnic groups has been studied by 
many groups (Fraser et al., 2012; Heyn et al., 2013; Winnefeld et al., 2012; Zhang et al., 
2011a). Terry et al. (2008) and Zhang et al. (2011a) reported DNA methylation levels in 
peripheral blood from Blacks, Whites and Hispanics. Both groups of researchers, similar to 
this study, identified the lowest methylation levels in the Black population. Fraser et al. 
(2012) compared differences of methylation patterns between European and Yorubans using 
lymphoblastoid cell lines (LCLs). In their investigation of 14 495 genes, over 4300 genes 
were found to display differential DNA methylation between the populations. In analysis of 
skin samples from Africans, Whites and Asians, Winnefeld and colleagues (2012) found that 
the intragenic CpG island of the CPXM2 (Carboxypeptidase X Member II) was 
hypomethylated in Asians, but hypermethylated in Whites and Africans; and the PM20D1 
peptidase gene was hypermethylated in Caucasians and hypomethylated in the other two 
ethnic groups. In South African research, two recent medical studies have found differential 
DNA methylation in Blacks (Matatiele et al., 2015) and Coloureds (Masemola et al., 2015). 
However, while these studies have researched differential DNA methylation in South Africa, 
they have not studied it across various ethnic groups. Thus, to our knowledge, differentiation 
of ethnic groups by differential DNA methylation for forensic application has not been 
studied in South Africa prior to the present study. 
While none of the markers displayed a significant variation across all three age groups 
(below 30, between 30 and 50, and above 50 years), a more consistent high level of 
methylation was observed in ages between 30-50 years when compared to those below 30 
years. At this stage it is inconclusive if age really affected the methylation levels of the 
tDMRs. Furthermore, it is acknowledged that the population size of the study was rather 
small.  
 An et al. (2013) studied USP49, DACT1, PFN3 and PRMT2 tDMRs for body fluid 
identification. Saliva was found to display highest peak height ratio in DACT1, followed by 
PFN3, USP49 and lowest methylation in PRMT2. Similarly, Choi and colleagues (2014) and 
Lee and colleagues (2012) found high methylation for the DACT1 tDMR in saliva. In the 
present study using saliva, highest methylation levels were also observed in the DACT1 
tDMR (phr = 109.46%). The semen-specific tDMR L81528 was found to be hypomethylated 
in saliva in the study by Choi et al. (2014). Consistently, the present study also showed a low 
methylation range of 5.07% in Blacks and 33.24% in Coloureds.  
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Previous studies have reported differential DNA methylation of the four tested 
tDMRs between forensically significant body fluids (An et al., 2013; Choi et al., 2014; Lee et 
al., 2012) and methylation variation between ethnic groups using body fluids (Fraser et al., 
2012; Heyn et al., 2013; Winnefeld et al., 2012; Zhang et al., 2011a). In this study, both 
aspects were integrated; studying differential DNA methylation of four tDMRs in saliva, 
between four ethnic groups. 
While the study motivates for the concept of differentiation between ethnic groups 
based on analysis of tDMRs, much debate exists around the forensic technique of 
categorizing humans by race or ethnicity, irrespective of the biomarker in use. The notion that 
humans can indeed be classified into various races has been enshrined by some researchers, 
especially those in medical research seeking information about disease susceptibility and 
therapeutic intervention (Fuhrman et al., 2000). However, the concept of human 
classification is also dismissed by others due to legal and ethical issues. Predominantly, using 
genetic variation for a description or inference of ethnicity of the perpetrator of a crime may 
lead to stigmatization of certain groups within society, especially concerning skin colour and 
diseases (Bamshad et al., 2004; Koops and Schellekens, 2008). The use of biological material 
from a crime scene sample to identify physical traits causes controversy because of fears that 
the technology may be abused. For example, privacy issues arise when sensitive matters such 
as inclination towards homosexuality and susceptibility to disease are made public (Koops 
and Schellekens, 2008; M’charek et al., 2012). Nevertheless, provided that the DNA analysis 
is restricted to gaining intelligence related to the case in question and not otherwise, inference 
of ethnic background adds a new dimension in forensic casework and will enable forensic 
scientists to narrow down the circle of possible suspects.  Currently the technique is not yet 
fully developed, however the present study shows promising results for use of tDMRs to 
differentiate between the four ethnic groups of South Africa.  
The multiplex MSRE-PCR method used in this study boasts several salient features 
for forensic casework. Analysis of DNA methylation by restriction enzymes is much simpler 
and less time-consuming than bisulfite conversions and is compatible with STR-typing 
methods. Furthermore, bisulfite treated DNA must be analysed within a certain time period 
due to instability of single strands (An et al., 2012). The only factor to be wary of is efficient 




4.2 Conclusion and Future Work 
The present study has demonstrated that the analysis of tDMRs holds much potential 
in forensics and once implemented, will likely be an indispensable tool to identify the nature 
of the biological fluid in question. To our knowledge, the panel of genes (HPCAL1, PTPRS, 
ZNF282 and PMEPA1) have not been previously targeted for identification of tDMRs and 
differentiation of forensically significant body fluids. The HPCAL1 tDMR was found to be a 
potential blood-specific hypomethylation marker and the PTPRS tDMR was found to be a 
potential vaginal fluid-specific hypermethylation marker. Future work would involve 
quantification of methylation and validation of the potential tDMRs identified in this study by 
different profiling methods such as Methylation-Specific PCR (Beri et al., 2007; Lee et al., 
2012) or the development of multiplex assays such as methylation SNaPshot (An et al., 
2013). Testing the identified markers on a larger and geographically diverse sample size as 
well as on a broad age range is also recommended.  Also, the identification of more tDMRs 
will contribute towards making methylation-based detection of forensic body fluid more 
robust.  
Additionally, two tDMRs; namely DACT1 and L81528 showed potential to 
differentiate between Coloured and Black ethnic groups of South Africa.  As this study was 
based solely on DNA from saliva, future work will involve analysis on other body fluids to 
determine if the same methylation status/level is observed. While studies have reported 
genetic variation between ethnic groups in South Africa (D’Amato et al., 2008; D’Amato et 
al., 2009), these were based on STR markers. Thus, to our knowledge differential DNA 
methylation between ethnic groups has not been previously studied. Future work in this 
regard would also involve testing the potential population-specific tDMRs on a larger sample 
size. The results are encouraging and pave the way for application of differential DNA 
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Figure 1: Sequence of the artificial DNA template obtained from PCR amplification of pCR®2.1 
TOPO® vector. Primers for template amplification are in blue. MSRE-PCR primers to confirm 
complete digestion with HhaI enzyme are in yellow. Enzyme recognition site in the MSRE-PCR 
















Table 1: Genes in which CGIs were not positioned. 
ENSG00000000971 ENSG00000085465 ENSG00000109205 
ENSG00000001561 ENSG00000085514 ENSG00000109208 
ENSG00000004939 ENSG00000086205 ENSG00000109272 
ENSG00000005844 ENSG00000086570 ENSG00000109471 
ENSG00000006534 ENSG00000086991 ENSG00000109684 
ENSG00000007952 ENSG00000088002 ENSG00000109846 
ENSG00000011143 ENSG00000089356 ENSG00000110077 
ENSG00000011465 ENSG00000090020 ENSG00000110104 
ENSG00000011600 ENSG00000090382 ENSG00000110195 
ENSG00000012223 ENSG00000091138 ENSG00000110203 
ENSG00000012822 ENSG00000092295 ENSG00000110484 
ENSG00000014257 ENSG00000094796 ENSG00000110852 
ENSG00000017427 ENSG00000095303 ENSG00000110876 
ENSG00000017483 ENSG00000096006 ENSG00000111331 
ENSG00000019582 ENSG00000099721 ENSG00000111348 
ENSG00000021826 ENSG00000100055 ENSG00000111358 
ENSG00000023445 ENSG00000100196 ENSG00000111361 
ENSG00000025434 ENSG00000100342 ENSG00000111404 
ENSG00000026652 ENSG00000100365 ENSG00000111704 
ENSG00000039139 ENSG00000100368 ENSG00000111729 
ENSG00000042832 ENSG00000100373 ENSG00000111796 
ENSG00000043462 ENSG00000100448 ENSG00000111846 
ENSG00000057149 ENSG00000100450 ENSG00000112077 
ENSG00000057657 ENSG00000100453 ENSG00000112079 
ENSG00000058085 ENSG00000101109 ENSG00000112303 
ENSG00000058668 ENSG00000101213 ENSG00000113522 
ENSG00000059804 ENSG00000101266 ENSG00000114638 
ENSG00000060140 ENSG00000101307 ENSG00000115165 
ENSG00000064201 ENSG00000101441 ENSG00000115523 
ENSG00000064545 ENSG00000101916 ENSG00000115607 
ENSG00000065615 ENSG00000102384 ENSG00000115919 
ENSG00000065618 ENSG00000102837 ENSG00000115956 
ENSG00000070526 ENSG00000102962 ENSG00000116701 
ENSG00000070915 ENSG00000103569 ENSG00000116785 
ENSG00000072042 ENSG00000103671 ENSG00000117595 
ENSG00000073282 ENSG00000104921 ENSG00000117600 
ENSG00000073803 ENSG00000105141 ENSG00000118217 
ENSG00000074706 ENSG00000105341 ENSG00000118520 
ENSG00000075884 ENSG00000105374 ENSG00000118640 
ENSG00000077984 ENSG00000105501 ENSG00000119535 
ENSG00000078098 ENSG00000105552 ENSG00000119922 
ENSG00000079257 ENSG00000105668 ENSG00000119943 
ENSG00000079263 ENSG00000105967 ENSG00000120915 
ENSG00000079385 ENSG00000106331 ENSG00000121552 
ENSG00000080986 ENSG00000106809 ENSG00000121807 
ENSG00000081237 ENSG00000106819 ENSG00000121858 
ENSG00000082074 ENSG00000107165 ENSG00000122122 
ENSG00000083782 ENSG00000108405 ENSG00000133048 
ENSG00000084110 ENSG00000108759 ENSG00000133063 
ENSG00000085265 ENSG00000109063 ENSG00000133110 
ENSG00000122133 ENSG00000128335 ENSG00000133195 
ENSG00000122180 ENSG00000128340 ENSG00000133574 
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ENSG00000122224 ENSG00000128383 ENSG00000133710 
ENSG00000123338 ENSG00000128422 ENSG00000133742 
ENSG00000123405 ENSG00000128510 ENSG00000134200 
ENSG00000123843 ENSG00000128513 ENSG00000134256 
ENSG00000124102 ENSG00000129460 ENSG00000134489 
ENSG00000124107 ENSG00000130176 ENSG00000134588 
ENSG00000124157 ENSG00000131050 ENSG00000134757 
ENSG00000124233 ENSG00000131355 ENSG00000134760 
ENSG00000124469 ENSG00000131686 ENSG00000134765 
ENSG00000124664 ENSG00000131738 ENSG00000135114 
ENSG00000124701 ENSG00000131746 ENSG00000135218 
ENSG00000124721 ENSG00000132109 ENSG00000135374 
ENSG00000124731 ENSG00000132297 ENSG00000135413 
ENSG00000124935 ENSG00000132517 ENSG00000135443 
ENSG00000125780 ENSG00000132704 ENSG00000135749 
ENSG00000125910 ENSG00000132746 ENSG00000135898 
ENSG00000126233 ENSG00000132965 ENSG00000135899 
ENSG00000126262 ENSG00000140067 ENSG00000135914 
ENSG00000126353 ENSG00000140379 ENSG00000136235 
ENSG00000126549 ENSG00000140506 ENSG00000136250 
ENSG00000126550 ENSG00000140749 ENSG00000136688 
ENSG00000126759 ENSG00000140798 ENSG00000136689 
ENSG00000127074 ENSG00000141378 ENSG00000136929 
ENSG00000127084 ENSG00000141469 ENSG00000137440 
ENSG00000127325 ENSG00000141499 ENSG00000137462 
ENSG00000127507 ENSG00000141756 ENSG00000137634 
ENSG00000127951 ENSG00000141968 ENSG00000137648 
ENSG00000128322 ENSG00000142512 ENSG00000137673 
ENSG00000170006 ENSG00000142515 ENSG00000137674 
ENSG00000170180 ENSG00000142619 ENSG00000137752 
ENSG00000170255 ENSG00000142676 ENSG00000137975 
ENSG00000170367 ENSG00000143105 ENSG00000137976 
ENSG00000170369 ENSG00000143110 ENSG00000138271 
ENSG00000170373 ENSG00000143119 ENSG00000138435 
ENSG00000170465 ENSG00000143178 ENSG00000138615 
ENSG00000170477 ENSG00000171346 ENSG00000138964 
ENSG00000170523 ENSG00000171401 ENSG00000172867 
ENSG00000171049 ENSG00000171711 ENSG00000173431 
ENSG00000171051 ENSG00000172232 ENSG00000173612 
ENSG00000171053 ENSG00000172243 ENSG00000174130 
ENSG00000171195 ENSG00000172331 ENSG00000174226 
ENSG00000171199 ENSG00000172349 ENSG00000174444 
ENSG00000171201 ENSG00000172543 ENSG00000174460 
ENSG00000171209 ENSG00000176024 ENSG00000174502 
ENSG00000178776 ENSG00000176714 ENSG00000175065 
ENSG00000179593 ENSG00000176920 ENSG00000175393 
ENSG00000179639 ENSG00000177138 ENSG00000175793 
ENSG00000179869 ENSG00000177954 ENSG00000176009 
ENSG00000143185 ENSG00000153029 ENSG00000163406 
ENSG00000143217 ENSG00000153233 ENSG00000163464 
ENSG00000143226 ENSG00000154451 ENSG00000163563 
ENSG00000143297 ENSG00000154589 ENSG00000163736 
ENSG00000143314 ENSG00000155561 ENSG00000163737 
ENSG00000143341 ENSG00000156234 ENSG00000163810 
ENSG00000143369 ENSG00000156265 ENSG00000163823 
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ENSG00000143374 ENSG00000157017 ENSG00000163914 
ENSG00000143409 ENSG00000158373 ENSG00000163993 
ENSG00000143486 ENSG00000158578 ENSG00000164047 
ENSG00000143536 ENSG00000158786 ENSG00000164077 
ENSG00000143546 ENSG00000158825 ENSG00000164509 
ENSG00000143556 ENSG00000158869 ENSG00000164609 
ENSG00000143624 ENSG00000159167 ENSG00000164691 
ENSG00000143851 ENSG00000159173 ENSG00000165071 
ENSG00000144061 ENSG00000159182 ENSG00000165125 
ENSG00000144481 ENSG00000159337 ENSG00000165168 
ENSG00000145649 ENSG00000159339 ENSG00000165272 
ENSG00000145879 ENSG00000159763 ENSG00000165349 
ENSG00000146094 ENSG00000160336 ENSG00000165390 
ENSG00000146143 ENSG00000160349 ENSG00000165794 
ENSG00000146411 ENSG00000160593 ENSG00000166523 
ENSG00000146859 ENSG00000160862 ENSG00000166535 
ENSG00000147162 ENSG00000160883 ENSG00000166670 
ENSG00000147168 ENSG00000162078 ENSG00000167207 
ENSG00000147606 ENSG00000162511 ENSG00000167210 
ENSG00000147689 ENSG00000162614 ENSG00000167261 
ENSG00000147873 ENSG00000162645 ENSG00000167332 
ENSG00000148215 ENSG00000162747 ENSG00000167346 
ENSG00000148346 ENSG00000162892 ENSG00000167656 
ENSG00000148604 ENSG00000162896 ENSG00000167749 
ENSG00000149021 ENSG00000163009 ENSG00000167751 
ENSG00000149516 ENSG00000163017 ENSG00000167759 
ENSG00000149781 ENSG00000163116 ENSG00000167768 
ENSG00000149968 ENSG00000163131 ENSG00000167825 
ENSG00000150540 ENSG00000163207 ENSG00000167851 
ENSG00000152266 ENSG00000163209 ENSG00000167925 
ENSG00000152931 ENSG00000163219 ENSG00000168515 
ENSG00000179934 ENSG00000163220 ENSG00000168907 
ENSG00000179941 ENSG00000163221 ENSG00000169035 
ENSG00000180353 ENSG00000185479 ENSG00000169248 
ENSG00000180785 ENSG00000185862 ENSG00000169385 
ENSG00000180871 ENSG00000186081 ENSG00000169397 
ENSG00000181631 ENSG00000186130 ENSG00000169413 
ENSG00000182165 ENSG00000186226 ENSG00000169442 
ENSG00000182795 ENSG00000186517 ENSG00000169469 
ENSG00000182885 ENSG00000186526 ENSG00000169474 
ENSG00000183036 ENSG00000186529 ENSG00000169605 
ENSG00000183486 ENSG00000186723 ENSG00000169877 
ENSG00000183542 ENSG00000186803 ENSG00000169908 
ENSG00000184148 ENSG00000186832 ENSG00000187871 
ENSG00000184330 ENSG00000186847 ENSG00000187908 
ENSG00000184357 ENSG00000186912 ENSG00000188015 
ENSG00000184564 ENSG00000186943 ENSG00000188153 
ENSG00000184635 ENSG00000186971 ENSG00000188293 
ENSG00000184730 ENSG00000187010 ENSG00000188404 
ENSG00000184752 ENSG00000187145 ENSG00000188710 
ENSG00000185186 ENSG00000189068 ENSG00000211967 
ENSG00000197641 ENSG00000189299 ENSG00000213398 
ENSG00000198077 ENSG00000189377 ENSG00000213417 
ENSG00000198223 ENSG00000196154 ENSG00000213762 
ENSG00000198523 ENSG00000196329 ENSG00000213809 
184 
 
ENSG00000198692 ENSG00000196748 ENSG00000214049 
ENSG00000198734 ENSG00000196754 ENSG00000214374 
ENSG00000198771 ENSG00000196805 ENSG00000215203 
ENSG00000203813 ENSG00000196878 ENSG00000218089 
ENSG00000204174 ENSG00000196954 ENSG00000221852 
ENSG00000204361 ENSG00000197061 ENSG00000222036 
ENSG00000204472 ENSG00000197079 ENSG00000223380 
ENSG00000204482 ENSG00000197405 ENSG00000223609 
ENSG00000204539 ENSG00000197487 ENSG00000223865 
ENSG00000204936 ENSG00000197565 ENSG00000225937 
ENSG00000205021 ENSG00000197588 ENSG00000226516 
ENSG00000205420 ENSG00000197591 ENSG00000226777 
ENSG00000205426 ENSG00000197617 ENSG00000227418 
ENSG00000205649 ENSG00000189068 ENSG00000244734 
ENSG00000205810 ENSG00000229035 ENSG00000248098 
ENSG00000205981 ENSG00000229637 ENSG00000250361 
ENSG00000206047 ENSG00000230389 ENSG00000251321 
ENSG00000206073 ENSG00000231887 ENSG00000251655 
ENSG00000206075 ENSG00000232258 ENSG00000254126 
ENSG00000206301 ENSG00000235568 ENSG00000254127 
ENSG00000207720 ENSG00000235942 ENSG00000255398 
ENSG00000211592 ENSG00000236699 ENSG00000255794 
ENSG00000211689 ENSG00000237330 ENSG00000256812 
ENSG00000211895 ENSG00000237599 ENSG00000257227 
ENSG00000260199 ENSG00000239590 ENSG00000257335 
ENSG00000262128 ENSG00000239839 ENSG00000258227 
ENSG00000262320 ENSG00000241058 ENSG00000268943 
ENSG00000262383 ENSG00000241794 ENSG00000268954 
ENSG00000262406 ENSG00000242180 ENSG00000269936 
ENSG00000262462 ENSG00000262827 ENSG00000271481 
ENSG00000262754 ENSG00000262936 ENSG00000271503 
ENSG00000262800 ENSG00000263639 ENSG00000271942 
ENSG00000260199 ENSG00000264162 ENSG00000272611 
ENSG00000266722 ENSG00000266109 ENSG00000272743 
ENSG00000268682 ENSG00000268090 ENSG00000272939 











Table 2: The mean, median and min-max methylation levels of CGIs associated with 50 
selected genes, with greater than 75% methylation. 
EnsEMBL ID Gene Mean|Median|Min-Max Methylation 
 
ENSG00000135636 DYSF 11.2750532534482|3.61764705882353|1.36842105263158-63.5333333333333  
  13.1832706177719|3.15789473684211|0.736842105263158-95.4285714 
  28571454.0085511074985|44.8571428571429|8.4-96.4285714285714  
  86.2662823868664|91.1016949152542|74.2272727272727-93.4698795180723 
ENSG00000172244 C5orf34 84.0185164329823|85|62.5-96 
ENSG00000065268 WDR18 86.7600793650794|91.31|76.9285714285714-92.0416666666667 
  19.5931142410016|16 |0.112676056338028-42.6666666666667 
ENSG00000082293 COL19A1 86.1407193375884|84.7058823529412|84.5227272727273-89.1935483870968 
  5.07732374702386|1.6530612244898|0.518518518518518-96.5918367346939 
ENSG00000160145 KALRN 85.7425535680253|93.9047619047619|68.7547169811321-94.5681818181818  
  7.22430604197057|2|0.636363636363636-76.2727272727273 
ENSG00000107077 KDM4C 91.7308360992571|91.8333333333333|89.2105263157895-94.1486486486486  
  96.8451937074094|97|91-100 
  2.53033039684938|1.3030303030303|0.36101083032491-29.5  
  93.8157722940332|93.1739130434783|90.2463768115942-98.027027027027 
ENSG00000155657 TTN 82.245447788926|79.4927536231884|77.5-89.7435897435897 
ENSG00000174564 IL20RB 92.1183932346723|96.7272727272727|82.5348837209302-97.0930232558139 
  81.4848484848485|83|61.4545454545455-100 
ENSG00000145934 TENM2 95.0315734989648|95.9642857142857|89.5-99.6304347826087  
  83.8511977925498|88.8235294117647|73.0285714285714-89.7014925373134 
ENSG00000196353 CPNE4 85.3280980371009|84.328125|75.1315789473684-96.5245901639344  
  71.0537988581467|74.5833333333333|57.7954545454545-80.7826086956522 
ENSG00000100266 PACSIN2 2.8875871343697|1.33567774936061|0.333333333333333-42.8  
  5.08376673818981|1.57627118644068|0.26530612244898-77.4090909090909  
  97.1091051805338|96.5|96.1538461538462-98.6734693877551  
  89.4076115650534|93.33 |80.6486486486486-94.2441860465116 
ENSG00000128641 MYO1B 5.98434426784891|1.6|0.59375-82.925  
  85.8585651936716|93.7872340425532|69.7884615384615-94 
ENSG00000130300 PLVAP 87.4240990990991|91.6125|77.3625-93.2972972972973 
  9.0953819784508|3.13194444444444|1.23188405797101-96.3787878787879 
ENSG00000149596 JPH2 83.0004094819862|79.3349753694581|76.2918454935622-93.3744075829384  
  37.9815157901293|27.1111111111111|6.6-92.8620689655172 
ENSG00000006459 KDM7A 87.85744596346|91.7761194029851 |78.9285714285714-92.8676470588235  
  3.45142039708166|1.55414012738854|0.531531531531532-47.8 
  12.8796572088108|7|1.25-62.5  
ENSG00000188419 CHM 89.9805617147081|91.7|86.3636363636364-91.8780487804878 
ENSG00000187605 TET3 94.6275452393032|94.925|93.5740740740741-95.3835616438356  
  6.98777996251653|1.58928571428571|0.761904761904762-92.2307692307692 
ENSG00000130803 ZNF317 97.0165996057797|97.6666666666667|84.1082802547771-100 
  22.1580086580087|10|0.974025974025974-55.5 
ENSG00000146205 ANO7 7.565024458572|2.54054054054054|1.16666666666667-61.2903225806452  
  82.680303030303|83.7833333333333|74.6212121212121-89.6363636363636  
ENSG00000088247 KHSRP 2.50888888888889|1.41666666666667|0.166666666666667-39.75  
  89.9094017473675|90.8518518518518|75.8857142857143-97.9 
ENSG00000167658 EEF2 94.1518947161268|94.4444444444444|85.4285714285714-99 




ENSG00000136231 IGF2BP3 96.1947419668939|98|92.4303797468354-98.1538461538462  
  5.56103087595058|2.28|0.634146341463415-83.925 
ENSG00000183570 PCBP3 81.0320132779149|86|11-100 
  85.8027065527065|86.4358974358974|74.0972222222222-96.875 
  85.5989289946222|85.3|81.6163522012579-89.8804347826087  
  88.5947978107232|88.650406504065|82.7450980392157-94.3888888888889 
  20.4766002493438|10.4461538461538|4.1-79.1666666666667 
  82.2842273521431|89.1836734693878|65.0952380952381-92.5737704918033 
ENSG00000115756 HPCAL1 4.96868581389298|1.99038461538462|1.25438596491228-51.3939393939394 
  94.2708596345888|94.7857142857143|83.3571428571429-98.8571428571429 
ENSG00000064012 CASP8 94.6370347998255|97.2790697674419|88.9047619047619-97.7272727272727 
ENSG00000030304 MUSK 85.0794205794206|84.1538461538462|82.8571428571429-88.2272727272727 
ENSG00000115306 SPTBN1 82.6227450980392|82.5882352941177|75.68-89.6  
  4.97683349565548|1.44|0.220125786163522-100  
  3.7819546472277|1.65151515151515|0.516483516483517-43.5 
ENSG00000196358 NTNG2 4.62538587305964|2.35443037974684|0.704918032786885-53.7272727272727 
  89.3429103500532|93.4285714285714|24-100  
  8.45191976953081|3.33695652173913|1.31132075471698-45.7582417582418  
  85.4282495905878|88.5686274509804|74.1594202898551-93.5567010309278 
ENSG00000165102 HGSNAT 2.57680019706837|1.53791574279379|0.0608695652173913-43  
  89.7561680469289|95.0869565217391|78.0357142857143-96.1458333333333 
ENSG00000197548 ATG7 95.8862716532579|96.75|82.75-100 
ENSG00000119121 TRPM6 84.3155187524457|86.421568627451 |75.1063829787234-91.4186046511628 
  3.83575549085048|1.3125|0.52-50 
ENSG00000113448 PDE4D 87.1639869281046|88.5166666666667 |83.24-89.7352941176471 
  17.7656531784963|3.90634920634921|1.12244897959184-97.0714285714286 
  3.50603286883218|1.69047619047619|0.478260869565217-27.5 
ENSG00000101868 POLA1 9.1268851358876|3.18181818181818|0.266666666666667-61.6324786324786 
  95.7310938845822|95.3488372093023 |91.8444444444444-100 
ENSG00000105426 PTPRS 95.3194876473019|95.9090909090909|88.2857142857143-98.6428571428571 
  66.3326482732733|75.1126126126126|21-100  
  93.6196047269877|94.725|81.2430555555556-97.6388888888889 
  5.19480788751105|2.28947368421053|0.760869565217391-30.25 
  5.14010592434024|1.6734693877551|0.516666666666667-76.1428571428571 
ENSG00000124225 PMEPA1 81.4122257053292|91.2424242424242 |61.1666666666667-91.8275862068966 
  66.5824894360971|70.5454545454545|1.11111111111111-97.3333333333333 
  5.51692921853267|1.75384615384615|0.775700934579439-59.25 
ENSG00000091831 ESR1 85.9675862593099|89.3488372093023 |76.4705882352941-92.0833333333333 
  11.9466195289074|2.79591836734694|0.566666666666667-92.4137931034483 
ENSG00000015475 BID BH3 3.57634733358342|1.84090909090909|0.230769230769231-50 
  83.7469158127386|85.8095238095238|78.1645569620253-87.2666666666667 
ENSG00000101096 NFATC1 10.0024597251936|3.75|0.9375-54.8701298701299 
  95.0845607407532|95.0217391304348 |86.1176470588235-98.1666666666667 
  4.84010094054851|1.90625|0.5-47.1875 
  42.0693740555536|37.8181818181818|0.636363636363636-97.2 
ENSG00000079482 OPHN1 22.2248068272873|22.9230769230769|0.714285714285714-72.4666666666667 
  76.6743445916378|83.1224489795918 |59.7894736842105-87.1111111111111 
  92.6984126984127|90|88.0952380952381-100 
  89.6658507893139|90.6885245901639|84.7777777777778-93.53125 
ENSG00000063169 GLTSCR1 88.4584657578446|89.5|76.6666666666667-95.5  
  93.4555915992439|93.2068965517241|87.3-97.625  
  93.781545600047|94.4|86.2-98.4  
187 
 
  3.64126293531793|1.88961038961039|0.71900826446281-41.75 
ENSG00000184470 TXNRD2 91.4721568627451|92.4705882352941 |89.24-92.7058823529412 
ENSG00000050767 COL23A1 85.9724206349206|88.5333333333333|78.5714285714286-90.8125 
  87.625577836082|92.5|38.3333333333333-100 
  9.15378658084283|3.76388888888889|1.05555555555556-98.2142857142857 
  27.8839109466504|12.3269230769231|1.75510204081633-97.4 
  91.6685518143184|91.8695652173913|86.7789473684211-96.3571428571429 
ENSG00000159733 ZFYVE28 83.8349462365591|88.8548387096774 |71.7666666666667-90.8833333333333 
  5.0399131624867|2.1875|1.11242603550296-48.4590163934426 
  35.7332857307299|21.3333333333333|3.76190476190476-97.4444444444444 
  83.4936779765021|88.5679012345679|71.3837209302326-90.5294117647059 
ENSG00000109572 CLCN3 9.99881796690308|12 |1.32978723404255-16.6666666666667  
  2.42065810560668|1.35294117647059|0.470588235294118-41.5  
  85.7906258850184|87.4333333333333|80.3030303030303-89.6355140186916 
ENSG00000127191 TRAF2 4.23557411210648|1.44761904761905|0.693877551020408-77.6666666666667 
  91.7861729704254|94.2317073170732|86.0434782608696-95.0833333333333 
ENSG00000206560 ANKRD28 3.05839206517669|1.54838709677419 |0.652173913043478-48.6666666666667 
  93.3603603603604|94.5945945945946 |88.7297297297297-96.7567567567568 
ENSG00000090889 KIF4A 82.1080986878281|87.9072164948454|69.4383561643836-88.9787234042553  
  91.5691884280594|93.4166666666667|84.9516129032258-96.3392857142857 
ENSG00000083223 ZCCHC6 92.9225957049487|91.7058823529412|90.5142857142857-96.5476190476191 
  3.65700724741376|1.54545454545455|0.540540540540541-63.8333333333333 
ENSG00000068024 HDAC4 93.0201739103857|93.7142857142857|81.725-100 
  70.9198343079922|73.3333333333333|1-100 
  3.62191859201892|1.80645161290323|0.720338983050847-39.65 
ENSG00000170265 ZNF282 95.1818913608771|95.5238095238095|88.358024691358-98.0714285714286 














Table 3: List of genes that displayed methylation levels below 75%. 
ENSG00000155545 ENSG00000184056 ENSG00000170961 ENSG00000182318 
ENSG00000178226 ENSG00000158417 ENSG00000130707 ENSG00000170802 
ENSG00000069011 ENSG00000132604 ENSG00000141298 ENSG00000162040 
ENSG00000215440 ENSG00000072786 ENSG00000196943 ENSG00000050628 
ENSG00000185947 ENSG00000120899 ENSG00000170581 ENSG00000161798 
ENSG00000111328 ENSG00000136937 ENSG00000149554 ENSG00000167130 
ENSG00000161992 ENSG00000162676 ENSG00000174292 ENSG00000125965 
ENSG00000164221 ENSG00000096070 ENSG00000157540 ENSG00000117480 
ENSG00000088205 ENSG00000177200 ENSG00000125257 ENSG00000135842 
ENSG00000173581 ENSG00000172197 ENSG00000114209 ENSG00000185100 
ENSG00000135636 ENSG00000151726 ENSG00000104267 ENSG00000198464 
ENSG00000172244 ENSG00000107159 ENSG00000155657 ENSG00000198863 
ENSG00000164164 ENSG00000104856 ENSG00000205133 ENSG00000092758 
ENSG00000167004 ENSG00000082293 ENSG00000185088 ENSG00000145592 
ENSG00000158019 ENSG00000184381 ENSG00000114779 ENSG00000134516 
ENSG00000158715 ENSG00000135698 ENSG00000151617 ENSG00000103174 
ENSG00000119559 ENSG00000145860 ENSG00000170485 ENSG00000179111 
ENSG00000185024 ENSG00000176597 ENSG00000109743 ENSG00000198001 
ENSG00000106780 ENSG00000136490 ENSG00000164284 ENSG00000163660 
ENSG00000140332 ENSG00000109255 ENSG00000065621 ENSG00000123609 
ENSG00000166451 ENSG00000100359 ENSG00000203747 ENSG00000134574 
ENSG00000241399 ENSG00000136161 ENSG00000158470 ENSG00000107738 
ENSG00000083307 ENSG00000242110 ENSG00000182858 ENSG00000185215 
ENSG00000134201 ENSG00000089639 ENSG00000167034 ENSG00000130119 
ENSG00000048140 ENSG00000046604 ENSG00000182796 ENSG00000174564 
ENSG00000062282 ENSG00000174851 ENSG00000196652 ENSG00000112062 
ENSG00000171055 ENSG00000183242 ENSG00000167202 ENSG00000168875 
ENSG00000101624 ENSG00000101333 ENSG00000008283 ENSG00000152822 
ENSG00000075218 ENSG00000148110 ENSG00000165527 ENSG00000111186 
ENSG00000180739 ENSG00000100461 ENSG00000153179 ENSG00000188372 
ENSG00000186205 ENSG00000137841 ENSG00000266714 ENSG00000151702 
ENSG00000161055 ENSG00000080815 ENSG00000038219 ENSG00000158483 
ENSG00000148773 ENSG00000113013 ENSG00000070371 ENSG00000068878 
ENSG00000082175 ENSG00000140993 ENSG00000169174 ENSG00000253293 
ENSG00000140564 ENSG00000156427 ENSG00000169599 ENSG00000169621 
ENSG00000181577 ENSG00000058866 ENSG00000144339 ENSG00000077063 
ENSG00000115963 ENSG00000091127 ENSG00000179583 ENSG00000175264 
ENSG00000184825 ENSG00000166900 ENSG00000133067 ENSG00000114480 
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ENSG00000125347 ENSG00000068831 ENSG00000106714 ENSG00000122592 
ENSG00000152359 ENSG00000169213 ENSG00000196914 ENSG00000141574 
ENSG00000204842 ENSG00000198729 ENSG00000073756 ENSG00000009413 
ENSG00000173535 ENSG00000184708 ENSG00000152229 ENSG00000198211 
ENSG00000143147 ENSG00000134215 ENSG00000180340 ENSG00000117525 
ENSG00000005073 ENSG00000130720 ENSG00000162493 ENSG00000146205 
ENSG00000165502 ENSG00000113916 ENSG00000168092 ENSG00000108932 
ENSG00000077782 ENSG00000099953 ENSG00000072195 ENSG00000153113 
ENSG00000112234 ENSG00000128652 ENSG00000113296 ENSG00000121742 
ENSG00000119760 ENSG00000140279 ENSG00000169020 ENSG00000244274 
ENSG00000149177 ENSG00000156983 ENSG00000104960 ENSG00000112699 
ENSG00000122335 ENSG00000104356 ENSG00000125845 ENSG00000145569 
ENSG00000168461 ENSG00000197561 ENSG00000184307 ENSG00000152256 
ENSG00000188130 ENSG00000136378 ENSG00000122585 ENSG00000110934 
ENSG00000075290 ENSG00000262209 ENSG00000173545 ENSG00000133028 
ENSG00000005381 ENSG00000148300 ENSG00000184012 ENSG00000140577 
ENSG00000121671 ENSG00000108669 ENSG00000104047 ENSG00000167815 
ENSG00000144668 ENSG00000117691 ENSG00000142765 ENSG00000157613 
ENSG00000165097 ENSG00000064115 ENSG00000168071 ENSG00000076662 
ENSG00000166938 ENSG00000150867 ENSG00000196428 ENSG00000133704 
ENSG00000060138 ENSG00000125967 ENSG00000008869 ENSG00000148803 
ENSG00000166006 ENSG00000021762 ENSG00000171462 ENSG00000165501 
ENSG00000166509 ENSG00000149489 ENSG00000105427 ENSG00000001167 
ENSG00000124251 ENSG00000137709 ENSG00000151835 ENSG00000167705 
ENSG00000198604 ENSG00000171840 ENSG00000153094 ENSG00000182230 
ENSG00000047648 ENSG00000225921 ENSG00000230989 ENSG00000178449 
ENSG00000038002 ENSG00000183166 ENSG00000178038 ENSG00000124614 
ENSG00000113119 ENSG00000109184 ENSG00000049319 ENSG00000115380 
ENSG00000182400 ENSG00000170540 ENSG00000185721 ENSG00000118849 
ENSG00000141506 ENSG00000121691 ENSG00000136819 ENSG00000109881 
ENSG00000182162 ENSG00000105538 ENSG00000176386 ENSG00000187583 
ENSG00000175938 ENSG00000043355 ENSG00000103222 ENSG00000110400 
ENSG00000059378 ENSG00000035664 ENSG00000197965 ENSG00000040608 
ENSG00000076928 ENSG00000006016 ENSG00000171174 ENSG00000085719 
ENSG00000070031 ENSG00000214160 ENSG00000145331 ENSG00000182566 
ENSG00000121316 ENSG00000132773 ENSG00000169981 ENSG00000145113 
ENSG00000196357 ENSG00000131018 ENSG00000137699 ENSG00000197261 
ENSG00000197622 ENSG00000154553 ENSG00000139190 ENSG00000135372 
ENSG00000142347 ENSG00000010017 ENSG00000145916 ENSG00000139289 
ENSG00000117280 ENSG00000101596 ENSG00000149488 ENSG00000180818 
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ENSG00000198315 ENSG00000103343 ENSG00000101773 ENSG00000128040 
ENSG00000106003 ENSG00000137193 ENSG00000119986 ENSG00000137273 
ENSG00000186523 ENSG00000169851 ENSG00000105835 ENSG00000198554 
ENSG00000204160 ENSG00000131351 ENSG00000124243 ENSG00000101654 
ENSG00000000938 ENSG00000032219 ENSG00000184922 ENSG00000106031 
ENSG00000084693 ENSG00000185761 ENSG00000005302 ENSG00000170425 
ENSG00000115163 ENSG00000101336 ENSG00000148655 ENSG00000179104 
ENSG00000077420 ENSG00000019186 ENSG00000066427 ENSG00000005961 
ENSG00000171517 ENSG00000006611 ENSG00000171135 ENSG00000167513 
ENSG00000138780 ENSG00000167580 ENSG00000198951 ENSG00000177105 
ENSG00000103257 ENSG00000170577 ENSG00000104064 ENSG00000166974 
ENSG00000135655 ENSG00000174669 ENSG00000186635 ENSG00000123146 
ENSG00000126822 ENSG00000169083 ENSG00000103381 ENSG00000167799 
ENSG00000036549 ENSG00000179361 ENSG00000110075 ENSG00000134901 
ENSG00000173480 ENSG00000267645 ENSG00000183943 ENSG00000187735 
ENSG00000118197 ENSG00000130741 ENSG00000165879 ENSG00000182481 
ENSG00000102554 ENSG00000124193 ENSG00000026103 ENSG00000173530 
ENSG00000169896 ENSG00000096696 ENSG00000104447 ENSG00000143061 
ENSG00000053747 ENSG00000115750 ENSG00000042286 ENSG00000130844 
ENSG00000066336 ENSG00000184076 ENSG00000174579 ENSG00000112164 
ENSG00000106351 ENSG00000223414 ENSG00000134046 ENSG00000165025 
ENSG00000108443 ENSG00000130635 ENSG00000145819 ENSG00000204219 
ENSG00000127989 ENSG00000128585 ENSG00000163067 ENSG00000105329 
ENSG00000015285 ENSG00000185567 ENSG00000125657 ENSG00000131389 
ENSG00000225930 ENSG00000128713 ENSG00000173546 ENSG00000124440 
ENSG00000089195 ENSG00000136718 ENSG00000124466 ENSG00000198858 
ENSG00000117151 ENSG00000152078 ENSG00000174562 ENSG00000180071 
ENSG00000167693 ENSG00000249859 ENSG00000196767 ENSG00000141380 
ENSG00000135604 ENSG00000134698 ENSG00000140836 ENSG00000183762 
ENSG00000168769 ENSG00000105122 ENSG00000221866 ENSG00000188672 
ENSG00000173511 ENSG00000144909 ENSG00000171097 ENSG00000187266 
ENSG00000173442 ENSG00000141655 ENSG00000254087 ENSG00000095261 
ENSG00000115361 ENSG00000198088 ENSG00000113719 ENSG00000120457 
ENSG00000100311 ENSG00000164920 ENSG00000187840 ENSG00000136536 
ENSG00000150281 ENSG00000057704 ENSG00000170178 ENSG00000117143 
ENSG00000197361 ENSG00000172006 ENSG00000090339 ENSG00000172432 
ENSG00000116478 ENSG00000187079 ENSG00000115138 ENSG00000128709 
ENSG00000110324 ENSG00000166923 ENSG00000162526 ENSG00000144674 
ENSG00000168476 ENSG00000182580 ENSG00000124766 ENSG00000129355 
ENSG00000110375 ENSG00000108055 ENSG00000140519 ENSG00000165533 
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ENSG00000174206 ENSG00000146457 ENSG00000021355 ENSG00000211456 
ENSG00000214021 ENSG00000204271 ENSG00000138162 ENSG00000122644 
ENSG00000158615 ENSG00000162129 ENSG00000156017 ENSG00000166710 
ENSG00000146733 ENSG00000112146 ENSG00000168209 ENSG00000156273 
ENSG00000112541 ENSG00000064270 ENSG00000100599 ENSG00000140396 
ENSG00000136286 ENSG00000149499 ENSG00000160703 ENSG00000137198 
ENSG00000136877 ENSG00000005020 ENSG00000151657 ENSG00000166133 
ENSG00000104976 ENSG00000137414 ENSG00000074319 ENSG00000146676 
ENSG00000138180 ENSG00000156113 ENSG00000115761 ENSG00000112208 
ENSG00000111913 ENSG00000148842 ENSG00000198108 ENSG00000160753 
ENSG00000130038 ENSG00000143761 ENSG00000117115 ENSG00000132334 
ENSG00000167700 ENSG00000163795 ENSG00000169567 ENSG00000077943 
ENSG00000134419 ENSG00000185009 ENSG00000117713 ENSG00000147889 
ENSG00000171700 ENSG00000107625 ENSG00000140406 ENSG00000105204 
ENSG00000130592 ENSG00000124383 ENSG00000135363 ENSG00000179029 
ENSG00000048740 ENSG00000081277 ENSG00000168010 ENSG00000136167 
ENSG00000198736 ENSG00000118855 ENSG00000139865 ENSG00000150893 
ENSG00000121749 ENSG00000157570 ENSG00000167173 ENSG00000089248 
ENSG00000133401 ENSG00000140368 ENSG00000154025 ENSG00000123388 
ENSG00000171307 ENSG00000111790 ENSG00000103544 ENSG00000130733 
ENSG00000181222 ENSG00000104154 ENSG00000129657 ENSG00000130775 
ENSG00000163357 ENSG00000006194 ENSG00000117148 ENSG00000141404 
ENSG00000169752 ENSG00000132570 ENSG00000078061 ENSG00000198900 
ENSG00000158711 ENSG00000130755 ENSG00000109775 ENSG00000183878 
ENSG00000104413 ENSG00000180447 ENSG00000166477 ENSG00000100285 
ENSG00000100350 ENSG00000182022 ENSG00000160712 ENSG00000071054 
ENSG00000119231 ENSG00000145088 ENSG00000135838 ENSG00000181274 
ENSG00000158406 ENSG00000143537 ENSG00000141480 ENSG00000167996 
ENSG00000182287 ENSG00000151651 ENSG00000123329 ENSG00000169180 
ENSG00000137857 ENSG00000116747 ENSG00000100416 ENSG00000092036 
ENSG00000168310 ENSG00000131759 ENSG00000101425 ENSG00000159648 
ENSG00000074657 ENSG00000187778 ENSG00000107551 ENSG00000136867 
ENSG00000183597 ENSG00000198755 ENSG00000184937 ENSG00000159461 
ENSG00000129933 ENSG00000108264 ENSG00000134202 ENSG00000182568 
ENSG00000159202 ENSG00000203685 ENSG00000164647 ENSG00000178935 
ENSG00000143815 ENSG00000147065 ENSG00000132507 ENSG00000103855 
ENSG00000144029 ENSG00000175643 ENSG00000100985 ENSG00000011198 
ENSG00000139874 ENSG00000128714 ENSG00000101236 ENSG00000204138 
ENSG00000173171 ENSG00000158042 ENSG00000117411 ENSG00000151503 
ENSG00000197045 ENSG00000107187 ENSG00000135069 ENSG00000176390 
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ENSG00000168077 ENSG00000122420 ENSG00000166592 ENSG00000165312 
ENSG00000181444 ENSG00000254806 ENSG00000177192 ENSG00000178403 
ENSG00000160796 ENSG00000184281 ENSG00000100983 ENSG00000157554 
ENSG00000149212 ENSG00000105656 ENSG00000213390 ENSG00000163798 
ENSG00000116815 ENSG00000114115 ENSG00000173214 ENSG00000167114 
ENSG00000104979 ENSG00000069275 ENSG00000107262 ENSG00000150051 
ENSG00000035928 ENSG00000075643 ENSG00000085982 ENSG00000161513 
ENSG00000137809 ENSG00000182257 ENSG00000138735 ENSG00000107968 
ENSG00000008516 ENSG00000113231 ENSG00000123364 ENSG00000149269 
ENSG00000198000 ENSG00000066468 ENSG00000105483 ENSG00000171729 
ENSG00000196422 ENSG00000141002 ENSG00000170456 ENSG00000171763 
ENSG00000168386 ENSG00000127191 ENSG00000075073 ENSG00000221829 
ENSG00000119684 ENSG00000099341 ENSG00000144554 ENSG00000197299 
ENSG00000132906 ENSG00000164032 ENSG00000120616 ENSG00000129451 
ENSG00000163069 ENSG00000131969 ENSG00000112996 ENSG00000164941 
ENSG00000146410 ENSG00000113648 ENSG00000117614 ENSG00000104765 
ENSG00000089154 ENSG00000077157 ENSG00000130590 ENSG00000159184 
ENSG00000138346 ENSG00000165816 ENSG00000137642 ENSG00000133392 
ENSG00000103202 ENSG00000101255 ENSG00000145808 ENSG00000100612 
ENSG00000163637 ENSG00000185811 ENSG00000180758 ENSG00000105676 
ENSG00000167419 ENSG00000110328 ENSG00000088386 ENSG00000005513 
ENSG00000173575 ENSG00000165752 ENSG00000109180 ENSG00000163497 
ENSG00000114626 ENSG00000076242 ENSG00000182463 ENSG00000116741 
ENSG00000141524 ENSG00000155506 ENSG00000187866 ENSG00000005339 
ENSG00000008382 ENSG00000012061 ENSG00000198924 ENSG00000007038 
ENSG00000100802 ENSG00000131873 ENSG00000172845 ENSG00000107018 
ENSG00000172987 ENSG00000173068 ENSG00000187741 ENSG00000067113 
ENSG00000243766 ENSG00000175054 ENSG00000090470 ENSG00000144468 
ENSG00000108306 ENSG00000179151 ENSG00000125457 ENSG00000133805 
ENSG00000186642 ENSG00000172789 ENSG00000160255 ENSG00000102539 
ENSG00000154229 ENSG00000128283 ENSG00000196655 ENSG00000087460 
ENSG00000165689 ENSG00000259112 ENSG00000163421 ENSG00000132676 
ENSG00000171608 ENSG00000102879 ENSG00000156026 ENSG00000151715 
ENSG00000133302 ENSG00000172936 ENSG00000115271 ENSG00000165912 
ENSG00000136040 ENSG00000168765 ENSG00000124171 ENSG00000139842 
ENSG00000015133 ENSG00000049239 ENSG00000145824 ENSG00000182132 
ENSG00000089159 ENSG00000132849 ENSG00000139132 ENSG00000130193 
ENSG00000135312 ENSG00000187210 ENSG00000136522 ENSG00000181192 
ENSG00000143669 ENSG00000109805 ENSG00000114738 ENSG00000101412 
ENSG00000076944 ENSG00000170571 ENSG00000143768 ENSG00000110090 
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ENSG00000158717 ENSG00000007541 ENSG00000179008 ENSG00000164078 
ENSG00000106591 ENSG00000029534 ENSG00000182307 ENSG00000176170 
ENSG00000106038 ENSG00000133627 ENSG00000135441 ENSG00000129514 
ENSG00000254470 ENSG00000072401 ENSG00000140044 ENSG00000102921 
ENSG00000088543 ENSG00000171862 ENSG00000113387 ENSG00000168556 
ENSG00000171444 ENSG00000127616 ENSG00000114026 ENSG00000170615 
ENSG00000147324 ENSG00000108591 ENSG00000143476 ENSG00000104093 
ENSG00000100504 ENSG00000088387 ENSG00000134996 ENSG00000088992 
ENSG00000112964 ENSG00000123700 ENSG00000169509 ENSG00000128965 
ENSG00000168067 ENSG00000175106 ENSG00000170370 ENSG00000198768 
ENSG00000102034 ENSG00000198918 ENSG00000062038 ENSG00000132436 
ENSG00000111432 ENSG00000133961 ENSG00000171777 ENSG00000138696 
ENSG00000119699 ENSG00000100314 ENSG00000144063 ENSG00000148572 
ENSG00000100393 ENSG00000177548 ENSG00000129534 ENSG00000111845 
ENSG00000115524 ENSG00000138376 ENSG00000165474 ENSG00000129474 
ENSG00000125691 ENSG00000034713 ENSG00000143801 ENSG00000104738 
ENSG00000175356 ENSG00000169826 ENSG00000088826 ENSG00000150361 
ENSG00000143578 ENSG00000136630 ENSG00000163975 ENSG00000173110 






Table 4: Sequences of CGIs targeted for primer design. The primer sequences are highlighted in yellow. 
 




































































































BLAST results for CGI sequences mapping uniquely to a single gene. 
 
 
Figure 2: The CGI sequence specific to gene DYSF. 
Genomic Location Overlapping 
Gene(s) 
Orientation Query start Query end Length Score E-val %ID 
19:3977535-3978039 [Sequence] EEF2 Forward 1 505 505 [Sequence] 1001 0.0 100.00 [Alignment] 
 
Figure 3: The CGI sequence specific to gene EEF2. 
Genomic Location Overlapping 
Gene(s) 
Orientation Query start Query end Length Score E-val %ID 
2:71560383-71560921 [Sequence] DYSF  Forward 1 539 539 [Sequence] 1068 0.0 100.00 [Alignment] 
2:66313933-66313958 [Sequence]  Reverse 468 493 26 [Sequence] 44.1 1.2 96.15 [Alignment] 
2:90009223-90009248 [Sequence]  Reverse 220 245 26 [Sequence] 44.1 1.2 96.15 [Alignment] 
10:132569812-132569833 [Sequence] INPP5A Reverse 218 239 22 [Sequence] 44.1 1.2 100.00 [Alignment] 
10:132570107-132570128 [Sequence] INPP5A Reverse 218 239 22 [Sequence] 44.1 1.2 100.00 [Alignment] 
7:5816172-5816192 [Sequence]  Reverse 233 253 21 [Sequence] 42.1 4.7 100.00 [Alignment] 
12:109422767-109422787 [Sequence] MYO1H Forward 220 240 21 [Sequence] 42.1 4.7 100.00 [Alignment] 
12:109769678-109769698 [Sequence] FAM222A, FAM222A-
AS1 
Forward 481 501 21 [Sequence] 42.1 4.7 100.00 [Alignment] 
11:2065060-2065080 [Sequence]  Reverse 511 531 21 [Sequence] 42.1 4.7 100.00 [Alignment] 
1:45843122-45843142 [Sequence] MAST2  Reverse 220 240 21 [Sequence] 42.1 4.7 100.00 [Alignment] 
1:160474723-160474743 [Sequence]  Reverse 472 492 21 [Sequence] 42.1 4.7 100.00 [Alignment] 
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Genomic Location Overlapping Gene(s) Orientation Query start Query end Length Score E-val %ID 
2:10419626-10419743 [Sequence] HPCAL1  Forward 1 118 118 [Sequence] 234 1e-58 100.00 [Alignment] 
21:37758974-37758993 [Sequence] KCNJ6 Forward 46 65 20 [Sequence] 40.1 3.5 100.00 [Alignment] 
19:810675-810694 [Sequence] PTBP1 Forward 90 109 20 [Sequence] 40.1 3.5 100.00 [Alignment] 
 
Figure 4: The CGI sequence specific to gene HPCAL1. 
Genomic Location Overlapping Gene(s) Orientation Query start Query end Length Score E-val %ID 
3:131951779-131952272 [Sequence] CPNE4 Forward 1 494 494 [Sequence] 979 0.0 100.00 [Alignment] 
8:21712315-21712808 [Sequence] GFRA2  Reverse 1 494 494 [Sequence] 876 0.0 97.37 [Alignment] 
22:29644229-29644722 [Sequence] NF2 Reverse 1 494 494 [Sequence] 876 0.0 97.37 [Alignment] 
2:27358971-27359464 [Sequence] AC074117.10 Forward 1 494 494 [Sequence] 876 0.0 97.37 [Alignment] 
X:77766529-77767021 [Sequence] ATRX  Reverse 1 494 494 [Sequence] 868 0.0 97.37 [Alignment] 
9:125459123-125459616 [Sequence] MAPKAP1 Reverse 1 494 494 [Sequence] 868 0.0 97.17 [Alignment] 
7:47959038-47959531 [Sequence] HUS1  Forward 1 494 494 [Sequence] 868 0.0 97.17 [Alignment] 
5:138777166-138777659 [Sequence] CTNNA1  Reverse 1 494 494 [Sequence] 868 0.0 97.17 [Alignment] 
8:37927337-37927830 [Sequence]  Forward 1 494 494 [Sequence] 860 0.0 96.96 [Alignment] 
1:231128116-231128609 [Sequence]  Forward 1 494 494 [Sequence] 844 0.0 96.56 [Alignment] 
 




Genomic Location Overlapping Gene(s) Orientation Query start Query end Length Score E-val %ID 
X:68217045-68217552 [Sequence] OPHN1 Forward 1 508 508 [Sequence] 1007 0.0 100.00 [Alignment] 
9:97586395-97586891 [Sequence] TMOD1  Reverse 12 508 497 [Sequence] 858 0.0 96.78 [Alignment] 
8:77088551-77089048 [Sequence]  Forward 11 508 498 [Sequence] 876 0.0 97.19 [Alignment] 
7:104563072-104563576 [Sequence] LHFPL3  Reverse 4 508 505 [Sequence] 882 0.0 97.03 [Alignment] 
6:83803133-83803637 [Sequence]  Reverse 4 508 505 [Sequence] 874 0.0 96.83 [Alignment] 
3:15186798-15187302 [Sequence] COL6A4P1 Forward 4 508 505 [Sequence] 858 0.0 96.44 [Alignment] 
18:60035071-60035568 [Sequence]  Reverse 11 508 498 [Sequence] 860 0.0 96.79 [Alignment] 
13:95740201-95740705 [Sequence] DNAJC3  Reverse 4 508 505 [Sequence] 842 0.0 96.04 [Alignment] 
13:94372333-94372837 [Sequence] GPC6 Forward 4 508 505 [Sequence] 858 0.0 96.44 [Alignment] 
12:108997081-108997584 [Sequence] SVOP  Forward 4 508 505 [Sequence] 850 0.0 96.44 [Alignment] 
 
Figure 6: The CGI sequence specific to gene ESR1. 
Genomic Location Overlapping Gene(s) Orientation Query start Query end Length Score E-val %ID 
1:43591527-43591555 [Sequence] PTPRF Reverse 33 61 29 [Sequence] 58.0 7e-05 100.00 [Alignment] 
1:43591279-43591374 [Sequence] PTPRF Reverse 214 309 96 [Sequence] 56.0 3e-04 82.29 [Alignment] 
19:5243867-5244323 [Sequence] PTPRS Forward 1 457 457 [Sequence] 906 0.0 100.00 [Alignment] 
 




Genomic Location Overlapping Gene(s) Orientation Query start Query end Length Score E-val %ID 
8:143296212-143296248 [Sequence] ZNF696 Forward 320 356 37 [Sequence] 42.1 3.8 89.19 [Alignment] 
7:149432531-149432592 [Sequence] ZNF777 Reverse 368 429 62 [Sequence] 75.8 3e-10 90.32 [Alignment] 
7:149432078-149432117 [Sequence] ZNF777 Reverse 399 438 40 [Sequence] 48.1 0.062 90.00 [Alignment] 
7:149224516-149224548 [Sequence] ZNF282 Forward 321 353 33 [Sequence] 42.1 3.8 90.91 [Alignment] 
7:149224342-149224375 [Sequence] ZNF282 Forward 399 432 34 [Sequence] 44.1 0.97 91.18 [Alignment] 
7:149223860-149224303 [Sequence] ZNF282 Forward 1 444 444 [Sequence] 880 0.0 100.00 [Alignment] 
1:119622838-119622872 [Sequence] ZNF697 Reverse 318 352 35 [Sequence] 46.1 0.24 91.43 [Alignment] 
19:58471321-58471355 [Sequence] ZNF324 Forward 384 418 35 [Sequence] 46.1 0.24 91.43 [Alignment] 
19:58455773-58455805 [Sequence] ZNF324B Forward 384 416 33 [Sequence] 42.1 3.8 90.91 [Alignment] 
19:58368420-58368447 [Sequence] ZNF837 Reverse 399 426 28 [Sequence] 48.1 0.062 96.43 [Alignment] 
19:58368139-58368168 [Sequence] ZNF837 Reverse 318 347 30 [Sequence] 52.0 0.004 96.67 [Alignment] 
16:57997463-57997503 [Sequence] ZNF319 Reverse 399 439 41 [Sequence] 42.1 3.8 87.80 [Alignment] 
16:3119995-3120031 [Sequence] ZNF205, ZNF213-AS1 Forward 317 353 37 [Sequence] 50.1 0.016 91.89 [Alignment] 
16:30783260-30783298 [Sequence] ZNF629 Reverse 318 356 39 [Sequence] 46.1 0.24 89.74 [Alignment] 
16:30783090-30783128 [Sequence] ZNF629 Reverse 320 358 39 [Sequence] 46.1 0.24 89.74 [Alignment] 
16:30782843-30782878 [Sequence] ZNF629 Reverse 318 353 36 [Sequence] 56.0 3e-04 94.44 [Alignment] 
16:30417759-30417787 [Sequence] ZNF771 Forward 399 427 29 [Sequence] 42.1 3.8 93.10 [Alignment] 
15:84621192-84621223 [Sequence] ZSCAN2  Forward 321 352 32 [Sequence] 48.1 0.062 93.75 [Alignment] 
12:70366242-70366263 [Sequence]  Forward 286 307 22 [Sequence] 44.1 0.97 100.00 [Alignment] 
 






Figure 9: The CGI sequence specific to gene IGF2BP3. 
Genomic Location Overlapping Gene(s) Orientation Query 
start 
Query end Length Score E-val %ID 
9:110791185-110791652 [Sequence] MUSK Forward 1 468 468 [Sequence] 928 0.0 100.00 [Alignment] 
4:78348067-78348534 [Sequence] FRAS1  Forward 1 468 468 [Sequence] 912 0.0 99.57 [Alignment] 
4:21159477-21159944 [Sequence] KCNIP4 Forward 1 468 468 [Sequence] 896 0.0 99.15 [Alignment] 
1:84057854-84058321 [Sequence]  Reverse 1 468 468 [Sequence] 896 0.0 99.15 [Alignment] 
1:80944711-80945178 [Sequence]  Reverse 1 468 468 [Sequence] 904 0.0 99.36 [Alignment] 
16:33958059-33958526 [Sequence]  Reverse 1 468 468 [Sequence] 896 0.0 99.15 [Alignment] 
13:29647184-29647651 [Sequence]  Reverse 1 468 468 [Sequence] 896 0.0 99.15 [Alignment] 
11:95436302-95436769 [Sequence]  Forward 1 468 468 [Sequence] 896 0.0 99.15 [Alignment] 
11:93136725-93137192 [Sequence]  Forward 1 468 468 [Sequence] 896 0.0 99.15 [Alignment] 
11:109182972-109183439 [Sequence]  Reverse 1 468 468 [Sequence] 896 0.0 99.15 [Alignment] 
 
Figure 10: The CGI sequence specific to gene MUSK. 
Genomic Location Overlapping 
Gene(s) 
Orientation Query start Query end Length Score E-val %ID 
7:23415400-23415593 [Sequence] IGF2BP3 Forward 3 196 195 [Sequence] 228 4e-56 90.77 [Alignment] 
7:23415364-23415562 [Sequence] IGF2BP3 Forward 3 201 200 [Sequence] 278 4e-71 93.50 [Alignment] 
7:23415323-23415522 [Sequence] IGF2BP3 Forward 68 267 201 [Sequence] 232 2e-57 90.55 [Alignment] 
7:23415323-23415527 [Sequence] IGF2BP3 Forward 32 236 206 [Sequence] 281 3e-72 93.20 [Alignment] 
7:23415327-23415850 [Sequence] IGF2BP3 Forward 1 524 524 [Sequence] 1039 0.0 100.00 [Alignment] 
7:23415202-23415439 [Sequence] IGF2BP3 Forward 15 256 243 [Sequence] 184 5e-43 86.01 [Alignment] 





Figure 11: The CGI sequence specific to gene PMEPA1. 
Genomic Location Overlapping Gene(s) Orientation Query 
start 
Query end Length Score E-val %ID 
X:153951536-153951556 [Sequence] HCFC1 Reverse 435 455 21 [Sequence] 42.1 4.5 100.00 [Alignment] 
CHR_HSCHR16_1_CTG1:15882124-
15882148 [Sequence] 
MYH11 Reverse 355 379 25 [Sequence] 42.1 4.5 96.00 [Alignment] 
9:93912123-93912145 [Sequence]  Forward 383 405 23 [Sequence] 46.1 0.29 100.00 [Alignment] 
20:57652333-57652852 [Sequence] PMEPA1  Forward 1 520 520 [Sequence] 1031 0.0 100.00 [Alignment] 
18:13645177-13645386 [Sequence] LDLRAD4, RP11-
701H16.4 
Reverse 1 210 210 [Sequence] 131 6e-27 82.86 [Alignment] 
16:15797000-15797024 [Sequence] MYH11 Reverse 355 379 25 [Sequence] 42.1 4.5 96.00 [Alignment] 


















































































UKZN BIOMEDICAL RESEARCH ETHICS COMMITTEE 
 
APPLICATION FOR ETHICS APPROVAL  
For research with human participants (Biomedical) 
 
 
INFORMED CONSENT RESOURCE FORM 
Information Sheet and Consent to Participate in Research - Volunteers 
 
Date: Jan 2014-Dec 2015 
 
Good day  
 
My name is Farzeen Kader from UKZN – Westville, School of Life Sciences (Genetics). 
Contact Number: 031 260 8617. Email address: farzeenkader68@gmail.com / 
209503949@stu.ukzn.ac.za.  
 
You are being invited to consider participating in a study that involves research. The title of 
the project is “The Identification of Tissue Specific Differential Methylation in Human Body 
Fluids and Its Potential Application in Forensics.” This research study is towards the Masters 
of Science Degree of the Principal Investigator Ms. Farzeen Kader.  
 
The aim and purpose of this research is to study the DNA methylation changes in different 
racial groups of the South African population, with respect to identified tissue-specific 
differentially methylated regions (tDMRs). 
The study aims to develop new primers that target differentially methylated CpGs and test 
these primers on blood, semen and vaginal fluid and saliva (from volunteers).  
The study is expected to enroll 80 participants i.e. 10 males and 10 females of 4 ethnic groups 
(Black, White, Indian, and Coloured). The study requires participants to provide saliva 
samples only. The duration of your participation if you choose to enroll is minimal, as all that 
is required of you is to fill in a questionnaire and provide only saliva samples. This is not a 
diagnostic study and all information disclosed is confidential. The study is funded by the 
National Research Foundation. 
The samples will stored at – 20 ˚C in UKZN - Westville. The study will provide no direct 
benefits to participants; however it may enable development of new markers within human 
body fluids that may be used in forensic analysis. 
 
There are no risks involved if you participate in this study.  
 
This study has been ethically reviewed and approved by the UKZN Biomedical research 
Ethics Committee (Approval Number: BE221/14). 
 
 
In the event of any problems or concerns/questions you may contact the researcher or the 







BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 
Email: BREC@ukzn.ac.za  
 
Participation in this research is voluntary and you may withdraw participation at any point. In 
the event of refusal/withdrawal of participation you will not incur any penalty or loss. 
Everything possible will be done to keep your details confidential and that they are not 
revealed to anyone else. We will provide you with a code name such as Volunteer 1, and this 
code will be written onto the tubes used for the sample collection as well as the 
accompanying body fluid data collection form.  
The above-mentioned body fluid samples will be collected and stored at -20˚C at the 
Department of Genetics, UKZN - Westville. DNA will be isolated from the body fluids and 
stored at -20˚C until the end of the study. Thereafter it will be destroyed. 







I (Full Name/Sample Number …………………………………………………) have been 
informed about the study entitled “Identification of Tissue Specific Differential Methylation 
in Human Body Fluids and Its Potential Application in Forensics” by Farzeen Kader. 
 
I understand the purpose and procedures of the study. 
 
I have been given an opportunity to answer questions about the study and have had answers 
to my satisfaction. 
 
I declare that my participation in this study is entirely voluntary and that I may withdraw at 
any time without affecting any treatment or care that I would usually be entitled to. 
 
I have been informed about any available compensation or medical treatment if injury occurs 
to me as a result of study-related procedures. 
 
If I have any further questions/concerns or queries related to the study I understand that I may 
contact the researcher at UKZN – Westville, School of Life Sciences (Genetics). Contact 
Number: 031 260 8617. Email address: farzeenkader68@gmail.com / 
209503949@stu.ukzn.ac.za.  
 
If I have any questions or concerns about my rights as a study participant, or if I am 





BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 




____________________      ____________________ 
Signature of Participant                            Date 
 
 
____________________   _____________________ 
Signature of Witness                                Date 
(Where applicable)      
 
 
____________________   _____________________ 
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QUESTIONNAIRE FOR STUDY ENTITLED:  
Identification of Tissue Specific Differential Methylation in Human Body Fluids and Its Potential Application in Forensics. 
 
Please tick the appropriate boxes where necessary. SAMPLE NUMBER :  
1. Age 
Below 30                             Between 30 – 50                         Above 50                 
2. Sex 
Male                                Female                 
3. Weight  
Below 40 kg                          Between 40 – 70 kg                              Above 70 kg                  
4. Are you a citizen of South Africa? 
Yes                      No                 
5. Race  
Black                     White                       Indian                             Coloured                       Other  
6. Have you lived outside South Africa for longer than 5 years? 
Yes                        No                 
7. Do you smoke? 
Yes                        No                
8. Do you consume alcohol? 
Yes                        No                
9. Have you had blood transfusion? 
 Yes                        No                
10. Do you suffer from any chronic illnesses? If yes, please elaborate. 
………………………………………………………………………………………… 
11. Do you suffer from any cardiovascular illnesses? If yes, please elaborate. 
………………………………………………………………………………………… 
12. Have you undergone any medical procedures? If yes, please elaborate.  
………………………………………………………………………………………… 
13. Do you take any medication? This includes steroids. If yes, please elaborate. 
………………………………………………………………………………………… 
14. Your assistance is well appreciated. Kindly note that the present study is not for diagnostic purposes. All 
information disclosed will be kept confidential. 
………………………………… Farzeen Kader (Principal Investigator) 
 
 
   
    
  



















1 Black Below 30 7.3 
2 Black Below 30 47.7 
3 Black Below 30 2.5 
4 Black Below 30 110 
5 Black Below 30 91.6 
6 Black Below 30 54.2 
7 Black 30-50 38.8 
8 Black 30-50 40 
9 Black 30-50 2.2 
10 Black 30-50 7.1 
11 Black 30-50 469.5 
12 Black Below 30 6 
13 Black Below 30 8 
14 Black Below 30 146.4 
15 Black Below 30 81.5 
16 Black Below 30 230.3 
17 Black Below 30 73.9 
18 Black Below 30 26.1 
19 Black 30-50 25.3 
20 Black 30-50 46.2 
21 Black 30-50 28.6 
22 Indian 30-50 64.4 
23 Indian 30-50 28.5 
24 Indian 30-50 48.7 
25 Indian 30-50 52.8 
26 Indian 30-50 27.3 
27 Indian 30-50 67.9 
28 Indian 30-50 48.3 
29 Indian 30-50 119.2 
30 Indian Above 50 13.2 
31 Indian Below 30 100.7 
32 Indian Below 30 15.1 
211 
 
33 Indian Below 30 241.1 
34 Indian Below 30 373.6 
35 Indian Below 30 0.6 
36 Indian Below 30 33.6 
37 Indian Below 30 29.9 
38 Indian Below 30 19.9 
39 Indian Below 30 13.8 
40 Indian Below 30 98.3 
41 White Below 30 42.3 
42 White Below 30 114.9 
43 White Below 30 2.9 
44 White Below 30 76.5 
45 White Below 30 55.1 
46 White 30-50 62.1 
47 White 30-50 91.2 
48 White 30-50 24.5 
49 White 30-50 21.8 
50 White 30-50 29.3 
51 White 30-50 36.5 
52 White Above 50 78 
53 White Below 30 65.2 
54 White Below 30 94.3 
55 White Below 30 37.2 
56 White Below 30 2.5 
57 White Below 30 192.8 
58 White 30-50 158.3 
59 White 30-50 1.7 
60 White 30-50 54.3 
61 Coloured 30-50 96 
62 Coloured 30-50 49.1 
63 Coloured 30-50 82.3 
64 Coloured 30-50 44.6 
65 Coloured 30-50 14.2 
66 Coloured 30-50 8.6 
67 Coloured 30-50 7.1 
68 Coloured 30-50 0.9 
212 
 
69 Coloured 30-50 5.6 
70 Coloured 30-50 8.3 
71 Coloured Below 30 41.3 
72 Coloured Below 30 29.3 
73 Coloured Below 30 12.4 
74 Coloured Below 30 74.9 
75 Coloured 30-50 40.1 
76 Coloured 30-50 134.5 
77 Coloured 30-50 28.8 
78 Coloured 30-50 1.6 
79 Coloured 30-50 3.9 

























Methylation profiling of restricted saliva obtained from Blacks as analysed by 





























































































































































Methylation profiling of restricted saliva obtained from Indians as analysed by 


























































































































































Methylation profiling of restricted saliva obtained from Whites as analysed by 





















































































































































































































































Methylation profiling of restricted saliva obtained from Coloureds as analysed by 



























































































































Methylation profiles of unrestricted saliva (positive controls) obtained from all 





























































Restricted Unmethylated Artificial DNA (pCR® 2.1 TOPO® vector) used as a positive 











































































Figure 51:  Graph showing normal distribution for the PFN3 tDMR across all ethnic groups. 
 

